{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.09652"}, {"@name": "filename", "#text": "14639_Tese_%20L%c3%bacia%20Patr%c3%adcia%20Bezerra%20Gomes%20da%20Silva_BC.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE FEDERAL DE PERNAMBUCO\nLABORAT\u00d3RIO DE IMUNOPATOLOGIA KEIZO ASAMI\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM BIOLOGIA APLICADA \u00c0 SA\u00daDE\nL\u00daCIA PATR\u00cdCIA BEZERRA GOMES DA SILVA\nINVESTIGA\u00c7\u00c3O HISTOQUIMILUMINESCENTE COM LECTINAS E AVALIA\u00c7\u00c3O DA INFLU\u00caNCIA DOS HORM\u00d4NIOS ESTER\u00d3IDES NA EXPRESS\u00c3O DE GLICOSILTRANSFERASES EM NEOPLASIAS PROST\u00c1TICAS.\nL\u00daCIA PATR\u00cdCIA BEZERRA GOMES DA SILVA\nInvestiga\u00e7\u00e3o histoquimiluminescente com lectinas e avalia\u00e7\u00e3o da influ\u00eancia dos\nhorm\u00f4nios ester\u00f3ides na express\u00e3o de glicosiltransferases em neoplasias\nprost\u00e1ticas.\nTese de doutorado apresentada ao Programa de P\u00f3s-Gradua\u00e7\u00e3o em Biologia Aplicada \u00e0 Sa\u00fade, do Laborat\u00f3rio de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco, como requisito para a obten\u00e7\u00e3o do t\u00edtulo de Doutora em Biologia Aplicada \u00e0 Sa\u00fade.\nOrientador:\nProf. Dr. Luiz Bezerra de Carvalho Junior\nDepartamento de Bioqu\u00edmica, CB/UFPE;\nLaborat\u00f3rio de Imunopatologia Keizo Asami - LIKA.\nCo-orientador:\nProf. Dr. Eduardo Isidoro Carneiro Beltr\u00e3o\nDepartamento de Bioqu\u00edmica, CB/UFPE;\nLaborat\u00f3rio de Imunopatologia Keizo Asami - LIKA.\n2016\nCataloga\u00e7\u00e3o na Fonte:\nBibliotec\u00e1rio Bruno M\u00e1rcio Gouveia, CRB-4/1788\nSilva, L\u00facia Patr\u00edcia Bezerra Gomes da\nInvestiga\u00e7\u00e3o histoquimiluminescente com lectinas e avalia\u00e7\u00e3o da influ\u00eancia dos horm\u00f4nios esteroides na express\u00e3o de glicosiltransferases em neoplasias prost\u00e1ticas / L\u00facia Patr\u00edcia Bezerra Gomes da Silva. - Recife: O Autor, 2016.\n117 f.: il.\nOrientadores: Luiz Bezerra de Carvalho J\u00fanior, Eduardo Isidoro Carneiro Beltr\u00e3o\nTese (doutorado) - Universidade Federal de Pernambuco. Centro de Bioci\u00eancias. Programa de P\u00f3s-gradua\u00e7\u00e3o em Biologia Aplicada \u00e0 Sa\u00fade, 2016.\nInclui refer\u00eancias\n1.\tPr\u00f3stata - C\u00e2ncer 2. Lectinas I. Carvalho J\u00fanior, Luiz Bezerra de (orient.) II. Beltr\u00e3o, Eduardo Isidoro Carneiro (coorient.) III. T\u00edtulo.\n616.67 CDD (22.ed.)\nUFPE/CCB-2017-012\nUniversidade Federal de Pernambuco Programa de P\u00f3s-Gradua\u00e7\u00e3o em Biologia Aplicada \u00e0 Sa\u00fade\nParecer da comiss\u00e3o examinadora da defesa de qualifica\u00e7\u00e3o de doutorado de\nL\u00facia Patr\u00edcia Bezerra Gomes da Silva\nINVESTIGA\u00c7\u00c3O HISTOQUIMILUMINESCENTE COM LECTINAS E AVALIA\u00c7\u00c3O DA INFLU\u00caNCIA DOS HORM\u00d4NIOS ESTER\u00d3IDES NA EXPRESS\u00c3O DE GLICOSILTRANSFERASES EM NEOPLASIAS PROST\u00c1TICAS.\nA comiss\u00e3o examinadora, composta pelos professores abaixo, sob a presid\u00eancia do primeiro, considera a candidata L\u00facia Patr\u00edcia Bezerra Gomes da Silva\nAPROVADA\nRecife, 12 de Agosto de 2016.\nProf. Dr. Luiz Bezerra de Carvalho Jr.\nOrientador Departamento de Bioqu\u00edmica Universidade Federal de Pernambuco - UFPE\nProf. Dr. Eduardo Isidoro Carneiro Beltr\u00e3o Departamento de Bioqu\u00edmica Universidade Federal de Pernambuco - UFPE\nProf. Dr. M\u00e1rio Ribeiro de Melo J\u00fanior Departamento de Patologia Universidade Federal de Pernambuco - UFPE\nProf. Dra. Jaqueline de Azev\u00eado Silva Departamento de Gen\u00e9tica Universidade Federal de Pernambuco - UFPE\nProf. Dra. Dayane Aparecida Gomes\nDepartamento de Fisiologia e Farmacologia\nUniversidade Federal de Pernambuco - UFPE\nAGRADECIMENTOS\nA Deus, o meu grande mestre, fonte infinita da mais importante sabedoria, pela for\u00e7a e presen\u00e7a constante, necess\u00e1ria a vida.\nAos meus pais, Severino Gomes da Silva e Maria L\u00facia Bezerra da Silva, cada um com suas caracter\u00edsticas pr\u00f3prias que juntas resultaram no nosso alicerce e fonte de inspira\u00e7\u00e3o que devemos levar por toda vida, ambos lutaram com muita humildade e perseveran\u00e7a para que f\u00f4ssemos educados e respeitados.\nAos meus irm\u00e3os e irm\u00e3s pelo amor que nos mant\u00eam unidos em busca de objetivos comuns, saibam que aqui existe muito de voc\u00eas, serei sempre muito grata pelo apoio e paci\u00eancia nos meus dias de aperreio, vejo em cada um de voc\u00eas a felicidade por me verem dando novos passos.\nAo Prof. Dr. Luiz Bezerra de Carvalho J\u00fanior, pela confian\u00e7a depositada, pelo apoio e principalmente pelos preciosos momentos de aprendizagem, al\u00e9m da total disponibilidade para a execu\u00e7\u00e3o deste projeto.\nAo meu co-orientador Prof. Dr. Eduardo Isidoro Carneiro Beltr\u00e3o, pelo apoio, pelos ensinamentos e principalmente pela capacidade de lidar de forma singular com cada um de seus alunos, respeitando e compreendendo seus limites, caracter\u00edstica t\u00edpica de um grande l\u00edder.\n\u00c0s minhas amigas Sinara e Luiza (L3S) pela parceria, apoio, paci\u00eancia, compreens\u00e3o e pelas horas de divers\u00e3o.\nAos meus amigos do laborat\u00f3rio de Bioqu\u00edmica do Laborat\u00f3rio de Imunopatologia Keizo Asami (LIKA) que fazem parte do grupo Imobiliza\u00e7\u00e3o de Biomol\u00e9culas\n(IMOBIO): Aurenice, Gabriela Ayres, Mariana Cabrera, Tiago Veras, pelo apoio, amizade e incentivo.\nAos meus amigos do Laborat\u00f3rio de Patologia do LIKA do grupo de pesquisa Biomarcadores no C\u00e2ncer (B///C): Amanda Albuquerque, Igor, Aline, Spencer, Geilza, Arthur Clark, Jo\u00e3o Luiz, Juliana Vasconcelos, Juliana Brand\u00e3o, Carmelita Cavalcanti, Marina Cartaxo, Steffany Ferreira e Bruno Trajano pela recep\u00e7\u00e3o e amizade.\nA professora Adriana Fontes e seus alunos Paulo Eus\u00e9bio, Aline Pitt e Jo\u00e3o Paulo pelo apoio, disponibilidade e ajuda que recebi em seu laborat\u00f3rio.\nA professora Dayane Gomes pelo acolhimento em seu laborat\u00f3rio, suporte e momentos de aprendizado.\nAos funcion\u00e1rios do PPGBAS e LIKA, F\u00e1bio, Rafael Padilha, Sr. Otaviano, Vera, Ilma, Concei\u00e7\u00e3o, Mois\u00e9s e Edson, pelo apoio e assist\u00eancia oferecida em todos os momentos. A FACEPE pelo suporte financeiro.\nRESUMO\nO c\u00e2ncer est\u00e1 associado a altera\u00e7\u00f5es na glicosila\u00e7\u00e3o de glicoprote\u00ednas e glicolip\u00eddios de superf\u00edcie celular que podem afetar as intera\u00e7\u00f5es entre esses glicanos de superf\u00edcie celular e lectinas end\u00f3genas determinando o potencial metast\u00e1tico do tumor. Este trabalho teve como objetivo avaliar o glicofen\u00f3tipo de tecidos de pr\u00f3stata normal, Hiperplasia Prost\u00e1tica Benigna (HPB) adenocarcinoma pr\u00f3statico (AP) e investigar se estr\u00f3geno regula a glicosila\u00e7\u00e3o alterada no c\u00e2ncer da pr\u00f3stata andr\u00f3geno refrat\u00e1rio usando as linhagens DU-145 e PC-3. As lectinas Concanavalin A (Con A), Ulex euro-paeus agglutinin (UEA-I) e Peanut agglutinin (PNA) foram conjugadas ao \u00e9ster de acridina (EA-lectinas). As amostras de tecido foram incubadas com lectinas-EA e a quimiluminesc\u00eancia do complexo lectina-tecido-EA foi expressa em unidades relativas de luz (URL). Tecidos transformados demonstraram uma express\u00e3o estatisticamente significativa inferior de a-D-glucose / manose e Gal-P (1-3) -GalNAc que os tecidos normais. No entanto, uma maior express\u00e3o de a-L-fucose foi observada em AP em rela\u00e7\u00e3o a tecidos normais e a BHP. Observou-se uma diminui\u00e7\u00e3o da express\u00e3o dos valores de URL por inibi\u00e7\u00e3o da intera\u00e7\u00e3o entre tecidos e lectinas-AE utilizando os seus carboidratos espec\u00edficos. A rela\u00e7\u00e3o entre URL e a \u00e1rea de tecido mostrou uma correla\u00e7\u00e3o linear para todos lectinas-AE em ambos os tecidos transformados. Nos estudos in vitro utilizando linhagens de c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio, DU-145 e PC-3 tratadas com estradiol ou estradiol associado \u00e0 fulvestranto, foi observado na linhagem PC-3 aumento de express\u00e3o de CMP-Neu5Ac: GalNAc-R a-2,6-sialiltransferase (ST6GALNac-I) quando exposta a estradiol e uma diminui\u00e7\u00e3o de express\u00e3o na presen\u00e7a do antagonista fulvestranto. Esse comportamento n\u00e3o foi observado na linhagem DU-145. O receptor de estr\u00f3geno ERa apresentou diminui\u00e7\u00e3o de express\u00e3o em c\u00e9lulas PC-3 tratadas com fulvestranto, n\u00e3o sendo observada diferen\u00e7a de express\u00e3o do receptor de estr\u00f3geno P em nenhuma das linhagens. Lectin blotting usando as lectinas VVA (Vicia Villosa Lectin) e SNA (Sambucus nigra aglutinin) possibilitou identificar a sialila\u00e7\u00e3o do ant\u00edgeno Tn nas c\u00e9lulas PC-3 tratadas com estradiol, bem como a express\u00e3o do ant\u00edgeno Tn n\u00e3o sialilado na linhagem DU-145 nas mesmas condi\u00e7\u00f5es de tratamento. A capacidade de migra\u00e7\u00e3o de c\u00e9lulas PC-3 tratadas com estradiol, estradiol combinado a fulvestranto e estradiol combinado a SNA foi avaliada atrav\u00e9s do ensaio migra\u00e7\u00e3o (cicatriza\u00e7\u00e3o de ferida), sendo observado que estradiol induz migra\u00e7\u00e3o celular enquanto que fulvestranto e SNA reduzem a capacidade migrat\u00f3ria. Portanto, podemos inferir que no c\u00e2ncer de pr\u00f3stata h\u00e1 uma altera\u00e7\u00e3o na glicosila\u00e7\u00e3o e que estr\u00f3geno possivelmente pode atuar regulando a express\u00e3o de glicosiltransferases respons\u00e1veis pela altera\u00e7\u00e3o da glicosila\u00e7\u00e3o conferindo um potencial metast\u00e1tico tumoral.\nPalavras-chave: Hiperplasia Prost\u00e1tica Benigna, Carboidratos, Quimiluminesc\u00eancia, Estr\u00f3geno,\tLectinas,\tC\u00e2ncer\tde\tPr\u00f3stata,\tST6GalNAc\nABSTRACT\nCancer is associated with glycosylation alterations in cell-surface glycoproteins and glycolipids that can affect interactions between those glycans and endogenous lectins, determining the metastatic potential of the tumor. This study aimed to evaluate the glycophenotype in normal prostate, benign prostatic hyperplasia (BPH) and prostatic adenocarcinoma (PCa) tissues and investigate as estrogen regulates the altered glycosylation in prostate cancer androgen refractory using DU-145 and PC-3 cells. Concanavalin A (Con A), Ulex europaeus agglutinin (UEA-I) and Peanut agglutinin (PNA) lectins were conjugated to acridinium ester (lectins-AE). Tissue samples were incubated with lectins-AE. The chemiluminescence of the tissue-lectin-AE complex was expressed in relative light units (RLU). Transformed tissues showed statistical significant lower a-D-glucose/mannose and Gal-P(1-3)-GalNAc expression than normal tissues. However, higher a-L-fucose expression was observed in PCa in relation to normal and BHP tissues. We observed an expressive decreasing of the values of RLU by inhibition of the interaction between tissues and lectins-AE using their specific carbohydrates. The relationship between RLU and tissue area showed a linear correlation for all lectin-AE in both transformed tissues. In vitro studies using DU-145 and PC-3 androgen-refractory cell lines treated with estradiol or estradiol associated to fulvestrant was observed in PC-3 cell line increased a 2,6-sialyltransferase (ST6GALNac-I) expression when exposed to estradiol and decreased of expression in presence of the fulvestrant antagonist. This behavior was not observed in DU -145 cells. The estrogen receptor ERa presented decreased expression in PC-3 cells treated with fulvestrant, not seen difference in estrogen receptor P expression in any of the cells lines. Through lectin blotting using the VVA lectins (Lectin Vicia villosa) and SNA (Sambucus nigra aglutinin) was identified sialylation Tn antigen (sTn) in PC-3 cells treated with estradiol as well as the Tn antigen in DU-145 under the same conditions of treatment. Migration capacity of the PC-3 cells treated with estradiol, fulvestrant and SNA was measured by wound-healing assay (n=2). We observed that estradiol induced cell migration while fulvestrant (ICI) and SNA lectin reduced migration capacity into the wounds. Representative image of the cell cultures with scratches at 24 h are shown. Therefore, we can infer that there is change in glycosylation in prostate cancer and that estrogen can act regulating the expression of glycosyltransferase responsible for the glycosylation altered conferring tumor metastatic potential.\nKeywords: Benign Prostatic Hyperplasia, Carbohydrates, Chemiluminescence, Estrogen, Lectins, Prostate Cancer, ST6GalNAc.\nLISTA DE ILUSTRA\u00c7\u00d5ES\nRevis\u00e3o Bibliogr\u00e1fica\nEsquema que demonstra mecanismos de a\u00e7\u00e3o direto e indireto do estr\u00f3geno ativando os receptores nuclear e ligando diretamente ao elemento de resposta a estr\u00f3geno ou ativando fatores transcricionais como, Fos/Jun, STAT, ATF-2/Jun, SP1 E NFk-P que ligam-se a\nFigura 1\t29\nseus s\u00edtios de liga\u00e7\u00e3o na regi\u00e3o promotora de genes alvo. E o receptor de estr\u00f3geno de membrana, cuja ativa\u00e7\u00e3o resulta na fosforila\u00e7\u00e3o e ativa\u00e7\u00e3o de fatores transcricionais como, AP-1, Sp1, Elk1, CREB.\nReceptores de estr\u00f3geno: (A) ERa e (B) ERp e suas respectivas isoformas produtos de processamento alternativo. DLD, Dom\u00ednio de liga\u00e7\u00e3o ao DNA; DLL, dom\u00ednio de liga\u00e7\u00e3o ao ligante; TADDI, isoformas cerebral com dele\u00e7\u00e3o na jun\u00e7\u00e3o entre os \u00e9xons 3 e 4;\nFigura 2 MB1, isoformas encontrada no c\u00e9rebro que tem dele\u00e7\u00e3o parcial do 32 \u00e9xonl; ERa36\u00e9 uma prote\u00edna de 36 kDa formada pela dele\u00e7\u00e3o de ambos AF1 e AF2; ERa e ERp seguido do s\u00edmbolo delta (A) s\u00e3o isoformas que apresentam dele\u00e7\u00f5es de \u00e9xon.\nRepresenta\u00e7\u00e3o esquem\u00e1tica das comuns classes de glicoconjugados expressos em c\u00e9lulas humanas. Prote\u00ednas podem ser glicosiladas\nFigura 3 pela liga\u00e7\u00e3o covalente de sacar\u00eddeos ao esqueleto polipept\u00eddico via 37 N-glicosila\u00e7ao (ligado a res\u00edduos de asparagina) ou O-glicosila\u00e7\u00e3o (ligado a res\u00edduo de serina/treonina).\nParticipa\u00e7\u00e3o dos glicanos no desenvolvimento e progress\u00e3o do\nFigura 4 c\u00e2ncer, estando envolvidos nas etapas de dissocia\u00e7\u00e3o, invas\u00e3o, 40 prolifera\u00e7\u00e3o, crescimento, migra\u00e7\u00e3o e met\u00e1stase de c\u00e9lulas tumorais.\nFigura 6\tIntera\u00e7\u00f5es entre diversos tipos celulares atrav\u00e9s do reconhecimento 45 entre lectinas-carboidratos.\nFigura 7\tMecanismo quimiluminescente do \u00e9ster de Acridina.\nFigura 8\tRea\u00e7\u00e3o de conjuga\u00e7\u00e3o da prote\u00edna (NH2 - R) ao \u00c9ster de Acridina 52 N-hidroxisuccinimida,\nCap\u00edtulo I\t\t\nFigure 1\tConA-AE (A), PNA-AE (B), UEA-AE (C) purification profile from a Sephadex G-25 column (10 x 1 cm). Elution was carried out with 10 mM phosphate buffer, pH 7.2. Fractions (aliquots of 1 mL) were\t81\nFigure 2\tcollected for protein 280 nm (\u25a1), chemiluminescence (o) and hemagglutinating activity (\u2022) assays. Scheme of the chemiluminescent lectin histochemistry. Paraffin section (8 pm) of biopsies being cut, transferred to glass slide, deparaffinized, rehydrated, treated with trypsin, washed with PBS, incubated with lectins-AE and again washed with PBS. Afterwards the squared-shaped area of tissue section being cut and transferred to\t82\nFigure 3\ta polypropylene test tub and, finally, the chemiluminescence measured and expressed as relative light unit (RLU). A duplicate of the deparaffinized and rehydrated tissue sample was hematoxilin eosin stained for transformed tissue identification. Chemiluminescence in normal prostate tissues (n=5), benign prostatic hyperplasia (n=49) and prostate adenocarcinoma (n=50), using the conjugate ConA-AE, PNA-AE and UEA-AE. Different\t83\nFigure 4\tletters indicate statistically significant. All measurements are mean \u00b1 SD of triplicate. Lectin binding inhibition assay in prostate tissues diagnostic as benign prostatic hyperplasia (n= 5) and prostate adenocarcinoma (n=5). The conjugate ConA-AE, PNA-AE and UEA-AE were\t83\nFigure 5\tinhibited using, respectively, methyl-a-D-mannopyranoside, D-galactose and D-fucose. All measurements are mean \u00b1 SD of triplicate. Relationship between RLU and area (0.125 to 1.0 cm2) of prostate tissue diagnosed as benign hyperplasia prostatic and adenocarcinoma\t84\n\tprostate by using Con A-AE (A), PNA-AE (B) and UEA-AE (C) conjugates. All measurements are mean \u00b1 SD of triplicate.\t\nCap\u00edtulo II\nFigure 1\nFigure 2\nFigure 3\nFigure 4\nFigure 5\nFigure 6\nCell viability measured by the MTT assay after 4 days of E2 treatment. PC-3 cells were submitted to treatment with E2 (10-6-10-11) by 24, 48, 72, 96h and was observed different cell viability in relation time and concentration of the E2. Experiment performed in duplicate..\nCell viability though MTT assay. DU-145 prostate cancer cells were submitted to treatment with E2 (10-6-10-11) in time 24, 48, 72, 96h and presented different viability only in relation the factor time. Experiment performed in duplicate.\nAnalyze of the expression of the ST6GalNac enzyme and estrogen receptor in PC-3 cells treated with estradiol and estradiol plus fulvestrant. In PC-3 cells, increase the expression the ST6GalNacI was significant statistically when treated with E2 and decreased when treated to E2 + fulvestrant at time 24 and 48h. The expression the ER-a was down-regulated when treated with E2 + fulvestrant at time 24 and 48h while that ERp no significant difference observed in same conditions and time (p<0.05). Experiment performed in duplicate.\nExpression of the ST6GalNac I and ER-P in DU-145 cell no demonstrated statistically significant differences (p<0.5) between treatment. Experiment performed in duplicate. .\nExpression profile of the ligands (Tn and sTn antigens) recognize to SNA and VVA in PC-3 and DU-145 cells treated with estradiol 106M and estradiol (10-6M) plus antagonist fulvestrant (10x10-6M) during 24 and 48 horas. Experiment performed in duplicate.\nMigration capacity of the PC-3 cells treated with E2 (10-6), E2 (10-6) plus antagonist fulvestrant (10x10-6M) and E2 (10-6) plus SNA were measured by wound-healing assay (n=2). We observed that estradiol induced cell migration while fulvestrant and SNA lectin reduced\n94\n95\n96\n97\n198\nmigration capacity into the wounds. Representative image of the cell cultures with scratches at 24 h are shown. The wound is marked by dotted lines. Percentages of filled wound area are presented lower.\nCap\u00edtulo II\nTable 1\tPC-3 cells treated with E2 (10-6-10-11) analyzed though of the MTT assay demonstrated statistical differences significant in relation time and concentration of the E2\t111\nTable 2\tCell viability after 4 days of E2 treatment. In DU-145 cells was observed statistical differences significant in relation time of the exposition.\t111\nLISTA DE ABREVIA\u00c7\u00d5ES\nADT\tTerapia de priva\u00e7\u00e3o androg\u00eanica\nAS\t\u00c1cidos si\u00e1licos\nCon A\tConcanavalina A\nDMAE-NHS\tN-hydroxysuccinamide-activated dimethyl acridinium ester\nE1\tEstrona\nE2\t17P-estradiol\nE3\tEstriol\nER\tReceptor de estr\u00f3geno\nEA\t\u00c9ster de acridina\nFuc\tFucose\nGnRH\tHorm\u00f4nio de libera\u00e7\u00e3o de gonadotropina\nGlc\tGlicose\nGal\tGalactose\nGlcNAc\tN-acetil-D-glicosamina\nGalNAc\tN-acetil-D-galactosamina\nMan\tManose\nNeuNAc\t\u00c1cidos neuram\u00ednicos\nPC\tC\u00e2ncer de pr\u00f3stata\nPNA\tPeanut agglutinin\nPVDF\tPolivinilideno difluoride\nPSA\tAntigeno prostatico especifico\nQL\tQuimiluminescencia\nSNA\tSambucus nigra aglutinin\nUEA-I\tUlex europaeus agglutinin\nURL\tunidade relativa de luz\nVVA\tVicia Villosa agglutinin\nSUM\u00c1RIO\n1.\tINTRODU\u00c7\u00c3O..................................................19\n2.\tREVIS\u00c3O BIBLIOGR\u00c1FICA.......................................21\n2.1C\u00e2ncer de pr\u00f3stata......................................21\n2.2\tC\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio................22\n2.3\tEstr\u00f3geno e suas implica\u00e7\u00f5es no C\u00e2ncer de Pr\u00f3stata.....26\n2.4\tGlicosila\u00e7\u00e3o...........................................35\n2.5\tLectinas e sua capacidade de reconhecer carboidratos...43\n2.6\tQuimiluminec\u00eancia......................................49\n3.\tJUSTIFICATIVA...............................................54\n4 OBJETIVO.....................................................55\n4.1\tGeral..................................................55\n4.2\tEspec\u00edfico.............................................55\n5.\tREFER\u00caNCIAS.................................................56\nCAP\u00cdTULO 1.....................................................77\nCAP\u00cdTULO 2.....................................................88\n8.\tPERSPECTIVAS...............................................112\n9.\tCONCLUS\u00d5ES.................................................113\n10.\tPRODU\u00c7\u00c3O CIENT\u00cdFICA DURANTE O DOUTORADO...................115\n1.\tINTRODU\u00c7\u00c3O\nSegundo o INCA (Instituto Nacional do C\u00e2ncer), o c\u00e2ncer de pr\u00f3stata \u00e9 o sexto tipo de c\u00e2ncer mais comum no mundo e o mais prevalente entre os homens, representando cerca de 10% do total de c\u00e2ncer. No Brasil, o c\u00e2ncer de pr\u00f3stata \u00e9 o segundo mais comum entre os homens (atr\u00e1s apenas do c\u00e2ncer de pele n\u00e3o-melanoma). Al\u00e9m disso, estat\u00edsticas v\u00e1lidas para os anos de 2016/2017 apontam uma incid\u00eancia de cerca de 61.200 novos casos para o Brasil e para o estado de Pernambuco estima-se 2.750 novos casos de c\u00e2ncer prost\u00e1tico.\nHistoricamente, os estr\u00f3genos t\u00eam sido usados pra tratar o c\u00e2ncer de pr\u00f3stata (BURNS-COX et al., 2002). O 17 P-estradiol (E2) previne indiretamente a progress\u00e3o de c\u00e2ncer de pr\u00f3stata atrav\u00e9s de feedback negativo na libera\u00e7\u00e3o hipotal\u00e2mica do horm\u00f4nio de libera\u00e7\u00e3o de gonadotropina (GnRH), que leva a diminui\u00e7\u00e3o da concentra\u00e7\u00e3o s\u00e9rica de andr\u00f3geno (testosterona e diidrotestosterona), caracterizando um efeito semelhante a castra\u00e7\u00e3o, sendo portanto, efetivos contra c\u00e2ncer de pr\u00f3stata dependente de andr\u00f3geno (HARKONEN; MAKELA, 2004).\nNo entanto, por mecanismos de a\u00e7\u00e3o direta no tecido prost\u00e1tico, o estr\u00f3geno pode estar envolvidos no desenvolvimento inicial e prolifera\u00e7\u00e3o celular no c\u00e2ncer de pr\u00f3stata (BOSLAND, 2005; RISBRIDGER; BIANCO; ELLEM, 2003; SINGH, MATANHELIA, MARTIN, 2008)\nO estr\u00f3geno exerce seus efeitos regulat\u00f3rios na express\u00e3o g\u00eanica atrav\u00e9s da liga\u00e7\u00e3o \u00e0 seus receptores, os quais na presen\u00e7a do ligante, atuam como fatores transcricionais interagindo com s\u00edtios espec\u00edficos no DNA, os Elementos Responsivo \u00e0\nA glicosila\u00e7\u00e3o \u00e9 um fen\u00f4meno comumente associado com transforma\u00e7\u00e3o maligna, invas\u00e3o e met\u00e1stase de c\u00e9lulas do c\u00e2ncer, de modo que, quase todos os tipos de c\u00e9lulas malignas demonstram altera\u00e7\u00f5es em seus padr\u00f5es de glicosila\u00e7\u00e3o quando comparadas as suas contrapartes normais (GHAZARIAN; IDONI; OPPENHEIMER, 2011).\nEmbora muitos fatores contribuam para a glicosila\u00e7\u00e3o aberrante no c\u00e2ncer, um dos mecanismos mais importante s\u00e3o a express\u00e3o de glicosiltransferases e glicosidases, de modo que, altera\u00e7\u00e3o na express\u00e3o dessas enzimas resulta na s\u00edntese cadeias glic\u00eddicas alteradas (ramificadas ou truncadas) (MEANY; CHAN, 2011).\nEstudos tem sugerido que antiestr\u00f3genos inibem efetivamente o desenvolvimento e progress\u00e3o de c\u00e2ncer de pr\u00f3stata experimental e cl\u00ednico (STEINER, RAGHOW, 2003; HO, 2004), por\u00e9m as regula\u00e7\u00f5es g\u00eanicas resultantes da a\u00e7\u00e3o desses f\u00e1rmacos continuam desconhecidos, sugerindo que identificar vias de regula\u00e7\u00e3o do estr\u00f3geno seja alvo de estudos nessa neoplasia.\nNo presente trabalho foram avaliados o perfil de glicanos em c\u00e2ncer de pr\u00f3stata comparado \u00e0 Hiperplasia Prost\u00e1tica Benigna e tecidos normais, utilizando lectinas conjugadas a \u00e9ster de acridina, bem como foram realizados estudos in vitro onde foram avaliados a influ\u00eancia do estr\u00f3geno na glicosila\u00e7\u00e3o aberrante em linhagens de c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio.\n2\tREVIS\u00c3O BIBLIOGR\u00c1FICA\n2.1\tC\u00e2ncer de Pr\u00f3stata\nO C\u00e2ncer de pr\u00f3stata (CaP), ou adenocarcinoma de pr\u00f3stata, \u00e9 o tipo de c\u00e2ncer mais comumente diagnosticado, cerca de 27% do total de c\u00e2nceres, e a segunda maior causa de morte em homens nos Estados Unidos (SIEGEL et al, 2014). A alta incid\u00eancia do c\u00e2ncer de pr\u00f3stata deve-se provavelmente, a maior expectativa de vida dos homens (GRONBERG, 2003) e pelo aperfei\u00e7oamento e acesso a t\u00e9cnicas de triagem diagn\u00f3sticas, especialmente, a an\u00e1lise do ant\u00edgeno prost\u00e1tico espec\u00edfico (HANKEY et al., 1999).\nPara os pacientes com c\u00e2ncer de pr\u00f3stata localizado, o tratamento curativo inclui prostatectomia radical e/ou radia\u00e7\u00e3o como um meio de destruir as c\u00e9lulas do tumor que estiverem localizados dentro da c\u00e1psula prost\u00e1tica (TAPLIN et al., 2001; NELSON et al., 2003).\nAqueles pacientes com c\u00e2ncer de pr\u00f3stata localmente avan\u00e7ado, c\u00e2ncer de pr\u00f3stata metast\u00e1tico e doen\u00e7a bioquimicamente recorrente ap\u00f3s falha dos tratamentos localizados, o tratamento consiste na terapia de priva\u00e7\u00e3o de andr\u00f3geno (orquiectomia ou an\u00e1logo do horm\u00f4nio de libera\u00e7\u00e3o de gonadotrofinas (GnRH) e antagonista do receptor de andr\u00f3geno), que na maioria dos pacientes produz boa resposta evidenciada pelo decl\u00ednio do biomarcador PSA (prostate-specific antigen) em torno de 90% dos pacientes (HARRIS etal., 2009).\nNo entanto, depois de um tempo m\u00e9dio de 2-3 anos, a doen\u00e7a progride, tornando-se resistentes \u00e0 manipula\u00e7\u00e3o hormonal e os tumores progridem rapidamente para um crescimento independente de andr\u00f3geno (MARQUES etal., 2010).\nDiante desse quadro, inicia-se a segunda linha de tratamento hormonal que visa inibir qualquer s\u00edntese de andr\u00f3geno, utiliza-se o dietilestilbestrol (DES), um an\u00e1logo do estr\u00f3geno, suplementando a terapia anti-andr\u00f3geno de primeira linha, que mostrou ser efetivo na supress\u00e3o do eixo hipot\u00e1lamo-hip\u00f3fise e consequente redu\u00e7\u00e3o nos n\u00edveis de testosterona (BURNS-COX et al, 2002). Devido \u00e0s complica\u00e7\u00f5es card\u00edacas associadas com a administra\u00e7\u00e3o de altas doses de DES, seu uso foi limitado a baixas doses.\nEm homens, a produ\u00e7\u00e3o extra testicular de andr\u00f3geno ocorre no tecido adiposo (90%) e na gl\u00e2ndula adrenal (10%) e podendo, portanto ser fonte de horm\u00f4nio para manter a progress\u00e3o tumoral, por isso, adota-se inibidores da s\u00edntese de andr\u00f3geno adrenal, o cetoconazol e com maior efici\u00eancia, o acetato de abiraterona s\u00e3o inibidores seletivo da citocromo P450 17 A (CYP17 A) a-hidroxilase e da enzima citocromo 17,20 (C17,20)-liase, que s\u00e3o criticas para a bioss\u00edntese de andr\u00f3geno (HASHMAN; TAPLIN, 2013).\nEsta abordagem terap\u00eautica aumenta o tempo de sobreviv\u00eancia de cerca de 4 meses, al\u00e9m de aumentar o tempo de progress\u00e3o de PSA e foi relativamente bem tolerado pelos pacientes que tinham falhas quimioter\u00e1picas (EFSTATHIOU et al., 2012) Por\u00e9m a progress\u00e3o tumoral persiste apesar das recentes abordagens, caracterizando-o como c\u00e2ncer de pr\u00f3stata Andr\u00f3geno refrat\u00e1rio.\n2.2\tC\u00e2ncer de Pr\u00f3stata Andr\u00f3geno Refrat\u00e1rio\nIndependentemente dos mecanismos envolvidos no desenvolvimento do c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio, o receptor de andr\u00f3geno (RA) \u00e9 considerado a prote\u00edna chave envolvida na maioria dos casos e \u00e9 cr\u00edtica para promover crescimento das c\u00e9lulas do c\u00e2ncer de pr\u00f3stata.\nO receptor de andr\u00f3geno \u00e9 uma fosfoprote\u00edna 110 kDa e um dos receptores nucleares da superfam\u00edlia de fatores de transcricionais ativados por testosterona, por\u00e9m \u00e9 mais sens\u00edvel a a\u00e7\u00e3o da diidrotestosterona produzida no epit\u00e9lio prost\u00e1tico pela a\u00e7\u00e3o da enzima 5a redutase, obtendo assim as respostas biol\u00f3gicas necess\u00e1rias ao tecido (LAMB; WEIGEL; MARCELL, 2001; DEHM; TINDALL, 2006).\nO receptor de andr\u00f3geno \u00e9 expresso em inicialmente todas as c\u00e9lulas de c\u00e2ncer de pr\u00f3stata e o desenvolvimento do c\u00e2ncer de pr\u00f3stata, bem como a progress\u00e3o tumoral em algumas circunst\u00e2ncias parece depender da fun\u00e7\u00e3o desse receptor (TAPLIN; BALK, 2004; SCHER; SAWYERS, 2005).\nO desenvolvimento do c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio ou independente de andr\u00f3geno foi inicialmente proposto em cinco teorias por Feldman &amp; Feldman (2001) e essas s\u00e3o amplamente consideradas atualmente, s\u00e3o elas:\n1- A hipersensibilidade de RA: em estado qu\u00edmico castrado induzido por terapia de priva\u00e7\u00e3o de andr\u00f3geno, tem sido observado maior express\u00e3o g\u00eanica e prot\u00e9ica do receptor de andr\u00f3geno, em modelos in vitro e in vivo, justificado pela amplifica\u00e7\u00e3o do gene do receptor de andr\u00f3geno em aproximadamente 25-30% dos tumores andr\u00f3geno, n\u00e3o sendo identificada amplifica\u00e7\u00e3o em nenhum cancer de pr\u00f3stata n\u00e3o tratado, sugerindo que esssa amplifica\u00e7\u00e3o \u00e9 decorrente da terapia de priva\u00e7\u00e3o androg\u00eanica (KOIVISTO P. et al, 1997).\nO aumento da express\u00e3o de RA sensibiliza a c\u00e9lula do c\u00e2ncer de pr\u00f3stata em n\u00edveis baixos de andr\u00f3geno possibilitando a sobreviv\u00eancia e prolifera\u00e7\u00e3o dessas em ambiente com n\u00edveis m\u00ednimos de andr\u00f3geno, como ocorre na terapia de priva\u00e7\u00e3o androg\u00eanica (WALTERING et al., 2009).\nEssa muta\u00e7\u00e3o ocorre no dom\u00ednio de liga\u00e7\u00e3o ao ligante comprometendo a especificidade desse receptor ao ligante, a capacidade de liga\u00e7\u00e3o ao andr\u00f3geno, possibilitando que outros horm\u00f4nios que n\u00e3o seja testosterona, tais como estr\u00f3geno e progestinas, atuam como um agonista de RA mutado (MARCELLI et al., 2000).\nPor outro lado, altera\u00e7\u00f5es epigen\u00e9ticas como hipermetila\u00e7\u00e3o de RA resultam em perda de express\u00e3o de AR em 20-30% dos c\u00e2nceres de pr\u00f3stata andr\u00f3geno refrat\u00e1rio, inclusive as duas linhagens altamente estudadas DU-145 e PC-3, n\u00e3o expressam RA, sugerindo que mecanismos alternativos independentes de andr\u00f3geno levam ao desenvolvimento de c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio (HOBISCH et al., 1996).\n3- A hip\u00f3tese \u201coutlaw\u201d de RA: o c\u00e2ncer de pr\u00f3stata cresce independente de horm\u00f4nios atrav\u00e9s PTEN mutada ou funcionalmente inativa, consiste em uma prote\u00edna pr\u00f3-apopt\u00f3tica que inibe a cascata de sinaliza\u00e7\u00e3o da Akt, que desempenha papel chave no controle da apoptose e prolifera\u00e7\u00e3o em c\u00e2ncer de pr\u00f3stata (SUM et al., 2003; LI et al, 1997).\n.\t4- A hip\u00f3tese de desvio de RA: no c\u00e2ncer de pr\u00f3stata andr\u00f3geno dependente,\ndurante a terapia de priva\u00e7\u00e3o de andr\u00f3geno as vias apopt\u00f3ticas est\u00e3o ativadas, assim a superexpress\u00e3o da prote\u00edna anti-apopt\u00f3tica Bcl-2, exclusiva do c\u00e2ncer refrat\u00e1rio \u00e9 uma importante via para burlar a morte celular programada na aus\u00eancia de sinaliza\u00e7\u00e3o por AR, ajudando a c\u00e9lulas do c\u00e2ncer de pr\u00f3stata a bloqueiar a apoptose (COLOMBEL et al ., 1993).\nAl\u00e9m disso, a efic\u00e1cia tempor\u00e1ria na inibi\u00e7\u00e3o da progress\u00e3o tumoral resultante da inibi\u00e7\u00e3o da s\u00edntese de andr\u00f3geno da adrenal revela que o c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio pode ser mantido por mecanismos que ultrapassam as teorias acima descritas. Um mecanismo que recentemente ganhou muita aten\u00e7\u00e3o e suporte \u00e9 a ativa\u00e7\u00e3o de esteroidog\u00eaneses intratumoral, resultando em aumento de testosterona que pode manter a via androg\u00eanica (ARMANDARI et al., 2014).\nBaseado nesse fato, foi observado que c\u00e9lulas de c\u00e2ncer de pr\u00f3stata s\u00e3o capazes de produzir o pr\u00f3prio andr\u00f3geno (testosterona e diidrotestosterona) via esteroidog\u00eanese, seja a partir do precursor de andr\u00f3geno adrenal (deidroepiandrosterona -DHEA) ou s\u00edntese de novo andr\u00f3geno a partir do colesterol (MOSTAGEL, et al., 2012).\nMontgomery e colaboradores (2008), observaram aumento da express\u00e3o dos genes que codificam as enzimas necess\u00e1rias para a s\u00edntese de andr\u00f3geno a partir do colesterol como as citocromos (CYP11A, CYP17A) e 3P-hidroester\u00f3ide desidrogenase (3pHSD)1 em c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1ria quando comparadas com tumor prim\u00e1rio, demonstrando a capacidade desse tumor em produzir andr\u00f3geno continuamente. Al\u00e9m disso, observou-se que a alta express\u00e3o de CYP17A foi significativamente correlacionado com altos n\u00edveis de colesterol s\u00e9rico (MOSTAGEL et al., 2012).\nAp\u00f3s a terapia de priva\u00e7\u00e3o de andr\u00f3geno, foi observado aumento na produ\u00e7\u00e3o de testosterona intratumoral (de 0,07-1,34 para 0,74-1,44) e comportamento inverso em rela\u00e7\u00e3o a diidrotestosterona (de 4,6\u20146,4 para 1,0-1,9) (TITUS et al., 2005; NISHIYAMA et al, 2007).\nAssociado a esses dados a enzima aromatase (CYP19) \u00e9 cerca de 30 vezes mais expressa em tecidos de c\u00e2ncer de pr\u00f3stata metast\u00e1tico quando comparado a tumores prim\u00e1rios, possibilitando que testosterona local seja metabolizada \u00e0 estr\u00f3geno intratumoral (ELLEM et al, 2004) sendo portanto, n\u00edveis de estr\u00f3geno teciduais mais importantes que n\u00edveis de estr\u00f3geno circulante na promo\u00e7\u00e3o da carcinog\u00eanese prost\u00e1tica e progress\u00e3o.\nDiante desse contexto, pode-se inferir o envolvimento do estr\u00f3geno no desenvolvimento normal da pr\u00f3stata, no desenvolvimento do c\u00e2ncer de pr\u00f3stata andr\u00f3geno sens\u00edvel e no c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio.\n2.3\tEstr\u00f3genos e suas implica\u00e7\u00f5es no c\u00e2ncer de pr\u00f3stata\nOs estr\u00f3genos s\u00e3o compostos esteroides que ocorrem naturalmente sobre a forma de 17p estradiol (E2), estrona (E1) e estriol (E3), obtidos a partir da testosterona, progesterona e androstenediona, respectivamente, pela a\u00e7\u00e3o da enzima aromatase, sendo o 17p estradiol (E2) o principal horm\u00f4nio estrog\u00eanico (MARINO; GALLUZO; ASCENZI, 2006).\nEm indiv\u00edduos do sexo masculino, o estradiol \u00e9 produzido em baixas concentra\u00e7\u00f5es (35ng/mL), cerca de um quinto da quantidade sintetizada em mulheres n\u00e3o gr\u00e1vidas. O 17p estradiol (E2) \u00e9 sintetizado nas c\u00e9lulas de Sertoli e nas c\u00e9lulas de Leydig atrav\u00e9s da a\u00e7\u00e3o da enzima aromatase que converte de forma irreversivel testosterona em estradiol (HESS, 2003; CARREAU et al., 2003). A enzima aromatase tamb\u00e9m est\u00e1 presente em regi\u00f5es do sistema nervoso central, tecido \u00f3sseo, tecido adiposo e pr\u00f3stata (SIMPSON; DAVIS, 2001).\nOs EREs podem ser agrupados em sequ\u00eancia pal\u00edndromo perfeito e imperfeito, de modo que a sequ\u00eancia imperfeita difere da sequ\u00eancia consenso (5'GGTCAnnnTGACC3' ou 3'CCAGTnnnACTGG5') de um ou mais nucleot\u00eddeos (GRUBER et al, 2004). No entanto, no genoma humano, a maioria dos genes alvo de estr\u00f3geno n\u00e3o cont\u00e9m um ERE pal\u00edndromo em sua regi\u00e3o promotora, mas tem EREs n\u00e3o pal\u00edndromos atrav\u00e9s do qual a regula\u00e7\u00e3o do estr\u00f3geno \u00e9 efetiva (ANOLIK, 1995).\nAl\u00e9m disso, tem sido frequentemente identificado sequ\u00eancias semelhantes a EREs na regi\u00e3o regulat\u00f3ria de genes alvo de estr\u00f3geno denominadas de unidades de resposta ao estr\u00f3geno (URE). Uma sequ\u00eancia URE compreende um elemento palindr\u00f4mico imperfeito ou mesmo a metade de um ERE, as vezes separados por centenas de pares de bases que por um mecanismo de sinergismo transcricional desses elementos separados ocorre indu\u00e7\u00e3o dos efeitos do estr\u00f3geno no gene alvo (BEEKMAN et al., 1991) .\nAl\u00e9m desse mecanismo de regula\u00e7\u00e3o da express\u00e3o g\u00eanica, o complexo estr\u00f3geno-receptor de estr\u00f3geno pode ativar a transcri\u00e7\u00e3o de genes interagindo com fatores transcricionais (Figura 1) como, a prote\u00edna Fos e Jun, STAT, ATF-2/c-Jun, Sp1 e NF-Kb agindo em s\u00edtios espec\u00edficos nas regi\u00e3o promotora de genes alvos ativando ou inibir a transcri\u00e7\u00e3o de genes alvo (BJORNSTROM; SJOBERG, 2005).\nAmbos os processos resultam no recrutamento de prote\u00ednas correguladoras (co-ativadoras ou correpressoras) da transcri\u00e7\u00e3o g\u00eanica para promover a resposta fisiol\u00f3gica (atrav\u00e9s do aumento ou diminui\u00e7\u00e3o dos n\u00edveis de mRNA), esse processo ocorre dentro de poucas horas (DERO; KORACK, 2006).\nOutro mecanismo de a\u00e7\u00e3o de estr\u00f3geno denominado \u201cindireto ou n\u00e3o gen\u00f4mico\u201d ocorre atrav\u00e9s do receptor de estr\u00f3geno acoplado a prote\u00edna G (REPG) localizado na membrana plasm\u00e1tica, cuja ativa\u00e7\u00e3o resulta na ativa\u00e7\u00e3o de cascatas de prote\u00ednas cinases, levando a fosforila\u00e7\u00e3o de fatores de transcri\u00e7\u00e3o alvo, como Jun, STATs, CREB (DERO; KORACK, 2006; BJORNSTROM; SJOBERG, 2005).\nFigura 1: Esquema que demonstra mecanismos de a\u00e7\u00e3o direto e indireto do estr\u00f3geno ativando os receptores nuclear e ligando diretamente ao elemento de resposta a estr\u00f3geno ou ativando fatores transcricionais como, Fos/Jun, STAT, ATF-2/Jun, SP1 E NFk-P que ligam-se a seus s\u00edtios de liga\u00e7\u00e3o na regi\u00e3o promotora de genes alvo. E o receptor de estr\u00f3geno de membrana, cuja ativa\u00e7\u00e3o resulta na fosforila\u00e7\u00e3o e ativa\u00e7\u00e3o de fatores transcricionais como, AP-1, Sp1, Elkl, CREB. Fonte: adaptado de Bjornstrom; Sjorberg, 2005\nO estr\u00f3geno medeia suas respostas atrav\u00e9s de intera\u00e7\u00e3o com receptores cl\u00e1ssicos, o receptor de estr\u00f3geno a (ERa) e o receptor de estr\u00f3geno P (ERP). O ERa e o ERp s\u00e3o codificados por genes diferentes, Esrl e Esr2, respectivamente, que s\u00e3o encontrados em diferentes cromossomos. O gene do ERa est\u00e1 localizado no cromossomo 6 (6q25.1) e codifica uma prote\u00edna de 595 amino\u00e1cidos, enquanto que o gene do ERp est\u00e1\nA estrutura do receptor nuclear \u00e9 caracter\u00edstico e bem conservado, consistindo em um dom\u00ednio de transativa\u00e7\u00e3o N-teminal vari\u00e1vel, um dom\u00ednio de liga\u00e7\u00e3o ao DNA e um dom\u00ednio de liga\u00e7\u00e3o ao ligante C-terminal. A liga\u00e7\u00e3o ao horm\u00f4nio induz uma mudan\u00e7a conformacional, com libera\u00e7\u00e3o da prote\u00edna de choque t\u00e9rmico, expondo o dom\u00ednio de liga\u00e7\u00e3o ao DNA, promovendo a dimeriza\u00e7\u00e3o e ativa\u00e7\u00e3o o receptor (EVANS, 1988; PIKE; BRZOZOWSKI; HUBBARD, 2000).\nEmbora ambos tenham afinidades semelhantes de liga\u00e7\u00e3o com o 17p-estradiol, os dom\u00ednios de liga\u00e7\u00e3o ao ligante desses receptores s\u00e3o diferentes, por isso, outras subst\u00e2ncias como fitoestr\u00f3genos e moduladores seletivos de receptores de estr\u00f3geno (MSREs), podem regular seletivamente ERa e ERp. Associado a isso, o dom\u00ednio de liga\u00e7\u00e3o ao DNA \u00e9 bastante diferente, justificando as diferentes afinidades por diferentes elementos de respostas, e isso resulta em diferentes efeitos transcricionais em um mesmo s\u00edtio (NELSON et al, 1999; KULAKOSKY et al, 2002).\nAmbos receptores de estr\u00f3geno possuem isoformas com v\u00e1rios processamentos alternativos de pr\u00e9-mRNA (splicing) que permite que um n\u00famero limitado de genes codifique muitos produtos (Figura2). A maioria dos processamentos alternativos dos receptores ERa e ERp s\u00e3o gerados por duplica\u00e7\u00e3o de \u00e9xons, inser\u00e7\u00e3o de material gen\u00e9tico adicional ou muta\u00e7\u00f5es som\u00e1ticas que levam a c\u00f3dons finalizadores alterados e/ou inclus\u00e3o de material intr\u00f4nico (PINK et al., 1996; MURPHY et al.,1996).\nExiste um conjunto crescente de evid\u00eancias de que alguns processamentos alternativos desempenham um papel importante em ambos os contextos, manuten\u00e7\u00e3o da fisiologia normal e influencia a susceptibilidade para doen\u00e7as. Comparando com o receptor selvagem, alguns processamentos alternativos variantes diferem na a\u00e7\u00e3o que\neles medeiam como consequ\u00eancia da falta de, ou diferente configura\u00e7\u00e3o de v\u00e1rios dom\u00ednios do receptor. Essas isoformas de receptores podem, portanto falhar na liga\u00e7\u00e3o ao ligante, falhar na transloca\u00e7\u00e3o para o n\u00facleo, falhar na dimeriza\u00e7\u00e3o, falhar na liga\u00e7\u00e3o ao elemento de resposta ou na estimula\u00e7\u00e3o de fatores transcricionais, al\u00e9m de promover falha no sistema como um todo devido a competi\u00e7\u00e3o com o receptor selvagem pelo ligante (PFEFFER et al, 1993; BOLLIG et al., 2000; INOUE et al, 2000; PRICE et al, 2001; TREECK et al, 2007);\nFigura 2: Receptores de estr\u00f3geno: (A) ERa e (B) ERp e suas respectivas isoformas produtos de processamento alternativo. DLD, Dom\u00ednio de liga\u00e7\u00e3o ao DNA; DLL, dom\u00ednio de liga\u00e7\u00e3o ao ligante; TADDI, isoformas cerebral com dele\u00e7\u00e3o na jun\u00e7\u00e3o entre os \u00e9xons 3 e 4; MB1, isoformas encontrada no c\u00e9rebro que tem dele\u00e7\u00e3o parcial do \u00e9xonl; ERa36\u00e9 uma prote\u00edna de 36 kDa formada pela dele\u00e7\u00e3o de ambos AF1 e AF2; ERa e ERp seguido do s\u00edmbolo delta (A) s\u00e3o isoformas que apresentam dele\u00e7\u00f5es de \u00e9xon. Fonte: adaptado de TAYLOR; MARTIN-HIRSCH; MARTIN, 2010.\ntire\u00f3ide. Em humanos e modelos animais, tem sido comprovado a a\u00e7\u00e3o de estr\u00f3geno em sinergismo com andr\u00f3geno como fator etiol\u00f3gico de doen\u00e7as da pr\u00f3stata, participando no desenvolvimento de processos hiperpl\u00e1sicos e neopl\u00e1sicos prost\u00e1ticos via receptores, como hiperplasia prost\u00e1tica benigna e c\u00e2ncer de pr\u00f3stata (HO; LEUNG; CHUNG, 2006).\nPor outro lado, a castra\u00e7\u00e3o qu\u00edmica resultante da inibi\u00e7\u00e3o da s\u00edntese de andr\u00f3geno atrav\u00e9s de estr\u00f3geno (17 P-estradiol (E2) e dietilestilbestrol via feedback negativo na libera\u00e7\u00e3o hipotal\u00e2mica de GnRH previne indiretamente o desenvolvimento e progress\u00e3o de c\u00e2ncer de pr\u00f3stata. Sendo assim, o estr\u00f3geno provavelmente possui um duplo comportamento em rela\u00e7\u00e3o ao c\u00e2ncer de pr\u00f3stata (HARKONEN; MAKELA, 2004).\nRatos NBL (estirpe de consangu\u00edneos) submetidos a tratamento com n\u00edveis fisiol\u00f3gicos normais de testosterona apenas e testosterona combinado com estr\u00f3geno demonstraram uma incid\u00eancia de c\u00e2ncer de pr\u00f3stata de 35-40% quando tratados com andr\u00f3geno para 90-100% no tratamento hormonal combinado, indicando que estr\u00f3geno desempenha papel cr\u00edtico na carcinog\u00eanese da pr\u00f3stata (BOSLAND; FORD; HORTON, 1995)\nDiferen\u00e7as \u00e9tnicas e geogr\u00e1fica nos n\u00edveis de estr\u00f3geno fornece uma prov\u00e1vel explica\u00e7\u00e3o para a disparidade na preval\u00eancia de c\u00e2ncer de pr\u00f3stata entre v\u00e1rias popula\u00e7\u00f5es em todo o mundo. Em um estudo com 1413 homens foi observado que diferentemente do que se postulava sobre diferen\u00e7a \u00e9tnicas e n\u00edveis hormonais, a concentra\u00e7\u00e3o de testosterona n\u00e3o diferiu notavelmente entre homens brancos e negros, no entanto, homens negros, onde c\u00e2ncer de pr\u00f3stata \u00e9 mais incidente, apresentam altos n\u00edveis de estradiol. Al\u00e9m disso, a rela\u00e7\u00e3o E2 total/ Testosterona total foi maior em homens negros que em outros grupos \u00e9tnicos (ROHRMANN et al., 2007).\nO efeito do estradiol em linhagens celulares de pr\u00f3stata parece ser dependente do tipo de receptor de estr\u00f3geno expresso, observando-se que os compartimentos de secre\u00e7\u00e3o e diferencia\u00e7\u00e3o (c\u00e9lulas luminais e basais) expressam altos n\u00edveis de ERp, enquanto que o ERa \u00e9 restrito ao compartimento estromal, por\u00e9m em altos graus de neoplasia prost\u00e1tica ERa est\u00e1 expresso em ambos os compartimentos (IMAMOV et al., 2005)\nA a\u00e7\u00e3o de estr\u00f3geno via ERa \u00e9 capaz de induzir tr\u00eas diferentes e distintas patologias na pr\u00f3stata: 1- Prolifera\u00e7\u00e3o aberrante da camada basal do epit\u00e9lio prost\u00e1tico observada em camundongos PERKO e ausente em aERKO (RISBRIDGER et al., 2001).\n2-\tInflama\u00e7\u00e3o, estudos onde camundongos selvagens, PERKO e aERKO s\u00e3o expostos a estrogeniza\u00e7\u00e3o, foi observado que apenas os dois primeiros desenvolveram inflama\u00e7\u00e3o (ELLEM et al., 2009).\n3-\tC\u00e2ncer de pr\u00f3stata, o papel do estr\u00f3geno e ERa no desenvolvimento do c\u00e2ncer \u00e9 suportada pela emergente e progressiva express\u00e3o de ERa especificamente dentro do tumor de alto grau, com evidente express\u00e3o nos tumores andr\u00f3genos refrat\u00e1rio e met\u00e1stases (RICKE et al., 2008).\nApesar desses efeitos adversos do estr\u00f3geno na pr\u00f3stata via ERa, existem evid\u00eancias substanciais para sugerir que estr\u00f3geno tamb\u00e9m apresenta efeitos ben\u00e9ficos na pr\u00f3stata. Esses efeitos s\u00e3o mediados atrav\u00e9s de ERP1 e consistem em atividade anti-proliferativa, anti-inflamat\u00f3ria e anti-carcinog\u00eanica.\nPravenotti e colaboradores (2005) relataram que em linhagens de c\u00e9lulas prost\u00e1ticas o 17P- estradiol estimula prolifera\u00e7\u00e3o na presen\u00e7a de ERa, mas inibe prolifera\u00e7\u00e3o, quando essa forma heterod\u00edmeros com ERpi. Assim, observa-se que o\nEstudos revelam que no tecido prost\u00e1tico h\u00e1 express\u00e3o das isoformas ERP-2, ERP-4 e ERP-5, que formam heterod\u00edmeros com ERa e com ERP-1, podendo modular a atividade biol\u00f3gica desses receptores, interferindo na sua afinidade de liga\u00e7\u00e3o ao ligante, na capacidade de liga\u00e7\u00e3o ao DNA, no recrutamento de coativadores e correpressores de transcri\u00e7\u00e3o. Por\u00e9m pouco se sabe sobre os efeitos da express\u00e3o g\u00eanica dessas isoformas do receptor de estr\u00f3geno no tecido prost\u00e1tico (FUJIMURA et al., 2001).\nNakajima e colaboradores (2013) demonstraram que o estradiol promove degrada\u00e7\u00e3o do fator transcricional KLF-5 diminuindo a express\u00e3o da prote\u00edna pr\u00f3-apopt\u00f3tica FOXO- 1, promovendo crescimento tumoral em xenoenxerto de linhagens de c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio (DU-145) e comportamento inverso \u00e9 observado quando tratado com o antagonista fulvestranto.\nRecente estudo revelou que o antagonista fulvestranto atua super-regulando o microRNA hsa-miR765, que apresenta forte atividade anti- c\u00e2ncer de pr\u00f3stata via receptor de estr\u00f3geno P, inibindo crescimento de migra\u00e7\u00e3o e invas\u00e3o em c\u00e9lulas DU-145 (LEUNG et al, 2014).\nAl\u00e9m disso, em modelos pr\u00e9-cl\u00ednicos, fulvestranto tem demonstrado caracter\u00edsticas de uma promissora terapia para c\u00e2ncer de pr\u00f3stata, por\u00e9m os mecanismos que est\u00e3o envolvidos nesses benef\u00edcios ainda n\u00e3o est\u00e3o bem esclarecidos (CHADHA et al, 2008; GASENT BLESA et al, 2010)\n2.4\tGlicosila\u00e7\u00e3o\nheterogeneidade dos hidratos de carbono em sistemas vivos \u00e9 o resultado direto de v\u00e1rias caracter\u00edsticas, como a capacidade de formar liga\u00e7\u00f5es glicos\u00eddicas entre os res\u00edduos de a\u00e7\u00facar, caracter\u00edstica estrutural dessa mol\u00e9cula, tipos de liga\u00e7\u00e3o anom\u00e9rica, a posi\u00e7\u00e3o e a aus\u00eancia ou presen\u00e7a de ramifica\u00e7\u00e3o (MODY; JOSHI; CHANEY, 1995).\nOs glicanos s\u00e3o encontrados em v\u00e1rios tipos de biomol\u00e9culas que podem ser classificadas em diferentes fam\u00edlias de glicocojugados: glicoprote\u00ednas, glicoesfingolip\u00eddios, proteoglicanos e glicosilfosfatoinositol (Figura 3).\nA maioria dos carboidratos em glicoconjugados s\u00e3o oligo ou polissacar\u00eddeos constitu\u00eddos de cadeias lineares ou ramificadas de a\u00e7\u00facar, estando os sete monossacar\u00eddeos manose (Man), fucose (Fuc), galactose (Gal), glicose (Glc), N-acetilgalactosamina (GalNAC), N-cetilglicosamina (GlcNAc) e \u00e1cido si\u00e1lico (NeuAc) em diferentes combina\u00e7\u00f5es, dando origem a alta variabilidade dos glicoconjugados, e assim a um alto n\u00famero de modifica\u00e7\u00f5es poss\u00edveis de prote\u00ednas e lip\u00eddios com diferentes propriedades e fun\u00e7\u00f5es (LAZAR et al., 2011).\nFigura 3: Representa\u00e7\u00e3o esquem\u00e1tica das comuns classes de glicoconjugados expressos em c\u00e9lulas humanas. Prote\u00ednas podem ser glicosiladas pela liga\u00e7\u00e3o covalente de sacar\u00eddeos ao esqueleto polipept\u00eddico via N-glicosila\u00e7ao (ligado a res\u00edduos de asparagina) ou O-glicosila\u00e7\u00e3o (ligado a res\u00edduo de serina/treonina). Fonte: Adaptado de PINHO; REIS, 2015.\nOCal\t\u2022 Glc\t0 Man\t* Xyl\t0 IdoA\t0 Sialic acid\t\u2022\tSulphate *\n0 GalNAc\t\u25a0 GlcNAc\ta gicn\tA Fuc\tGlcA\tO Inositol\tT Glycosphingolipid\nA sequ\u00eancia da prote\u00edna \u00e9 completamente codificada pelo genoma, no entanto, a diversidade da prote\u00edna pode ser alcan\u00e7ada por diferentes estruturas da fra\u00e7\u00e3o glic\u00eddica, que depende da sequ\u00eancia ou do tipo de glicanos ligado. A apropriada ou acurada bioss\u00edntese de a\u00e7\u00facar ou glicanos ocorre no ret\u00edculo endoplasm\u00e1tico e no complexo de Golgi e depende da a\u00e7\u00e3o de enzimas altamente espec\u00edficas, denominadas as glicosidases e glicosiltransferases, as quais atuam removendo um ou mais monossacar\u00eddeos dos glicanos e readicionando novos monossacar\u00eddeos conforme a via enzim\u00e1tica a que os glicoconjugados est\u00e3o sujeitos dependendo de c\u00e9lulas ou tecidos onde ocorram (FUKUDA e BAO, 2008; GAO, et al., 2008; OHTSUBO e MARTH, 2006).\nDevido \u00e0 diversidade estrutural dos glicoconjugados, os glicanos atuam como mol\u00e9culas de armazenamento de informa\u00e7\u00e3o, sendo atribu\u00eddo a eles significado funcional, de modo que muitas informa\u00e7\u00f5es biol\u00f3gicas podem residir nas estruturas de glicanos complexos, devido ao enorme potencial de codifica\u00e7\u00e3o que est\u00e1 muito al\u00e9m do potencial de codifica\u00e7\u00e3o dos amino\u00e1cidos ou nucleot\u00eddeos. Este potencial \u00e9 baseado n\u00e3o apenas na varia\u00e7\u00e3o da sequ\u00eancia de monossacar\u00eddeos nas cadeias oligossacar\u00eddicas, mas tamb\u00e9m sobre a possibilidade de modifica\u00e7\u00e3o p\u00f3s-transcricional dos a\u00e7\u00facares (JANKOVIC; KOSANOVI; MILUTINOV, 2008).\n2.4.1\tPapel da glicosila\u00e7\u00e3o na biologia do c\u00e2ncer\nEm virtude de sua localiza\u00e7\u00e3o perif\u00e9rica e a sua capacidade de interagir com prote\u00ednas e modular a atividade destas na interface c\u00e9lula-c\u00e9lula e c\u00e9lula-meio extracelular, ep\u00edtopos de oligossacar\u00eddeos em prote\u00ednas e lip\u00eddios exercem importantes fun\u00e7\u00f5es tais como, desenvolvimento embrion\u00e1rio normal, diferencia\u00e7\u00e3o e crescimento celular, morte celular (apoptose), inibi\u00e7\u00e3o por contato, reconhecimento c\u00e9lula-c\u00e9lula, intera\u00e7\u00e3o pat\u00f3geno-hospedeiro, reconhecimento imunol\u00f3gico e desenvolvimento de doen\u00e7as como o c\u00e2ncer (GHAZARIAN; IDONI; OPPENHEIMER, 2011).\nA glicosila\u00e7\u00e3o aberrante desempenha um papel fundamental nas etapas de desenvolvimento e progress\u00e3o tumoral interferindo em vias intracelulares importantes como via de morte por apoptose e como ep\u00edtopos de superf\u00edcie atuam inibindo as intera\u00e7\u00f5es c\u00e9lula- c\u00e9lula (MUNKLEY; ELLIOTT, 2016).\nglicosidases envolvidas na s\u00edntese e catabolismo dos glicanos, respectivamente. Por esta raz\u00e3o, altera\u00e7\u00f5es na express\u00e3o dessas enzimas pode desencadear uma cascata de eventos envolvidos na transforma\u00e7\u00e3o oncog\u00eanica das c\u00e9lulas (MEANY; CHAN, 2011; BLOME et al., 2009).\nOs glicanos modificados t\u00eam a capacidade de interferir na intera\u00e7\u00e3o carboidratos-prote\u00ednas receptoras ou lectinas e, portanto, inibem o reconhecimento c\u00e9lula-c\u00e9lula e os processos de ades\u00e3o, que desempenham papel importante no crescimento e progress\u00e3o do c\u00e2ncer (Figura 4), incluindo eventos como: prolifera\u00e7\u00e3o celular, dissocia\u00e7\u00e3o da c\u00e9lula do tumor e invas\u00e3o local, angiog\u00eanese, ades\u00e3o a plaquetas (evas\u00e3o do sistema imune), ades\u00e3o ao endot\u00e9lio, extravas\u00e3o e met\u00e1stase (FUSTER; ESKO, 2005; PINHO; REIS, 2015).\nVECFR\nCalectin\nIntegrina\nC\u00e9lula tumoral\ni C\u00e9lula ' endotelial\nCadeia pept\u00eddica\nProteoglicanos\n\u2014iVs r\"\n\u2022 z\nC\u00e9lula tumoral\n;________________\nT proliferation \u2022\nE-selectin j\nC\u00e9lula ! tumoral i\nO Cal\nFibroblast\n\u25a1 Cal N Ac\nO Man\nErythrocyte\n\u2606 Xy&lt;A Fue\nSialic acid\n\u2666 CIcA\n\u25a0 CIcNAc\nGlycosphingolipid\nECM\tMacrophage Qo\u00b0 Platelets\nNeutrophil\tEndothelial\nEpithelial cell&lt;\\C^) ^\u00a1J\u2019our\nA glicosila\u00e7\u00e3o de prote\u00ednas pode ser dividida em dois tipos, incluindo O- e N-\nglicosila\u00e7\u00e3o e elas respondem de maneira diferente na tumorig\u00eanese e na progress\u00e3o tumoral\n2.4.2\tO- glicosila\u00e7\u00e3o e bioss\u00edntese de ant\u00edgenos Tn e sTn\nA O-glicosila\u00e7\u00e3o consiste na adi\u00e7\u00e3o covalente de carboidratos \u00e0 hidroxila (-OH) em res\u00edduos de amino\u00e1cidos serina (Ser) ou treonina (Tre), onde a N-acetilgalactosaminiltransferase ou polipept\u00eddeo GalNAc transferase \u00e9 a primeira enzima a atuar nessa via transferindo GalNAc para o res\u00edduo de esqueleto pept\u00eddico de uma\n40\nO ant\u00edgeno Tn atua como o precursor para todas as estruturas core da O-glicosila\u00e7\u00e3o. As enzimas pi,3-galactosiltransferase e pi,3-N-acetilglicosaminiltransferase utilizam o ant\u00edgeno Tn como um substrato para produzir o core 1 e core 3, respectivamente. Os core 1 e 3 podem ser mais ramificados atrav\u00e9s das enzimas pi,6-N-acetilglicosaminiltransferase 1 e pi,6-N-acetilglicosaminiltransferase 2 para formar O-glicanos complexos correspondentes aos cores 2 e 4, respectivamente. (VAVASSEUR, et al., 1995).\nAl\u00e9m das rotas acima descritas, o ant\u00edgeno Tn pode ser substrato de enzimas que transfere \u00e1cido si\u00e1lico. As sialiltransferases humanas s\u00e3o uma fam\u00edlia de pelo menos 20 prote\u00ednas glicosiltransferases normalmente, ligadas \u00e0 membrana do Complexo de Golgi, mas tamb\u00e9m podem ser sol\u00faveis ou ligadas \u00e0 membrana citoplasm\u00e1tica e cada uma catalisa um tipo de liga\u00e7\u00e3o e tem uma especificidade pr\u00f3pria para com o substrato (GROSS et al., 1996; HARDUIN-LEPERS et al., 2001; CABRAL et al., 2010).\nAs sialitransferases catalisam a transfer\u00eancia de um res\u00edduo de \u00e1cido si\u00e1lico proveniente do acido N-acetilneuram\u00ednico citidina monofosfato (CMP-Neu 5Ac) para a unidade aceptora na posi\u00e7\u00e3o terminal da cadeia oligossacar\u00eddica de glicoprote\u00ednas e glicolip\u00eddios (MARCOS etal., 2004).\nA sialila\u00e7\u00e3o do ant\u00edgeno Tn (O-GalNAc) pode ser realizada por dois membros da fam\u00edlia de sialiltransferases, s\u00e3o elas, a2,6-sialiltransferase I (ST6GalNAc) I e a2,6-sialiltransferase II (ST6GalNAc II), formando o ant\u00edgeno sTn (Neu5Ac_2-6GalNAc_1-Ser/Thr). No entanto, estudos utilizando c\u00e9lulas transfectadas por cada uma dessas enzimas tem demonstrado que no contexto celular, apenas ST6GalNAc-I \u00e9 capaz de\n41\nFigura 5: Vias de bioss\u00edntese de ant\u00edgenos O-glicanos truncados. Em destaque a a\u00e7\u00e3o da enzima ST6GalNAc-I respons\u00e1vel pela s\u00edntese de ant\u00edgeno sTn. Fonte: LIMA, 2014\nO aumento na express\u00e3o de sialil-Tn tem sido associado com diminui\u00e7\u00e3o de ades\u00e3o e aumento de migra\u00e7\u00e3o de c\u00e9lulas de c\u00e2ncer de mama (CAZET, A. et al., 2010). Al\u00e9m disso, em c\u00e2ncer g\u00e1strico (MARCOS et al., 2011), ov\u00e1rios (VAN ELSEEN et al., 2010), mama (KIM et al., 2002) e pancre\u00e1tico a superexpress\u00e3o de ST6GalNAc-I leva ao aumento da express\u00e3o do ant\u00edgeno sialil-Tn, onde o constitui com marcador de pobre progn\u00f3stico.\n42\nmet\u00e1stase \u00f3ssea (PC-3) e a linhagem de c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio derivada de met\u00e1stase cerebral (DU-145) foi observado que a express\u00e3o de ST6GalNAc-I e ant\u00edgeno sTn foi maior nas condi\u00e7\u00f5es malignas, e entre elas foi maior na linhagem PC-3 (GAO, 2012).\nEmbora o estudo anterior seja realizado com linhagem de c\u00e9lulas provenientes de met\u00e1stase, observa-se a manuten\u00e7\u00e3o das caracter\u00edsticas do prim\u00e1rio quando esses dados s\u00e3o corroborados com an\u00e1lise imunohistoqu\u00edmica de adenocarcinoma prost\u00e1tico. Al\u00e9m de ser observado que a express\u00e3o de ant\u00edgenos STn est\u00e1 diretamente associado a progress\u00e3o tumoral, uma vez que ant\u00edgenos sTn foram mais expressos na condi\u00e7\u00e3o maligna quando comparada a hiperpl\u00e1sica benigna e a neoplasia intraepitelial prost\u00e1tica (GARBAR; MASEAUX; WESPES, 2008).\nA mucina 1 (MUC1), uma glicoprote\u00edna de membrana rica em res\u00edduos de serina e treonina pass\u00edveis de serem o-glicosilados inclusive ant\u00edgeno sTn tamb\u00e9m \u00e9 altamente expressa nas linhagens de c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio PC-3 e Du-145 (SINGH et al, 2006).\nO aumento de express\u00e3o de mucinas-sTn foi detectado in c\u00e2ncer de pr\u00f3stata e est\u00e1 diretamente relacionada com grau patol\u00f3gico e n\u00edvel de ant\u00edgeno prost\u00e1tico espec\u00edfico sendo correlacionado com pior progn\u00f3stico (ARAI et al., 2005).\n2.5\tLectinas e sua capacidade em reconhecer carboidratos\nAs lectinas s\u00e3o prote\u00ednas ou glicoprote\u00ednas de origem n\u00e3o imunol\u00f3gica que reconhecem carboidratos espec\u00edficos, por meio de ao menos, dois s\u00edtios de liga\u00e7\u00e3o ao carboidrato, atrav\u00e9s do dom\u00ednio de reconhecimento de carboidratos (SHARON; LIS, 2004). Estas mol\u00e9culas aglutinam c\u00e9lulas animais e vegetais, precipitam polissacar\u00eddeos e glicoconjugados. S\u00e3o amplamente distribu\u00eddas na natureza, sendo encontradas em seres unicelulares, pluricelulares e plantas (WANG; HG, 2006).\n43\nA pesquisa por lectinas iniciou-se em 1888 quando Herrmann Stilmark estudando a toxicidade de extratos da mamona (Ricinus communis) descobriu que uma prote\u00edna, a qual chamou de ricina, era capaz de aglutinar eritr\u00f3citos animais e humanos, por\u00e9m o estudo sobre estas prote\u00ednas s\u00f3 come\u00e7ou a ganhar \u00edmpeto em 1960 (SHARON; LIS, 1998); abrindo uma vasta \u00e1rea de aplica\u00e7\u00e3o para lectinas (GABOR et al.,2001)\nA \u00eanfase que \u00e9 dada quanto \u00e0 origem n\u00e3o imune das lectinas serve para distingui-las de anticorpos anti-carboidratos que aglutina c\u00e9lulas. Enquanto os anticorpos s\u00e3o estruturalmente similares, as lectinas diferem entre si quanto \u00e0 composi\u00e7\u00e3o aminoac\u00eddica, requerimento de metais, peso molecular e estrutura tridimensional. Al\u00e9m disso, as lectinas est\u00e3o presentes em organismos que n\u00e3o possuem sistema imune, como plantas e bact\u00e9rias (GABIUS, 2001).\nDe acordo com a quantidade e especificidade dos dom\u00ednios de liga\u00e7\u00e3o a carboidratos, as lectinas s\u00e3o subdivididas em: merolectina, hololectina, quimerolectina e superlectina. As lectinas de plantas geralmente pertencem a classe das hololectinas por possu\u00edrem pelo menos dois dom\u00ednios id\u00eanticos ou mais dom\u00ednios hom\u00f3logos ligantes a a\u00e7\u00facares, ou seja, s\u00e3o di ou multivalentes, aglutinam c\u00e9lulas e/ou precipitam glicoconjugados (VAN DAMME et al., 1996).\nV\u00e1rias lectinas end\u00f3genas animais s\u00e3o importantes em diversos processos biol\u00f3gicos fundamentais, tais como controle de qualidade de prote\u00ednas secretadas, reconhecimento c\u00e9lula-c\u00e9lula, intera\u00e7\u00f5es c\u00e9lulas-matriz extracelular fertiliza\u00e7\u00e3o de gametas, desenvolvimento embrion\u00e1rio, crescimento celular, diferencia\u00e7\u00e3o celular, sinaliza\u00e7\u00e3o celular, apoptose, imunomodula\u00e7\u00e3o, inflama\u00e7\u00e3o, ades\u00e3o e motilidade celular, e reconhecimento pat\u00f3geno-hospedeiro (Figura 6). Muitas lectinas existem na superf\u00edcie das c\u00e9lulas imunes e c\u00e9lulas endoteliais que revestem a vasculatura, como prote\u00ednas da matrix extracelular ou como mol\u00e9culas de ades\u00e3o sol\u00faveis tais como, prote\u00ednas\n44\nFigura 6: Vias de intera\u00e7\u00e3o entre glicanos de superf\u00edcie celular com lectinas end\u00f3genas, promovendo ades\u00e3o c\u00e9lula a c\u00e9lula, bem como pat\u00f3genos-hospedeiro. Fonte: Kappor et al, 2014\n\nA/Vrrrv\nBacteria\nglycoprotein\nToxin\n3\t' Lec\u00abn\nJ\u00ed\u00ed/r\tc\n\nAs lectinas de leguminosas existem como olig\u00f4meros, caracter\u00edstica natural das prot\u00e9inas que exercem tantas implica\u00e7\u00f5es funcionais importantes, tais como aglutina\u00e7\u00e3o de c\u00e9lulas, atividade mitog\u00eanica, entre outras. Todas as lectinas de leguminosas apresentam estrutura terci\u00e1ria similar, no entanto, elas diferem consideravelmente na especificidade ao ligante e estruturas quatern\u00e1ria (SRINIVAS etal., 2001).\n45\nA Concanavalina A (Con A) \u00e9 uma lectina vegetal obtida das sementes de Canavalia ensiformes, \u00e9 o membro mais bem conhecido das lectinas de leguminosas devido as in\u00fameras aplica\u00e7\u00f5es biol\u00f3gicas. Ela reconhece e se liga especificamente \u00e0 res\u00edduos de a-D-glicose/manose de carboidratos complexos, exibindo alta afinidade por oligossacar\u00eddeos de glicoprote\u00ednas e glicolip\u00eddios de superf\u00edcie celular. A estrutura molecular \u00e9 apresentada como um tetr\u00e2mero acima de pH 7 e um d\u00edmero abaixo de pH 6, com cada mon\u00f4mero de Con A apresentando peso molecular de 26 KDa e um s\u00edtio de liga\u00e7\u00e3o \u00e0 carboidratos (CHATTERJEE; MANDAL, 2005).\nA lectina Peanut agglutinin (PNA), isolada a partir do amendoim Arachis hypogea, \u00e9 uma prote\u00edna n\u00e3o glicosilada, homotetram\u00e9rica com mon\u00f4meros de 27 KDa que possuem especificidade id\u00eantica a sequ\u00eancia de carboidratos Gal-P(1-3)-GalNAc. O tetr\u00e2mero possui um peso molecular em torno de 110 KDa e apresenta uma incomum estrutura quatern\u00e1ria aberta, que pode ser descrita como um d\u00edmero de um d\u00edmero. A PNA em pH neutro consiste em um tetr\u00e2mero, enquanto que em pH \u00e1cido ela se dissocia formando d\u00edmero. O termo \u201cpeanut agglutinin\u201d foi originado a partir da sua habilidade em aglutinar linf\u00f3citos T e hem\u00e1cias tratadas com a enzima neuraminidase (DEV; KHAN; SUROLIA, 2006).\nA lectina Ulex europaeus agglutinin-I (UEA-I) \u00e9 uma metalo-glicoprote\u00edna que reconhece especificamente res\u00edduos de a-L-fucose e oligossacar\u00eddeos que cont\u00eam fucose, como por exemplo, a-L-fuc(l>2)p-D-Gal(l>4)p-D-GlcNAc. A organiza\u00e7\u00e3o estrutural quatern\u00e1ria dim\u00e9rica da lectina UEA-I, bem como as estruturas terci\u00e1rias das subunidades monom\u00e9ricas s\u00e3o semelhantes as que ocorrem entre as lectinas de leguminosas. Todavia, algumas diferen\u00e7as estruturais monom\u00e9ricas s\u00e3o observadas, estas incluem substitui\u00e7\u00e3o dos res\u00edduos de alanina que atuam no sitio de liga\u00e7\u00e3o aos glicanos espec\u00edficos comuns \u00e0s demais lectinas, por treonina nos mon\u00f4meros de UEA,\n46\nA lectina Vicia villosa aglutinin (VVA) \u00e9 uma glicoprote\u00edna obtida de sementes da vicia villosa que reconhece preferencialmente terminal a ou p ligados a N-acetilgalactosamina, especificamente a um res\u00edduo \u00fanico de N-acetilgalactosamina ligado a serina ou treonina em um polipept\u00eddeo, denominado ant\u00edgeno Tn. Sua estrutura tetram\u00e9rica consiste na combina\u00e7\u00e3o de subunidades A e B, por\u00e9m a alta a similaridade na composi\u00e7\u00e3o de amino\u00e1cidos dessas subunidades resultam em lectinas compostas de ambas subunidades Aou B, sugerindo que a vicia villosa pode conter isolectinas (TOLLEFEN SE, KORNEFELD R., 1983) .\nA Sambucus nigra agglutinin (SNA) \u00e9 uma lectina obtida da \u00e1rvore sambucus nigra, tem especificidade de liga\u00e7\u00e3o pela sequ\u00eancia sacar\u00eddica NeuAc (a2,6) Gal/GalNAc, ou seja reconhece res\u00edduos de \u00e1cido si\u00e1lico na posi\u00e7\u00e3o a2,6 (L\u00d3PES-MORALES et al., 2010).\n2.5.1\tAplica\u00e7\u00f5es\nAs lectinas v\u00eam se mostrando como preciosa ferramenta nas pesquisas bioqu\u00edmicas e biom\u00e9dicas, devido a sua estabilidade qu\u00edmica, f\u00e1cil utiliza\u00e7\u00e3o e sua alta especificidade no reconhecimento de carboidratos distintos, associada a grande disponibilidade na natureza, sendo otimizadas em diversas aplica\u00e7\u00f5es biol\u00f3gicas (SAMES et al, 2001).\n47\nEssa caracter\u00edstica das lectinas em reconhecer carboidratos de superf\u00edcie de c\u00e9lulas tumorais, tem refor\u00e7ado o uso dessas como mol\u00e9culas transportadoras que podem ser conjugados com as drogas quimioter\u00e1picas e entregar os agentes anti-c\u00e2ncer diretamente no local da doen\u00e7a, al\u00e9m disso, como algumas lectinas s\u00e3o mitog\u00eanicas, ela pode potencializar a efic\u00e1cia da droga em sinergia (OPPENHEIMER; ALVAREZ; NNOLI, 2008).\nAs lectinas tamb\u00e9m tem sido utilizadas em outras aplica\u00e7\u00f5es, como atividade antimicrobiana, inibindo a crescimento de fungos (FREIRE, 2002), identifica\u00e7\u00e3o de microorganismo (COBO, et al, 2004) atividade inseticida (MACEDO, 2007), isolamento enzim\u00e1tico (LIMA, 1997).\nA capacidade das lectinas em reconhecer e ligar-se a glicanos espec\u00edficos, associado \u00e0 mudan\u00e7a no perfil de express\u00e3o de carboidratos de superf\u00edcie nas c\u00e9lulas tumorais, permite que as lectinas sejam utilizadas na caracteriza\u00e7\u00e3o e diferencia\u00e7\u00e3o de tecidos normais e transformados, sendo uma t\u00e9cnica sens\u00edvel, est\u00e1vel e de f\u00e1cil manipula\u00e7\u00e3o, contribuindo com informa\u00e7\u00f5es sobre o desenvolvimento, est\u00e1gios de diferencia\u00e7\u00e3o, grau de malignidade e potencial do tecido em desenvolver met\u00e1stase a partir do estabelecimento de perfil de carboidratos do tecido estudado.\nA revela\u00e7\u00e3o do reconhecimento do perfil de glicosila\u00e7\u00e3o tecidual atrav\u00e9s de lectinas tem sido realizada utilizando v\u00e1rios tipos de subst\u00e2ncias reveladoras, tais como os reveladores crom\u00f3genos cujas lectinas est\u00e3o conjugadas a peroxidase ou biotina, as quais foram utilizadas na investiga\u00e7\u00e3o de carcinoma ductal infiltrante (BELTR\u00c3O et al., 1998), meningioma (BELTR\u00c3O, et al., 2003), c\u00e2ncer de pele (MELO-J\u00daNIOR, et\n48\nal., 2006), colite ulcerativa (MELO-J\u00daNIOR et al, 2004), carcinoma mucoepiderm\u00f3ide de gl\u00e2ndula par\u00f3tida (SOBRAL, et al, 2010), estudo de les\u00f5es granulomatosas ( MELO-J\u00daNIOR, et al., 2008), mucosa g\u00e1strica com e sem H. pilory (MELO-J\u00daNIOR, et al., 2008), altera\u00e7\u00f5es no sistema nervoso central (NISHIMURA, et al., 2000) e neoplasias prost\u00e1ticas (ARENAS, et al, 1999), (LIMA et al., 2010), os reveladores fluorescentes como isotiocionato de fluoresce\u00edna utilizados em marca\u00e7\u00f5es em mucosa g\u00e1strica (MELO-J\u00daNIOR, et al, 2008) e quantum dots utilizados em fibroadenoma mam\u00e1rio (SANTOS et al, 2006) e por fim, os reveladores quimiluminescentes, como \u00e9ster de acridina, utilizado em tumores mam\u00e1rios como fibroadenoma e carcinoma ductal infiltrante (CAMPOS et al, 2006; BRUSTEIN et al, 2011)\n2.6\tQuimiluminesc\u00eancia\nA luminesc\u00eancia foi definida depois da descoberta do el\u00e9tron e da estrutura do \u00e1tomo, como sendo um processo no qual mol\u00e9culas ou \u00e1tomos excitados liberam o excesso de energia na forma de luz, proveniente de fonte biol\u00f3gica ou qu\u00edmica (VAN DYKE, 1988). A denomina\u00e7\u00e3o desses fen\u00f4menos luminescentes depende da fonte de energia respons\u00e1vel pela produ\u00e7\u00e3o do estado excitado, de modo que, se a fonte de energia for proveniente de uma rea\u00e7\u00e3o qu\u00edmica, esse fen\u00f4meno luminescente ser\u00e1 denominado quimiluminesc\u00eancia (CAMPBELL et al., 1985).\nOs primeiros relatos a cerca do fen\u00f4meno quimiluminescente foram descritos em 1877, quando Radziszewski sintetizou a lofina e observou que a mesma emitia luz verde ao reagir com o oxig\u00eanio na presen\u00e7a de uma base forte, e em 1887, quando Eder sintetizou o pirogalol. No entanto, a defini\u00e7\u00e3o do termo quimiluminesc\u00eancia foi descrito\n49\nA quimiluminesc\u00eancia \u00e9 a emiss\u00e3o de radia\u00e7\u00e3o eletromagn\u00e9tica (ultravioleta ou infravermelho) que \u00e9 observada quando o produto excitado vibronicamente a partir de uma rea\u00e7\u00e3o qu\u00edmica exerg\u00f4nica relaxa ao seu estado fundamental emitindo luz (WEEKS et al.,1992). Essa rea\u00e7\u00e3o qu\u00edmica \u00e9 capaz de produzir energia em quantidade suficiente para induzir a transi\u00e7\u00e3o de um el\u00e9tron de seu estado fundamental para um estado eletronicamente excitado, de modo que, o retorno desse el\u00e9tron para o estado inicial resulta na emiss\u00e3o de um f\u00f3ton (DODEIGNE; THUNUS; LEJEUNE, 2000).\nSubst\u00e2ncias quimioluminescentes podem ser detectadas na faixa de fentomoles ou atomoles (10- a 10- ) e abaixo de tipomoles (10- mol), com sensibilidade superior aos ensaios espectrofom\u00e9tricos (10-6 a 10-12) e fluorim\u00e9tricos (10-9 a 10-12 mol) (CAMPBELL et al.,1985). V\u00e1rios compostos org\u00e2nicos exibem quimiluminesc\u00eancia em condi\u00e7\u00f5es apropriadas, dentre os quais destacam-se o luminol, isoluminol e \u00e9ster de acridina ou seus derivados como marcadores utilizados em imunoensaios quimiluminescentes (RODA et al., 2000).\nEmbora o luminol tenha sido um dos primeiros compostos a ser descritos juntamente com o isoluminol e seus derivados, como marcadores de prote\u00ednas, eles apresentam desvantagens a serem consideradas, como a diminui\u00e7\u00e3o do quantum de luz quando acoplado \u00e0s prote\u00ednas e o requerimento de um catalisador na rea\u00e7\u00e3o, o que aumenta o \u201cbackground\u201d, reduzindo a sensibilidade da t\u00e9cnica (STUART; WEEK, 1985).\n50\nDiferente do luminol e isoluminol, os esteres de acridina possuem o seu mecanismo de a\u00e7\u00e3o totalmente esclarecido em condi\u00e7\u00e3o aquosa, de modo que a rea\u00e7\u00e3o quimiluminescente do \u00e9ster de acridina, observada na figura 7, \u00e9 realizada em solu\u00e7\u00e3o alcalina de per\u00f3xido de hidrog\u00eanio, o qual \u00e9 dissociado para formar sua base conjugada, o \u00e2nion hidroxiperoxil (HO2'), que ataca a estrutura do anel da acridina clivando m\u00faltiplas liga\u00e7\u00f5es, resultando em um rearranjo intermolecular formando o intermedi\u00e1rio dioxetano, e a sua decomposi\u00e7\u00e3o resulta na s\u00edntese de uma mol\u00e9cula excitada, a N-metilacridona, que retorna a seu estado energ\u00e9tico basal com emiss\u00e3o de luz a cerca de 430nm, a qual \u00e9 registrada por detectores de f\u00f3tons, lumin\u00f4metros (GARCIA-CAMPA\u00d1A et al,2003).\nFigura 7: Mecanismo quimiluminescente do \u00e9ster de Acridina. Fonte: WOODHEAD e\nWEEKS, 1985.\n51\ndevido \u00e0 sua curta meia vida, ao perigo potencial \u00e0 sa\u00fade e aos problemas quanto aos dejetos gerados (WEEKS et al.,1986). Sendo considerado um eficaz marcador para biomacromol\u00e9culas recebeu um grande interesse como base para o desenvolvimento de ensaios quimioluminescentes de alta performance usando mol\u00e9culas marcadas com essa subst\u00e2ncia (YANG et al., 2002)\nA aplica\u00e7\u00e3o dos \u00e9steres de acridina em imunoensaios quimioluminecentes foi realizada pela primeira vez por Weeks et al.,1983, na prepara\u00e7\u00e3o de anticorpos monoou policlonal marcado contra a alfa 1- fetoproteina, onde foi observado que o marcador reagia sob condi\u00e7\u00f5es brandas com aminas alif\u00e1ticas prim\u00e1rias e secund\u00e1rias, sendo portanto capaz de marcar prote\u00ednas (Figura 8) e al\u00e9m disso foi demonstrado que este composto tinha alta sensibilidade de detec\u00e7\u00e3o, igual ou superior ao I .\nFigura 8: Rea\u00e7\u00e3o de conjuga\u00e7\u00e3o da prote\u00edna (NH2 - R) ao \u00c9ster de Acridina N-\nhidroxisuccinimida. Fonte: GARCIA-CAMPA\u00d1A et al., 2003.\n52\ntanto na rotina cl\u00ednica quanto na pesquisa cl\u00ednica, isso se deve aos benef\u00edcios que incluem alta sensibilidade com limites de detec\u00e7\u00e3o ultrassens\u00edvel (attomole-zeptomole), sendo capazes de detectar com precis\u00e3o, em concentra\u00e7\u00f5es muito baixas, enzimas, esp\u00e9cies reativas, prote\u00ednas e \u00e1cidos n\u00facleicos, entre outros compostos de interesse biol\u00f3gico, seletividade, desenvolvimento de ensaios r\u00e1pidos e uma ampla gama de aplica\u00e7\u00f5es anal\u00edtica (KRICKA, 2003).\nEntre os v\u00e1rios marcadores quimiluminescentes, os \u00e9steres de acridina s\u00e3o particularmente atraentes porque t\u00eam altos rendimentos qu\u00e2nticos, com limites de detec\u00e7\u00e3o na faixa de atomoles, exibem emiss\u00e3o r\u00e1pida de luz, possui um pequeno tamanho que permite protocolos de marca\u00e7\u00e3o simples para prote\u00ednas e \u00e1cidos nucl\u00e9icos, s\u00e3o sol\u00faveis em agua e est\u00e1veis contra hidr\u00f3lise (NATRAJAN et al., 2010) Baseados em tais propriedades, eles s\u00e3o usados em an\u00e1lise ambiental, testes bioqu\u00edmicos e imunol\u00f3gicos, ensaios de atividade enzim\u00e1tica e marca\u00e7\u00e3o de fragmentos de oligossacar\u00eddeos para quantificar bact\u00e9rias, v\u00edrus ou outros biomarcadores (XIAO-JING et al., 2009).\n53\n3\tJUSTIFICATIVA\nA identifica\u00e7\u00e3o de biomol\u00e9culas com potencial para serem biomarcadores que revele caracter\u00edsticas biol\u00f3gicas ou que seja capaz de predizer progn\u00f3stico em uma doen\u00e7a com comportamento heterog\u00eaneo como o c\u00e2ncer, \u00e9 alvo de investiga\u00e7\u00e3o na comunidade cient\u00edfica. Este estudo se postula a investigar o perfil de glicosila\u00e7\u00e3o em tecidos hiperpl\u00e1sico prost\u00e1tico e c\u00e2ncer de pr\u00f3stata utilizando sondas sintetizadas a partir da conjuga\u00e7\u00e3o de lectinas ao \u00e9ster de acridina. Prosseguindo essa investiga\u00e7\u00e3o buscaremos corroborar os resultados obtidos inicialmente, avaliando in vitro se os horm\u00f4nios esteroides, especialmente, estr\u00f3geno podem atuar regulando a express\u00e3o de glicosiltransferases em linhagens de c\u00e2ncer de pr\u00f3stata refrat\u00e1rio (DU-145 e PC-3), e como isso pode afetar a s\u00edntese de cadeias de glicanos alteradas no c\u00e2ncer de pr\u00f3stata, bem com se podem est\u00e1 atreladas a progress\u00e3o tumoral.\n54\n4\tOBJETIVOS\n4.1\tGeral\nInvestigar o perfil de express\u00e3o de res\u00edduos de carboidratos em tecidos prost\u00e1ticos humanos em condi\u00e7\u00f5es normais, hiperpl\u00e1sica (Hiperplasia Prost\u00e1tica Benigna) e neopl\u00e1sica (Adenocarcinoma Prost\u00e1tico) e investigar os efeitos do 17 P-estradiol frente aos aspectos glicobiol\u00f3gicos em c\u00e9lulas de c\u00e2ncer de pr\u00f3stata horm\u00f4nio refrat\u00e1rio (linhagens DU-145 e PC-3).\n4.4\tEspec\u00edficos\n\u2022\tDesenvolver os conjugados lectinas (Con A, PNA e UEA-I) \u00e9ster de acridina;\n\u2022\tMarcar os tecidos prost\u00e1ticos em condi\u00e7\u00f5es normais, hiperpl\u00e1sicas e neopl\u00e1sicas com os conjugados e quantificar por quimiluminesc\u00eancia os grupos;\n\u2022\tCorrelacionar a intensidade de emiss\u00e3o de f\u00f3tons (RLU) com as condi\u00e7\u00f5es neopl\u00e1sicas e sua subsequente express\u00e3o de res\u00edduos de carboidratos;\n\u2022\tAvaliar in vitro a express\u00e3o proteica da glicosiltransferase ST6GalNAc, os receptores de estr\u00f3genos subtipos a e P, em linhagens de c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1ria (DU-145 e PC-3) na presen\u00e7a de estradiol (10-6M) e estradiol (10-6M) + fulvestranto (10x10-6M);\n\u2022\tAvaliar a express\u00e3o de glicanos correspondentes em linhagens de c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1ria na presen\u00e7a de estradiol (10-6M) e estradiol (106M) + fulvestranto (10x10-6M);\n\u2022\tAvaliar a influ\u00eancia da glicosila\u00e7\u00e3o no comportamento celular, atrav\u00e9s de ensaio de migra\u00e7\u00e3o.\n55\n5\tREFER\u00caNCIAS BIBLIOGR\u00c1FICAS\nANOLIK, J.H.; KLINGE, C.R.; HILF, R.; BAMBARA, R.A. Cooperative binding of estrogen receptor to DNA depends on spacing of binding sites, flanking sequence, and ligand. Biochemistry. v.34, p.2511-2520, 1995.\nARAI, T.; FUJITA, K.; FUJIME, M.; IRIMURA, T. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. International journal of urology: official journal of the Japanese Urological Association. 12:654661, 2005.\nARENAS, M.I.; ROMO, E.; GASPAR, I.; BETHENCOURT, F.R.; SANCHEZ-CHAPADO, M.; FRAILE, B.; PANIAQUA, R. A lectin histochemistry comparative study in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Glicoconj J. v.16, p.375-382, 1999.\nAUDETTE, G.F.; VANDONSELAAR, M.; DELBAERE, L.T. The 2.2 A resolution structure of the O(H) blood-group-specific lectin I from Ulex europaeus. J Mol Biol, v.304, p.423-433, 2000.\nARMANDARI, I.; HAMID, A. R.; VERHAEGH, G.; SCHALKEN, J.; Intratumoral steroidogenesis in castration-resistant prostate cancer: A target for theraphy. Prostate Int. v. 2, p. 105-113, 2014.\nBEEKMAN, J.M.; WIJNHOLDS, J.; SCHIPPERS, I.J.; POT, W.; GRUBER, M.; AB, G. Regulatory elements and DNA-binding proteins mediating transcription from the chicken very-low-density apolipoprotein II gene. Nucleic Acids Res. v.19, p.5371-5377, 1991.\n56\nBELTR\u00c3O, E.I.C.; CABRAL, T.; FIGUEIREDO-SILVA, J.; COELHO, L.; CARVALHO JUNIOR, L.B. Infiltrating ductal carcinoma: a lectin histochemistry study. Anais da Faculdade de Medicina da Universidade Federal de Pernambuco, Recife, n.46, p.32-35, 2001.\nBELTR\u00c3O, E.I.C. MEDEIROS, P.L.; RODRIGUES O.G.; FIGUEIREDO-SILVA, J.; VALEN\u00c7A, M.M.; COELHO, L.C.; CARVALHO J\u00daNIOR, L.B. Parkia pendula lectin as histochemistry marker for meningothelial tumour. Eur J Histochem, n.47, p. 139-42, 2003.\nBJORNSTROM, L.; SJOBERG, M. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol, v. 19, p.833-842, 2005.\nBLOME, B.; VAN, S.C.; CALLEWAERT, N.; VAN, V. H. Alteration of protein glycosylation in liver diseases. J Hepatol, v.50, p. 592-603, 2009.\nBOLLIG, A.; MIKSICEK, R.J. An estrogen receptor-a splicing variant mediates both positive and negative effects on gene transcription. Mol. Endocrinol. v.14 p.634649, 2000.\nBOSLAND, M.C.; FORD, H.; HORTON, L. Induction at high incidence of ductal prostate adenocarcinoma in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethyltulbestrol. Carcinogenesis, v.16, p. 1311-17, 1995.\n57\nBRUSTEIN, V.P.; CAVALCANTI, C.L.B.; MELO-JUNIOR, M. R.; CORREIA, T.S.; BELTR\u00c3O, E. I. C.; CARVALHO-J\u00daNIOR, L. B. Chemiluminescent detection of carbohydrates in the tumoral breast diseases. Appl Biochem Biotechnol, 2011.\nBURNS-COX, N.L.; BASKETTER, V.; HUGGINS, B.; HOLMES, S. Randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. Int J Urol. v. 9, p. 431-434, 2002.\nCABRAL, M.G. Human dendritic cells contain cell surface sialyltransferase activity. Immunology Letters, v.131, p. 89-96, 2010.\nCAMPBELL, A.K., HALLET, M.B. e WEEKS, I. Chemiluminescent as na analytical tool in cell biology and medicine. Methods in Biochemical Analysis, v.31,p.317-416, 1985.\nCAMPBELL, C.T.; SAMPATHKUMAR, S.G.; YAREMA, K.J. Metalolic oligosaccharide engineering: perspectives, applications, and future directions. Mol BioSyst, v.3, p. 187-194, 2007.\nCAMPOS, L.M.; CAVALCANTI, C.L.L.; LIMA-FILHO, J.L.; CARVALHO-J\u00daNIOR, L.B.; BELTR\u00c3O, E.I. Acridinium Ester conjugated to lectin as chemiluminescent histochemistry marker. Biomarkers, n. 11, p. 480 - 484, 2006.\nCHADHA, M.K.; ASHRAF, U.; LAWRENCE, D.; TIAN, L.; LEVINE, E.; SILIMAN, C.; ESCOTT, P.; PAYNE, V.; TRUMP, D. L. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate. v. 68, p.1461-1466, 2008.\n58\nCAZET, A.; JULIEN, S.; BOBOWSKI. M.; KRZEWISKI-RECCHI, M. A.; HARDUIN-LEPERS, A.; GROUX-DEGROOTE, S.; DELANNOY, P. Consequences of the expression of sialylated antigens in breast cancer. Carbohydr. Res., v. 345, p. 1377-1383, 2010.\nCHAN F.L.; CHOI H. L.; HO S.M. Analysis of glycoconjugate patterns of normal and hormone-induced dysplasic noble rat prostates, and an androgenindependent noble rat prostate tumor, by lectin histochemistry and protein blotting. The Prostate. v. 46, p. 21-32, 2001.\nCOBO, E.R.; CAMPERO, C.M.; GIMENO, E.J.; BARBEITO, C.G. Lectin binding patterns and immunohistochemical antigen detection in the genitalia of Tritrichomonas foetus-infected heifers. J. Comp. Path, V.131, 127-134, 2004.\nCOLOMBEL M; SYMMANS, F.; GIL, S.; O'TOOLE, K. M.; CHOPIN, D.; BENSON, M.; OLSSON, C. A.; KORSMEYER, S.; BUTTYAN, R. Detection of the apoptosis-suppressing oncoprotein bc1 -2 in hormone-refractory human prostate cancers. Am J Pathol .v.143, p.390-400, 1993.\nDEHM, S.M.; TINDALL, D.J. Molecular regulation of androgen action in prostate cancer. Journal of Cellular Biochemistry, v. 99, p. 333-344, 2006.\nDERO, B.J.; KORACK, K.S. Estrogen receptors and human disease. J. Clin. Invest. v.116, p. 561-570, 2006.\n59\nEFSTATHIOU E.; TITUS, M.; TSAVACHIDOU, D.; TZELEPI, V.; WEN, S.;\nHOANG, A.; MOLINA, A.; CHIEFFO, N.; SMITH, L.A.; KARLOU, M.; TRONCOSO, P.; LOGOTHETIS, C.J. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. v.30, p. 637-643, 2012.\nELLEM, S.J.; SCHIMITT, J.F.; PEDERSEN, J.S.; FRYDENBERG, M.; RISBRIDGER, G.P. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab. v. 89, p.2431-2441, 2004.\nELLEM, S.J.; HONG, W.; POUTENEN, M.; RISBRIDGER, G.P. Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy, Am. J. Pathol. v.3, p.11871199, 2009.\nENMARK, E.; PELTO-HUKKO, M.; GRANDIEN, K.; LAGERCRANTZ, J.; LAGERCRANTZ, J.; FRIED, G.; NORDENSKJOID, M.; GUSTAFSSON, J.A. Human estrogen receptor b-gene structure, chromosomal localization, and expression pattern, J. Clin. Endocrinol. Metab, v.82 p.4258-4265, 1997.\nEVANS, R.M. The steroid and thyroid hormone receptor superfamily, Science, v. 240 889-895, 1988.\nFELDMAN, B.J.; FELDMAN, D. The development of androgen independent prostate cancer. Nature Reviews Cancer, v. 1, p. 34-45, 2001.\nFREIRE, M.G.M.; GOMES, V.M.; CORSINI, R.E.; MACHADO, O. L.T.; DE\n60\nFUSTER, M.M.; ASKO, J.D. Sweet and sour of cancer: glicans as novel therapeutic targets. Nature, v. 5, p. 526-542, 2005.\nFUJIMURA, T.; TAKAHASHI, S.; URANO, T.; OGAWA, S.; OUCHI, Y.;\nKITAMURA, T.; MURAMATSU, M.; INOUE, S. Differential expression of estrogen receptor p (ERP) and its C-terminal truncated splice variant ERPcx as prognostic predictors in human prostatic cancer. Biochem. Biophys. Res. Commun. v. 289, p. 692-699, 2001.\nFUKUDA, M.; BAO, X. Seeing cellular sialidase transform sugars. Nature Chemical Biology, v.4, p. 721-722, 2008.\nGABIUS, H.J. Glycohistochemistry: The why and how of detection and localization of endogenous lectins. Anat Histol Embryol, v.30, p. 3-31, 2001.\nGABOR, F.; KLAUSEGGER, U. WITRTH, M. The Interaction between wheat grerm agglutimin and other plant lectins With prostate cancer cells DU-145. International Journal of Pharmaceutics, n. 221, p.35-47, 2001.\nGAO, J.Q.; OKADA, N.; MAYUMI, T.; NAKAGAWA, S. Immune cell recruitment and cell-based sstem for cancer therapy. Pharmaceutical Research, v.25, p.752-768, 2008.\nGAO, Y. Glycosylation potential of human prostate cancer cell lines. Glycoconj J. v. 29, p. 525-537, 2012.\nGARBAR, C., MASEAUX, C., WESPES, E. Expression of MUC1 and sialil-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and maligant prostatic glands:a preliminar study. Anal. Quant. Cytol.Histol. v.30 , p.71-77, 2008.\n61\nGARCIA-CAMPA\u00d1A, A.M. Derivatization of biomol\u00e9culas for chemiluminescent detection in capillary electrophoresis. Journal of Chromatography B, v. 793, p. 49-74, 2003.\nGASENT BLESA, J.M.; CANDEL, V.A.; MARCO, MV.G.; GINER-BOSCH, V.; PULLA, M. P.; CANALES, J.B.L.; Experience with fulvestrant acetate in castration-resistant prostate cancer patients. Ann Oncol. v. 21, p. 1131-1132, 2010.\nGHAZARIAN, H.; IDONI, B.; OPPENHEIMER, S. B. A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem., v. 113, p. 236-254, 2011.\nGRONBERG, H. Prostate cancer epidemiology. Lancet. v.361, p. 859-864, 2009.\nGROSS, H.J.; MERLING, A.; MOLDENHAUER, G.; SCHWARTZ-ALBIEZ, R. Ecto-sialyltransferase of human B lymphocytes reconstitutes differentiation markers in the presence of exogenous CMP-N-Acetyl neuraminic acid. Blood, v.87, p.51135126, 1996.\nGRUBER, C.J.; GRUBER, D.M.; GRUBER, I.M.; WIESER, F.; HUBER, J.C. Anatomy of the estrogen response element. Trends in Endocrinologyand Metabolism. V. 15, p.73-78, 2004.\n62\nHARDUIN-LEPERS, A.; VALLEJO-RUIZ, V.; KRZEWINSKI-RECCHI, M.A.; SAMYN-PETIT, B.; JULIEN, S.; DELANNOY, P. The human sialyltransferase family. Biochimie, v.83, p.727-737, 2001.\nHARKONEN P.L.; MAKELA S.I. Role of estrogens in development of prostate cancer. J. Steroid Biochem. Mol. Biol. v. 92, p. 297-305, 2004.\nHARRIS W.P.; MOSTAGHEL, E.A.; NELSON, P.S.; MONTGOMERY, B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract Urol. v. 6, p. 76-85, 2009.\nHASHMAN, L., TAPLIN, M.E. Abiraterone Acetate: Taregeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer. Adv. Ther. v.30, p. 727-747, 2013.\nHATANO K.; MIYAMOTO, Y.; MORI, M.; NIMURA, K.; NAKAI, Y.; NONOMURA, N.; KANEDA, Y. Androgen- regulated transcriptional control of sialyltransferases in prostate cancer cells. PloS ONE. v.7, p. e 31234, 2012.\nHEIDLASK, J.E.; WILLIAMS, K.W.E.; WHITESIDES, G.M. Nucleoside phosphate sugars: syntheses on practical scales for use as reagents in the enzymatic preparation of oligosaccharides and glycoconjugates. Accounts of Chemical Research. v.25, p.307-314, 1992.\nHELDRING, N.; PIKE, A.; ANDERSSON, S.; MATTHEWS, J. Estrogen receptors: How do they signal and what are their targets. Physiol.Rev., v. 87, p. 905931, 2007.\n63\nHO, S.M., LEUNG, Y.K., CHUNG, I. Estrogen and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann.N.Y.Acad. Sci. v.1089, p. 177-193, 2006.\nHO, S.M., ROY, D. Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. Cancer Lett. v.84, p.155-162, 1994.\nHO, C.K.M.; NANDA, J.; CHAPMAN, K.E.; HABIB, F.K. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. Journal of Endocrinology, v.197, p.483-491, 2008.\nHO, S.M. et al. Estrogens and Prostate Cancer: Etiology, Mediators, Prevention, and Management. Endocrinol Metab Clin N Am, v.40,p. 591-614, 2011.\nHOBISCH A.; CULIG, Z.; RADMAYR, C.; BARTSCH, G.; KLOCKER, H.; HITTMAIR, A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate. v.28, p.129-135, 1996.\nHUGGINS C, HODGES CV. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastic carcinoma of the prostate. Cancer Res. v.1, p. 294-297, 1941.\nIMAMOV, O., SHIM, G.J., WARNER, M. Estrogen receptor beta in health and disease. Biol. Rep. v. 73, p, 866-871, 2005.\nINGBER, D.E. Can cancer be reserved by engineering the tumor. Sem. Cancer Biol. V.18, p.356-364, 2008.\n64\nJANKOVIC, M.; KOSANONI, M.; MILUTINOVI, B. Glycans as a target in the detection of reproductive tract cancers. JMB, v.27 p. 17-29, 2008.\nJULIEN, S.; LAGADEC, C.; KRZEWINSKI-RECCHI, M.A.; COURTAND, G.; LE BOURHIS, X.; DELANNOY, P. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Research and Treatment, v.90, p.77-84, 2005.\nKHABAZ, M.N.; MCCLURE, J.; MCCLURE, S.; STODDART, R.W.; Glycophenotype of prostatic carcinomas. Folia Histochem Cytobiol. p.48, v. 637-645 2010.\nKARANTANOS T.; COM P.G.; THOMPSON T.C. Prostate cancer progression after androgen deprivation therapy. Mechanisms of castrate tesistance and novel therapeutic approaches. Oncogene. p.1-11, 2003.\nKIM S.O.; CHO, H.J.; KANG, J.Y.; KANG, H.K.; YOO, T.K. Inhibition of androgen receptor expression with small interfering RNA enhances cancer cell apoptosis by suppressing survival factors in androgen insensitive, late stage LNCaP cells. The Scientific World Journal, 2013.\nKIM, G.E.; BAE, H.I.; PARK, H.U.; KUAN, S.F.; CRAWLEY, S.C.; HO, J.J.; KIM, Y.S. Aberrant expression. Of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasm of the pancreas. Gastroenterology. v.123, p. 10521060, 2002.\n65\nKOIVISTO P.; KONONEN, J.; PALMBERG, C.; TAMMELA, T.; HYYTINEN, E.; ISOLA, J.; TRAPMAN, J.; CLEUTJENS, K.; NOORDSIJ, A.; VISAKORPI, T.; KALLIONIEMI, O.P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. v.57, p.314 -9, 1997.\nKOPF, E., ZHARHARY, D. Antibodys arrays - Na emerging tool in c\u00e2ncer proteomics. Int JBiochem &amp; Cell Biol. V. 39, p. 1305-1317, 2007.\nKOONG, L.Y., WATSON, C.S. DIrect estradiol and diethylstilbestrol actions on early-versus-late stage prostate cells cancer. The prostate. V. 75, p. 1580-1603, 2014.\nKRICKA, L. J. Clinical applications of chemiluminescence. Anal Chim Acta, v. 500, p. 279- 286, 2003.\nLAMB, D. J.; WEIGEL, N. L.; MARCELL, M. Androgen receptors and their biology. Vitamins and Hormones, v. 62, p. 199-230, 2001.\nLEUNG, Y.K.; MAK, P.; HASSAN, S.; HO, S.M. Estrogen receptor ER-P isoforms: a key to undestanding ER-P signaling. Proc. Natl. Acad.Sci. v.103, p.1316213167, 2006.\nLEUNG, Y.K.; CHAN, Q.K.Y.; NG, C.F.; MA, F.M.T.; TSE, H.M.; TO, K.F.; MARANCHIE, J.; HO, S.M.; LAU, K.M. Hsa-miRNA-765 as a Key Mediator for Inhibiting Growth,Migration and Invasion in Fulvestrant-Treated Prostate Cancer. Plos One. v.9, p. e98037, 2014.\nLI, J.; YEN, C.; LIAW, D.; PODSYPANINA, K.; BOSE, S.; WANG, S.I.; PUC, J.; MLIARESIS, C.; RODGERS, L.; McCOMBIE, R.; BIGNER, S.H.; GIOVANELLA, B.C.; ITTMANN, M.; TYCKO, B.; HIBSHOOSH, H.; WIGLER, M.H,. PARSONS, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Wash DC). v. 275, p.1943-1947, 1997\n66\nLIMA A.L.R.; CAVALCANTI, C.C.B.; SILVA, M.C.C.; PAIVA, P.M.G.; COELHO, L.C.B.B.; BELTR\u00c3O, E.I.C.; CORREIA, M.T.S. Histochemical evaluation of human prostatic tissues with Cratylia mollis seed lectin. J Biomed Biotechnol 2010: 1-6, 2010.\nLIMA, L.F. Sweet and Sour: the impact off differential glycosylation in cancer cells undergoing epithelias-mesenchymal transition. Frontiers in oncology. v. 4, p. 110, 2014.\nL\u00d3PES-MORALES, D.; VELAZQUEZ-MARQUEZ, N.; VALENZUELA, O.; SANTOS-LOPEZ, G.; REYES-LEYVA, J.; VALLEJO-RUIZ, V. Increment de la transcripci\u00f3n de sialiltransferases en muestras de c\u00e9rvix con neoplasia intraepitelial cervical. Invest Clin. v. 50, p. 45-53, 2010.\nLOUREIRO, L.R.; CARRASCAL, M.A.; BARBAS, A.; RAMALHO, J.S.; NOVO, C.; DELANNOY, P.; VIDEIRA, P.A. Challenges in antibody development against Tn and Sialyl-Tn antigens. Biomolecules. v.5, p.1783-1809, 2015.\nLUNARDI A. A co-clinical approach identifies mechanisms and potencial therapies for androgen deprivation resistance in prostate cancer. Nat. Genet. v. 45, p. 747-755, 2013.\nMARCELLI M.; ITTMANN, M.; MARIANI, S.; SUTHERLAND, R.; NIGAM, R.; MURTHY, L.; ZHAO, Y.; DICONCINI, D.; UXEDDU, E.; ESEN, A.; EASTHAM, J.; WEIGEL, N.L.; LAMB, D. J. Androgen receptor mutations in prostate cancer. Cancer Res. v. 60, p.944-949, 2000.\n67\nB.\t; HARDUIN-LEPERS, A.; ALMEIDA, R.; SILVA, F.; MORAIS, V.; COSTA, J.; KIHLBERG, J.; CLAUSEN, H.; REIS, C.A. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Research, v.64, p.7050-7057, 2004.\nMARCOS, N.T.; BENNETT E.P.; GOMES, J.; MAGALH\u00c3ES, A.; GOMES,\nC.\t; DAVID, L.; DAR, I.; JEANNEAU, C.; DEFREES, S.; KRUSTRUP, D.; VOGEL, L.K.; KURE, E.H.; BURCHELL, J.; TAYLOR-PAPADIMITRIOU, J.; CLAUSEN, H.; MANDEL, U.; REIS, C.A. ST6GalNAc I controls expression. Of sialyl-tn antigen in gastrointestinal tissues. Front. Biosci, v.3, p. 1443-1455, 2011.\nMARINO, M.; GALLUZO, P.; ASCENZI, P. Estrogen signaling multiple patways to impact gene transcription. Current Genomics. v.7, p. 497-508, 2006.\nMARQUES R.B.; DITS N.F.; ERKENS-SCHULZE, S.; WEERDEN, W.M.; JENSTER, G. Bypass mechanisms of the androgen receptor pathway in therapyresistant prostate cancer cell models. PloS One. 5: 1-16, 2010.\nMEANY, D. L.; CHAN, D. W. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clinical Proteomics. v. 8, p. 7, 2011.\nMEDVEDOVA, L.; KNOPP, J.; FARKAS, R. Steroid regulation of terminal protein glycosiltransferase genes: Molecular and functional homologies within sialyltransferase and fucosyltransferase families. Endocrine Regulation. v.37, p.203210, 2003.\nMELO-J\u00daNIOR, M. R.; TELLES, A.M.S.; ALBUQUERQUE, F.E.B.; PONTES-FILHO, N.T.; CARVALHO J\u00daNIOR, L.B.; BELTR\u00c3O, E.I.C.Altered lectin-binding sites in normal colon and ulcerative colitis. J Bras Patol Med Lab, v. 40, p. 123-125, 2004.\n68\nMELO-J\u00daNIOR, M.R.; CAVALCANTI, C.L.B.; PONTES-FILHO, N.T.; CARVALHO-J\u00daNIOR, L.B.; BELTR\u00c3O, E.I.C. Digital image analysis of skin neoplasms evaluated by lectin histochemistry: potencial marker to biochemical alterations and tumor differential diagnosis. J Bras Patol Med Lab, v. 42, p. 455-560, 2006.\nMELO-J\u00daNIOR, M.R.; CAVALCANTI, C.L.B.; PONTES-FILHO, N.T.; CARVALHO-J\u00daNIOR, L.B.; BELTR\u00c3O, E.I.C. Carbohydrates detection in the hepatic egg-granuloma system using lectin histochemistry. Int J Morphol, v. 26, p. 967-972, 2008.\nMELO-J\u00daNIOR, M.R.; CAVALCANTI, C.L.B.; PONTES-FILHO, N.T.; CARVALHO-J\u00daNIOR, L.B.; BELTR\u00c3O, E.I.C. Lectin staining patterns in human gastric mucosae with and without exposure to Helicobacter pylori. Brazilian Journal of Microbiology, v. 39, p. 238-240, 2008.\nMENASCE, L.P.; WHITE, G.R.M.; HARRISON, C.J.; BOYLE, J.M.\nLocalization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique, Genomics, v. 17, p. 263-265, 1993.\nMODY, R.; JOSHI, S.; CHANEY, W. Use of lectins as diagnostic and therapeutic tools for c\u00e2ncer. J Pharmacol Toxicol Methods, v. 33, p. 1-10, 1995.\nMONTGOMERY, R.B., MOSTAGHEL, E.A., VESSELA, R..; HESS, D.L., KARLHORN, T.F.; HIGANO, C.S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. v. 68, p. 4474-4454, 2008.\n69\nMOSTAGEL, E.A., SOLOMON, K.R., PELTON, K., FREEMAN, M.R., MONTGOMERY, R.B. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLOS ONE. v.7, p. e30062, 2012.\nMULHOLLAND D.J.; DEDHAR, S.; WU, H.; NELSON, C.C. PTEN and GSK3b: key regulators of progression to androgen-independent prostate cancer. Oncogene 25, 329-337, 2006.\nMURPHY, L.C., WANG, M., COUTT, A., DOTZLAW, H. Novel mutations in the estrogen receptor messenger RNA in human breast cancers. J. Clin. Endocrinol. Metab. v.81, p.1420-1427, 1996.\nNAKAJIMA, Y. Estrogen Regulates Tumor Growth Through a Nonclassical Pathway that Includes the Transcription Factors ERb and KLF5. Science Signaling, v.4, p. 1-12, 2011.\nNANGIA-MAKKER, P.; CONKLIN, J.; HOGAN, V.; RAZ, A. Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents. Trends in Molecular Medicine, v. 8, p. 187-192, 2002.\nNELSON, C.C.; HENDY, S.C.; SHUKIN, R.J.; CHENG, H.; BRUCHOVSKY, N.; KOOP, B.F.; RENNIE, P.S. Determinants of DNA sequence specifity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. Mol. Endocrinol. v.13, p. 2090-2107, 1999.\nNIKHIL K.; SHARAN, S.; CHAKRABORTY, A.; ROY, P. Pterostilbene-Isothiocyanate conjugate suppresses growth of prostate cancer cells irrespective of androgen receptor status. Plos one. e93335, 2014.\n70\nOGAWA, S.; INOUE, S.; WATANABE, T.; HIROI, H.; ORIMO, A.; HOSOI, T.; OUCHI, Y.; MURAMATSU, M. The complete primary structure of human estrogen receptor P (ER P) and its heterodimerization with ER a in vivo and in vitro, Biochem. Biophys. Res. Commun. V. 243, p.122-126, 1998.\nOHTSUBO, K.; MARTH, J.D. Glycosylation in cellular mechanisms of health and disease. Cell, v.126, p.855-867, 2006.\nOPPENHEIMER, S. B.; ALVAREZ, M.; NNOLI, J. Carbohydrate-based experimental therapeutics for c\u00e2ncer, HIV/AIDS and other disease. Acta Histochemica, v. 110, p. 6-13, 2008.\nPAULE, B.; TERRY, S.; KHEUANG, L.; SOYEUX, P.; VACHEROT, F.; DE LA TAILLE, A. The NF-_B/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol. 25:477-489, 2007.\nPETRESCU, A.J. Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology v.14, p.103-114, 2004.\nPETROSSIAN, K.; BANNER, L.R.; OPPENHEIMER, S. B. Lectins binding and effects in culture on human cancer and non-cancer cell lines: Examination of issues of interest in drug design strategies. Acta Histochemica, v. 109, p. 491-500, 2007.\n71\nPIKE, A.C.W.; BROZOWSKI, A.M.; HUBBARD, R.E. A structural biologist\u2019s view of the oestrogen receptor, J. Steroid Biochem. Mol. Biol. v.74 p.261-268, 2000.\nPINKJ.J. A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucl. Acids Res. v. 24 p. 962-969, 1996.\nPRAVENOTTI, A.; MORNATI, O.; MORNATI, P. Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU-145 cells. Mol.Cell.Endocrinol. v.263, p.46-54, 2007.\nPRICE J.R.; BUTLER, C.A.; WEBB, P.; UHT, R.; KUSHNER, P.; HANDA, R.J. A splice variant of estrogen receptor p missing exon 3 displays altered subnuclear localization and capacity for transcriptional activation. Endocrinology, v.142, p. 20392049, 2001.\nPRINS G. S.; Korach K. S. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids v.73, p. 233-244, 2008.\nREIS, C.A. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol, v.63, p.322-29, 2010.\nRICKE, W.A.; McPHERSON, S.J.; BIANCO, J.J.; CUNHA, G.R.; WANG, Y.; RISBRIDGER, G.P. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling, FASEB J. v. 5 p.1512-1520, 2008.\nRISBRIDGER, G.; WANG, H.; YOUNG, P.; KURITA, T.; WONG, Y.Z.;\nLUBAHN, D.; GUSTAFSSON, J.A.; CUNHA, G. Evidence that epithelial and\n72\nmesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium, Dev. Biol.\nv. 2, p. 432-442, 2001.\nRISBRIDGER G.P.; BIANCO J.J.; ELLEM S.J.; MCPHERSON S. J. Oestrogens and prostate cancer. Endocrine-Related Cancer. v. 10, p. 187-191, 2003.\nROHRMANN, S. Serum Estrogen, But Not Testosterone, Levels Differ between Black and White Men in a Nationally Representative Sample of Americans. The Journal of Clinical Endocrinology &amp; Metabolism. V. 92, p. 2519-2525, 2007.\nSADI, M. V.; WALSH, P. C.; BARRACK, E. R. Immunohistochemical study of androgen receptors in metastatic prostate cancer: comparison of receptor content and response to hormonal therapy. Cancer, v. 67, p. 3057-3064, 1991.\nSAMES, K.H.; SCHUMACHER, U.; HALATA, Z.; VAN DAMME, E.J.M.; PEUMANS, W.J.; ASMUS, B.; MOLL, R.; MOLL, I. Proteoglycan and lectin histochemistry of neuroendocrine carcinomas of the ski. FASEB Journal, v.15, p. 1072, 2001.\nSANTOS, B.S.; FARIAS, P.M.A.; MENEZES, F.D.; FERREIRA, R.C.; J\u00daNIOR, S.A.; FIGUEIREDO, R.C.B.Q.; CARVALHO-JUNIOR, L.B.; BELTR\u00c3O, E.I.C. Cds-Cd (OH)2 core shell quantum dots functionalized with Concanavalin A for recognition of mammary tumors. Phys Stat Sol, v. 3, p. 4017-4022, 2006.\nSANTOS, V.C.T., MILITO, M.A., MARCHIORI E. O papel atual da ultra-sonografia transretal da pr\u00f3stata na detec\u00e7\u00e3o precoce do c\u00e2ncer prost\u00e1tico. Radiol. Bras. v.39, n.3, 2006.\n73\nSEWELL, R. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumorassociated sialyl-Tn O-glycan in human breast cancer. J. Biol. Chem. V.281, p.3586-3594, 2006.\nSHARON, N.; LIS, H. Lectins: carbohydrate-specific protein that mediate cellular recognition. Chem Rev, v.98, p.637-674, 1998.\nSHARON, N.; LIS, H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology, v. 14, p. 53-62, 2004\nSIMPSON, E.R.; DAVIS, S.R Minireview: aromatase and the regulation of estrogen biosynthesis- some new perspectives. Endocrinology, v. 142, p. 4589-4594, 2001.\nSINGH, A.P.; CHAUHAN, S.C.; BAFINA, S.; JOHANSSON S.L.; SMITH, L.M.; MONIAUX, N.; LIN, M.F.; BATRA, S.K. Aberrant expression of transmembrane mucins, MUC1 e MUC4, in human prostate carcinomas. The Prostate. v.66, p. 421-429, 2006.\nSINGH P.B.; MATANHELIA S.S. MARTIN F.L. A potential paradox in prostate adenocarcinoma progression: Oestrogen as the initiating driver. Eur. J. Cancer v.44, p. 928-936, 2008.\n74\nSRINIVAS, V. R.; REDDY, G.B.; AHMAD, N.; SWAMINATYHAN, C.P.; MITRA, N.; SUROLIA, A. Legume lectin family, the \u2018natural mutants of the quaternary state', provide insights into the relationship between protein stability and oligomerization. Biochim Biophys. Acta 1527, 102 - 111. 2001.\nSTEINER M. S.; RAGHOW S. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J. Urol. v. 21, p. 31-36, 2003.\nTAPLIN, M. E.; BALK, S. P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence, Journal of Cellular Biochemistry, v. 91, no. 3, pp. 483- 490, 2004.\nTAYLOR, S. E.; MARTIN-HIRSCH, P; MARTIN, F. L. Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Letters, v. 288, p. 133-148, 2010.\nTREECK, O. Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. Mol. Cell. Endocrinol. v.264 p.50-60, 2007.\nTITUS, M.A., SCHELL, M.J., LIH, F.B., TOMER, K.B., MOHLER,J.L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. v. 11, p.4653-4657, 2005.\nVAN ELSSEN, C.H., FRINGS, P.W., BOT, F.J., VAN DE VIJER, K.K., HULS, M.B., MEEK, B., HUPPERETS, P., GERMERAAD, W.T., BOSS, G.M. Expression of aberrant glycosylated mucin-1 in ovarian cancer. Histopatology. v 57, p.597-606, 2010.\nVAVASSEUR, F. Synthesis of O-glycan core 3: Characterization of UDP-GlcNAc: GalNAc-R _3-N-acetyl- glucosaminyltransferase activity from colonic mucosal tissues and lack of the activity in human cancer cell lines. Glycobiology. v.5, p.351-357, 1995.\n75\nVERZE, P.; CAI, T.; LORENZETTI, S. The role of the prostate in male fertility, health and disease. Nature Review Urology, 2016.WIN H.Y.; DUNCAN M.A. Role of protein kinase C-iota in transformed non-malignant RWPE-1 cells and androgenindependent prostate carcinoma DU-145 cells. Cell Prolif. v.42, p.182-194, 2009.\nXIAO-JING, M. U.; SHANG-YOU, X.; JIAN-CHAO, W.;YAN-LEI, W.; ZHI-NING, X. Synthesis and spectroscopic properties of acridinium- 9- sulfonamides. Chin J Anal Chem, v.37, p. 970-974, 2009.\nYANG, M.; LIU, C.; HU, X.; HE, P.; FANG, Y. Electrochemiluminescence assay for the detection of acridinium esters. Anal\u00edtica et Chimica Acta, v.461, p.141146, 2002.\nWALTERING KK. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. v. 69, p.8141-9, 2009.\nWANG, H. X.; HG, T.B. Concurrent isolation of a Kunitz-type trypsin inhibitor with antifungal activity and a novel lectin from Pseudostellaria heterophylla roots. Biochem Biophys Commun, v. 342, p. 349-353,\t2006.\n76\nCAP\u00cdTULO 1\n77\nFator de Impacto: 1,891\nQualis Capes: B2\nEvaluation of glycophenotype in prostatic neoplasm by chemiluminescent assay\nL\u00facia Patr\u00edcia Bezerra Gomes Silva , Sinara M\u00f4nica Vitalino Almeida , , Luiza Rayanna Amorim Lima1, Carmelita de Lima Bezerra Cavalcanti1, Mariana Montenegro de Melo Lira , Maria da Paz Carvalho da Silva , Eduardo Isidoro Carneiro Beltr\u00e3o , Luiz Bezerra Carvalho J\u00fanior1\n1Departamento de Bioqu\u00edmica and Laborat\u00f3rio de Imunopatologia Keizo Asami (LIKA), Universidade Federal de Pernambuco, Cidade Universit\u00e1ria, 50030 Recife, PE, Brazil. 2Faculdade de Ci\u00eancias, Educa\u00e7\u00e3o e Tecnologia de Garanhuns (FACETEG), Universidade de Pernambuco (UPE), 50100 Garanhuns, PE, Brazil.\n3Departamento de Patologia e Hospital das Clinicas, Universidade Federal de Pernambuco, Cidade Universit\u00e1ria, 50030 Recife, PE, Brazil.\n78\nIrrtJOrt Effl =a:lto 2014;7(7|3>\u00abJ-3K>h\nOriginal Article\nEvaluation of glycophenotype in prostatic neoplasm by cli emi luminescent assay\nLucji Ftercia Secs\u2019a Lotik da Ci wL. 5 r.ana Mfinlin tftalinn da 41m*da'Luiza P J. anna Amar m do Lima:. Camal ta da L ma Bezera Cana cant'. Mar era M \u25a1 nterotro da Moto Lira3. Marta da Faz CarFaltw da Sha1. Ecl anc la rfcm Canwim Eeto\u00e1o', Luz Bederre do CarvalhoJun\u00edw1\n\u2018AdpadMoetita * Scq jt-Jw aid Laioradartb dn IflUMSprtoaiq^la fte\u00fcn JbailrlrtOM. UtihMJttHfc rrfera\u00ed df Fnmnm\u00f3MO. Ll\u00b1>i! LMwiWti, HfcwJfc-, flcr.\u2019um\u00edijco. EhkU Tfcsut\u00edMertoCfticla; Edoca^Ai \u25a0 Je C.i.~ rk Ji:i rHT\u00cdTTrj, \u00fcnAers\u00bffcde rt .Aenuw-iuca \u00edMAEJ Qvanhuns. Rvnamhuce. ErasJt 'ft^wtamenta * Ewtokj\u00e7J\u00fa f Macpriai Ir, chi\u00e9js LyAcrsIdacfc Fwtora' \u00fck rM.^^-h.ro. C\u00edw\u00edt? 1 v-.Mvs.wd .6c:*. Ema buce. 6w;l!\ntaaahHi Vzrc-h H, 2014. tacW Mto2.3,2D14:E&amp;zj lune 13.2014: Pudiste d lui? 1.21114\nAftur\u00ab. This *or* J rrnd ta \u00ed^alueto dne jf/cnfihirrdYdc In rnnral prasute, tantoa prorurtk hypcrpiKli iBFH; and pHHira iidmonrvdnr^u \u00a1PCn; lesnas tx e Eh\u00abnli.rrlnesMnt -werr. Corica.'hMto A iConAi, UUu ejo n if-jfi ARftWito lUEAIl and ,*%aiiuT rysihd.'-.^ ; P'UAi I \u00abfina wira oonjUBtoee tr&lt;nr.dd ri j\"i \u00abtar 1 Ik Uns AEj. Those EonluBflta rcmnlredcnpcoetonKOfinzedi&amp;rr.\u00edeisflEcnrbnh\u00ed\u00edatns.Tlss ucsdnidcs >MfBlmib8tod>*Mi lactins 4E. Tha i'.x-rrli j'i r<\u00fci.cri'.c- M d\u00eda Lteun ln\u00b1r-AE compio was nciruoea h reiatbn IlaJit unte (RU.1l Transhimcc flsr>j\u00ab \u00a10 cm3 by E un nf thiduinisi stawm rrurttlail \u25a0iirtfr.\u00fcT lower \u25a1 D ilucnse.-Tnennasn \u00a1EFH: 236,331 \u00b1 17.43fi; Fia: 235,520 1 12 3 56:) end \u00bfielftl 3irJMrfc lEiPt-L 2R,7r?4 t 2zL5T; F01. U6,72Et 1,204;\nston than norma flsr.jer. ]367,.r>ES t 43.5 M and 4M.2HS t 22,336, rnspncthnt/L Hcwffrtf. h lit er n.L1umsc tDcprasr.on .\u00absotMftBd to POi (251,113 t l^liBlin relrrtfe-. to rnnrel (2nO37E t 2113iHjnnri EHP !in!k.75R + 12,2641 tlsr.j\u00abi h was nhscrHndan oternsske aomasarg al the dtuos cf Hill to Inhlaitfon o' the Interacmr ten\u00bbeer tteuas end lactins 4E Laing rhei- SapeeHe cartotod atte. \u201che ruetnashlp terreen R.U 1 nd tissue nren shriwad a Enoar uirriutiwi tor ail locln 4E to tint trars.to'mrri Lteuns. Those resLttr, Indicaind test the used mrntind Is en nrttoent tool tor \u00a1ap\u00e9ate, ianiHi\u00abn and r.iiaThacino anal/iK ri priKtate \u00bfyocohenrr/pn.\nIQywcdLChartliriresennco. lactins, \\inohve rates. pro&amp;tattc uiroer, ten\u00edan prostate nvpcrpiDslD\nInrimducIlDn\nHotochBm airy boa been a powerflj tool in cancar dafnnato a rd many tec nniquoo hano noon rapomd in enter ta idorrify tneir parffnlntical nnlPCLlar aterstiona. Amont call d'lerentc-ton.'rlodiffomrrjatcn tna nl\u00fcoaaccnarido enm-poalonanrldtorjtaution in the cel atr^cefy-cnccri.n\u00a3atea a ender interativo a nd ya 0 [1]. Lactina howl nneri mee to cnararte'ize the car:e ce \u00a3ycDphenotypa.Thp root wr atojad vtojalicctinn of the brndtot bat.'ser. Inctn-cor-boh: d'ate in hintochnm atr/ to baaed c<i enzynwL porticulary. pernzdana. The cnn>en-Lorwi meth oda ard paranotere adaptad to the analynta in the niripey analyau am Leualy baaed on subject .e crrocedLFM [21. ttahoud beadveaolPtointrodLceapeci\u00f1cand ouantita-\nUve oroceduraa tc CM\u00abt ten rrc-r-nnlncjcal onalynu.\nto alt lab. htotochemintry chomiumirwocenca nan neon aropoaed \u25a0oallacto \u00a3 enigma an aanl to' hJmineacent cnruDund p-C|. Ctiam Lmi-macnr^ce hoa nnen hnn^n Id be a pri<or\"ul ofiolyt ca 'jsehn quo that exhib ta hiib oenoit v-1y with utia-Bona live de'jctcn lim to idbo-moie-epptnrote\u00ed, onlnct >ity. rtaialcpmenit of rapid CMton and a broad ranfie of analytical acrplicatonu [7],\n79\nCIteinilijrnih&amp;sserJtdeteca-Dh cf pr-DEtatic g \u00abopltef>otype\nF'cczncs pencar iatTB eecond moat frequent die\u00a3.Tnnpd c\u00e1ncer nnd dio Ined ni cauce \u25a1f c\u00e1ncer deubi in malee j9-]_TD date. tnn d a\u00a1-no: o nf PCa o tcced an terjrr cr: Btste-Bpo \u25a0 z fie nrrJ\u00edtHi |P3A) zaatn\u00a3. d \u00a3 tul \"ectn eaermi-nalien DfE) anc dofinad \u25a1? I* ctnln\u00edical flnan'irwition nf prootart\u00bb core needla b canina de\u00ednindtTB detrae af turnar m ai i \u00bfnano blTe Ole\u00e1cea >:orc [3], -o/- nver. tn c v a lc deaerrda \u25a1n ttio annivat. For tilia mcot aome rrefriad-\u25a1Io\u00a3m trn>o tenn tBiited for heprt\u00ed diia Aide \u25a0/ Leed teccinique [101.\nIn tira work bis ectina CbntMnbvs\u00c1nA ICdoAi, Deamrt a\u00a3\u00bf\u2018jtrwi IFHAJ end \u00fcIek eurapaeua qdtikitnu d.JEA-11. impik\u00fcW, apecific tu n-D-dlLccoo.'merncrio. 3oi-pil-3;-CalNAc nnd a-L-f jccen. wer\u00ab oanju\u00edutad \"j> sr\u00eddn-un wjt (AEL TTe dtwrortivea (eczina-AEJ wore jo\u00bb ba avnlLeta the \u00a3 ycopiiennt^pe nf o reate: o tia-\u00abLee iPCa, HB= nnd norme 1 Roinua rapo_o ha>o Leed dieee lactina la ovalante ttio t\u00edjrco-ende of pl\u00e1ntate tinnLeo tpjt oaBlinftnBm witn c\u00ed'o.dK\u00ed ;i_l-13|. TTjja e campar con ccl d be estant\u00eda nnd nntoBentre primer.: prncectjre nnd ITioae oantributicn*. Be: cea zheee a*a b\u00f3-n\u00a3.cn idnwrt cnmaT^drate ros id Lea smcnj utilera [1]_\nMalem and t sItucs\nResdenb\nN-tTyTfruoQWJOcinimido-flCtiwted cimotn*! ecrr dinLm Botar iDM4E-NI-EZlBea-l-EJ-2.T0r&amp;-nic Lnb wm k\u00edrdi/ajpp \u00a1ed Cr. h. h. Vinetull. Dnn A, FH4. UHH, H.r-dimetrytformnm l\u00ede, tr/pain frnrr porcino pane nos. metTirl-o-C-mannoada, D-\u00a3aiactoM, a-Lfjcosb end So-ptadox Q-2S we*e pircheced rrorn S\u00edrra-AJfricii fBt. Lauta, M\u00fc. USAL Chernilumnoocont dezoction aob ce-,:med ja t\u00ed Sierre-m R?e\u00a3e-rt TSH =\u00bf0T lE-amena Mari cal So Jtom \u00fc\u00a1a\u00bfnontcn: Msvom; P4; U8AI ccmpoaed of 091 H]O] in U N HWD\u00ed nnd Dz25 M NwQH. XvetiB anc odie mi ware ootainnd rrem Merck zOarmotadt. Cnnron^). Al other chomicnl ron perro uced -ce of nr.a trtical \u00a3 nade\nEamplea\nP*mctBtB 'pa\u00edTOT:a de\u00a3mued ae EPH \u00fat=4&amp;i, FCa&lt;t=5O\u00a1 nnd norme turnar ircetHlB m=Ej -ce ootoimd tr -cl\u00a3h praraffn-emtedded\nb c no es re ti Teeue = ark of tm \u00fc ir.c -Inapto et tm federal nriVBraty af =eTambj:o. h ai tea ote t Brnz I. Thn \u2022enico ceciic o\u00a3 n__B UTder Dr. Marenn h*ontene\u00a3ro ce Main Lira leedBranfci perfenred tilo dinerosa of precia! ic no up cerra. Patenta a;ec fnr EPH anc PGa \u25a0. ar ed te:-xe sr 47 anc \u00abe. snr: m\u00abTfi4:nrd Ex end \u00ab4 . enre TieaT 37:. rencect -.e.-. The Hoarj- Scotcb Centro Eootnical Bacd f-'cm Federal iiri'HBraity o' =eraTibj:5. Btk\u00ed CEP.-' CCEHJFPE Nb uayi\u00bb. dXMWOdtniB etJttr.\nCan A. P.\u2019ua and 'JEfl-! oc\u2019jL\u00ed'etijr-: w>tr- arvi-d.ir.:jn- \u00abcer cj\u00edf.\nAE vraa cortiuffatar\u00ed u> cerina aoc\u00abifn\u00a3 ti> ^4]. Br efl.. ec~Jnn il mL certa t t\u00ed 2 m\u00a3 of prnte ti wce incLbated witt ID |_il_ nT acridinium ee\u2019jir nulLtion (Du2 m\u00a3 d utod in -CC pi_ nf NJ4-d rretT; \u25a0\u2018aTTurr dni fe 1 h nt 25\u2018C under rota-rfa-Jrriri. The cnnju\u00bfate iiactn-4=J \u00abna app \u00a1ed to a coKjmri of Sepl-ado?: -3-2S ilC- \u00ab Icrrilnro-'.'oiHib' bou ib*iatBd w til LC mM \u25a1tioaphnto bjf-or. centsrnrid 0.1= M FtaD \u00cdFBS; oH 7J!, dTdehJted AtUntha tuTar. Aliquazn il. mLi T>Bre cnllocted and UiBir prnte n cnntont wna apee-tTC'Z'hc\u00ednmetricnltr deionririod nt 2>->D nm. Ctio-m lu ti incoe once nrtheanrre nliquocn woaaloa aoBayod wth cc L\u00b1cr-a of O.E% F_C in \u00fc.l N HIJOj 1=0 pLz and 0.2 = M HaCH 50 pL- jo r.\u00a3 a iLirinometer Modulua 3ir\u00a3e Tute 02D\u00fc-DCd. mimar E ai. ate tic. U8AJ. ITe err se ct meri-Bit? wan determinad aan\u00bbdlive iflrt un ta (RUUi wth a cnerrtn\u00a3tma oTE neconda peranrrale. A'Ter cofi\u00a1u\u00a3ation; Con A-AE ard PNA.-AE \u00abore o/nlLf-jid m\u00a3n id n\u00a3 the mninbenc nce of ita car-boTiCfi1:? roca\u00edniton propecrr i ti arread tint\u00edn wt n\u00a3 ectirit?\u25a0 jo t\u00a3 \u00ed Jta* a deh.- de t,*eated ratb t orj\u00fcTrocytoa end hLnmn eF; tt \u25a0cc.-tee fe F \u25a0\u25a0 =A-l-AE iH\u00edzio at H_,\tFtactianm cure-\napC'Tdinc -ji peamin anc dmnr Lminoaconce pe-aks wwb ponled and protain concsritraton \u25a0\u25a0'. a: meoeLred [14J.\nLahz.t hi'ahwtitmi'atT^-\nPensffT Decton (S pmQ of nnma>BD were cut, beisferred tn \u00ed\u00a1la\u00f1o a dea. deanruffiT zod in X: ore (anca E mil, and thrBe-'nld 1 min| nnd rer.-dpaLed t \u00a3padec a cot\u00ed n tTpee-'o d IjOO--'-srd ctzo 7CM \u25a0 1 min saz!\u2019:. El dea waretrno od wtii U3k luf/v) trrpain aouton el J7cC1tir t.vn miTLlBa. SldM wwiewaatied rtwico, E mn Bttch timei w til PEE. Afzer/Aarda UnnLe el-con\n80\n81\nFlfljW' 2. Scheme d1 rhe chemi urn In meant IwhIti htd\u2122\u00b1omif7trr Fnratfln reazizr \u00a1H jmi al hiapslm he ng per, tie-Klam\u00bb in \u00bfam side, dcporatflniiad, rmharmea, treated wtti trypsin, w*shDd with PBS. Inuibetnd with lectins AF and .\u2019gar \u00abimbed with FBS Afinr^nrds the sauarcd- shaped area al tis&amp;je saatiaH tci_i s.t and tTansl&amp;red ta \u25a1 pctypnipptena test nib *nd, nrattr- the dnefnlljrTinaswnce measured and fi-pressed ns\tI \u00a1\u00bfhi uni \u00a1RLL l A dupliraie cf he daporattihrad\nand mhydnnbd Umun sarnpfa was hcnurtadllri easin stained Mr transtixmad tissue IdenttflaitlrrL\nQtanilurnirrfsceirt. detection of prcstatic gFyoopIlenatype\n5&amp;0B\nI rd J C n Exd P \u00e1rbol 2014;7\u00ed:7\u00a1<3h0\u00fc-3h0h\n\u25a1 o\u00fasi\u00ed-\u00ed\nWish nqs vrilh PBSpH?.?\nTryp\u00edri\u00fc.1%\n2nr i13?<\ncurt\n\u00bfhisin&lt;.1ai\u00eding\nLKtiivfiE\n:1M- ML.' IMpgni. J\nDJSirrr\nHemal eq Im\nDqnraifrsztlcn ttvialion r*\nHemal eq Im\n82\nFI\u00a3_i*\u00fa 3. Ctwniunirasaflrnt! r nnrm\u00fal pr\u00f3stata Usuo*\tfrenen rireitft.\u00ed prv?cri.i:lp m-4\u00edl;\nand :e:<.tatr; rKlnnoGnrdm^i: \u00a1n-MJ, usrfig dio KVjLRaic- r ?i\u00c1\u00c1F \u201c\\AAE and I.E4.AE. DHntam Irtftarr. Indlomn s'jrbtluly slfiir^int =J mcasute manta ,ire irnon * SD o\u00ed IrpUcim.\n*e*e incLbated witF locttia-AE i\u00fc\u00fc |J_ contri n-n\u00a3 iD of crzte ni Tor 2 F ot jV-D. fcllawed bj oahfri\u00ed nt-ee fc d 5 min| >itti 15 mL of =B3. Ttie aren caneeoondinj I\u00bb t04ue oezlcn loquaie-ahs ondi *^aa dafinad as \u00fc_2S tm1 os i i j hor'iBnade n\u00bbd. Pm\u00edoLMto chorniKimineB-en ni sccsj aicaq from tao eeected paraf-Fn-Btntedded bofnee we'\u00ab tas red '.'\u25a0\u25a0itn hema-tosilin aoein and essminad by.^rtc rriteTMicapj !?\u25a0 ItrcalLinc tte un\u00bb oras. ITen the (\u00a1hubo \u2022wb ciot wth a bietoury. nnroned Trnrri \u00bfIodo a Id ni and -junatared Id e \u00abI?ptao?lana :oet tajt containini =C yjL dTFES. Final y.\n144 ue-acuate d entr\u00f3les ww\u00ab oesayed nci deecribed uby-e. Tr picata mas4u erisrta \u25a0\u25a0ce csrried cut PiroaiFcut diiq stud;. Lactn tindin\u00a1 nhibitcfi aosayo ^o^oaccamolianBdbgf incLbatri aach lact n \u00aboluttem witin 3DO mbl metbcrl-a-D-manncada (Dan A) D-\u00bfalnctoee |FNA) and O--J'.cc-:e [UEA-Qlta-45 mri at 2S',C [Miar to tteir ncuost on wilF tiaauec. Tha TaF law ni otaca \u201c\u25a0ti biaoe deM*\u00edbedTerina tind-inip'utocal :cTte^ Leedin-AE ncLlration;.\n\u00bf/m \u00abw canw/u-id.'sts t\u00edcrses.'c.n aptrt'a-Lian\nTtie profie o\u00ed carbotrdrata e^prnalon. wasled ty chemilum noocan: etriDDinn cce Id npezific laotn ain t\u00ed ni w un alto e v\u00edalo otad no aUncton \u25a1If'jMJB aran i\u00fc.125 1d l.D cmr uaini sponopri' ata h \u00f3rneme de moda). TTeaB d tte\u2019er: t44ue \u00abda lampee cf HPH and F\u201ds ww pracecaed aimilnri a o abane deqcrtaed ilactn hiatonam-\nFlfp_i-e 4. Lnt\u00fcn tindl\u2019j. iniititii'm \u00absoy in pr\u00f3stata ttaus da cunte .i; frenen [irmL\u2019t.r h^peji\u00far. n in\u00bb Si and pnastate Brienotacinema \u00a1n\u00bbSL Ti? con |U\u00a3tae CanAAE. F\u2019,A As and JEAAE wora inhltited ur. hg, i Dsp\u00editSArfi-. rrcttYla\u25a1 mtircfXLirnr.iXi, \u25a1 CDlutnsa iinrl D Tu\u00bb se. Al me os u rentante am mean \u00b1\u00f1 tatrp\u00edoa-ie.\nintryi Laini Can A-AE PNA-AE and UEA h.AE c:r.L\u00a3aLeo.\nanaMiB\nTTs pc'i^sr? Crin =to S iC\u2019iSn Ljt Cor-poratian. Dne ^ount*iDuae Haza. F.ortriamcrtcfi. M- CdC-E\u00fc UBAJ we 'J\u00bbd Te tte ctatte-Jcal s na bula and data warn a^oreMed oa mean \u00b1 utandard dac atiern t8Dl Cota nad data \u00ab\u25a0 cnfbonrBd os n\u00a1\u00a1 AN\u00dcVA Leo: fotwed bj peet-IwcTL\u00edcey<Nit Idr Doa A-AE and UEA l-AJE reeu -ji and F noeles -/jslli-s To lewed W ODOt-nac iJanoier teatro rtfie PtJA.-A.E resolta iF &lt;OjJE i.\nFteeuka\nA. trpicsl \u25a1LrifiDatcn cnuf e nf Can A_ FT-l-j nnd UEA-I iBctna carLqiated la acrdnium Mtar in denonnroatad n Rujure 1 |A, E and C, -eeps: \u25a0 L\u00f1fflljfL H. can be aboerved ttiat al eutian cro-filNi ahowed abeartence 280 nm&lt;prote n) and chemi MmineeceicB pesaje araLnd :te 1D^ fnset zn. tidioatni tta\u00ed the lactna ottained ron trs?s anquera \u25a0^ceccr.J\u00edstsdLoac'dr.-iuiFieeter. Tbe otnsr ctemilLm iBacnncepeako wthout coficomitanl proteg\u00ed p\u2019ecemw c\u25a1 responded tedio'ree estar. Flrdienriare. tFe fi\u00ed-ut d\u00bb*nara>trataetfiatBTsr'3iepn>csea urcon-juifition and ehjtc<i al lactin coqjjfatBa wore Dt II caps dio toracoinze mera pe: i fie cartiary-treten bj remsi\u00edlotnatri actiity eeeay. These raoLlta -ahowed itaLil-e ccr^Miatcn dd\n83\nnal cauce \u00abclin atructure a lo ruteno te rrtw-feTedier\trere \u00bfni ton Ditez.\nFipLpe I DCiomat-ca Ijr \u00a1I uairatee tnie chnrri u-rr neecent Ipctr. hiatcct\u2019en\u2019iDby prncedire. Dan A-AE. PfJA-AE o\u00edd UFA l-AE coi] Jiotes to nveati\u00a3aiB Lib \u00fcycopherotj-pe n prootatc normal ond neopluotc toauee. TTe findr\u00bf reedite ht\u00bb diap uyel in Figure 3 tt vhbd \u25a1teerved a la^v e\u2018p^ee4ion of 'i-C-[\u00a1lLCMa.-' rrannoee reodLeq. \"eco\u00ediiiBd by Con A-.AE, tezweBnihe BHF 1226'3211 1?.42E: RUUi ard FOa&lt;22E&lt;53D \u00b1 12;2&amp;u- RLH\u00a1 ti bou es ard ttw normal i2*7.5Be = 4K.5S0 RUfl. ThB tmne-To'mad proatatc :-ssjc4 preoBntBd ar. Bxoroe-\u25a0km of 'iC-tlJCDDB.'mnr.iDDB e^iifcaTty lm*w 13 &lt;D.CE; unan comparad to normal proatctc t44uea. Haws>w friB dffe'eice terween nal \u00a1nar.t ard beign t aauee wdo nct otatot ca ly ei\u00a1tn fcant\nThe BxireMon zatteTi zf p-\u00edaJ(l-3>\u00eda Noc \u25a1Ido dec-eaced in BPH 128,75 4 f 2.137 RUUr ard P\u00eda&lt;16.726 f i_2\u00fc4 RLUj compmd tn nc-T-iul taquee iJCB.ZM1 = 22L33B RLUi. N^rertbeteM. otatctic eitr.-ficar.t dTsreiDM \u25a0vera ooeer<ed orront t\u00eda tioauee i BU P ard FCai aid bdtwowi tinao-cond~JMiq ard no'mal t-ooLe.\nIn relaten to \u25a03-_-iljcddb t '.'.as otean sd an nereoM zf dio exprnaaon in POa&lt;25111^ -14 1HC3 RUJ) rnrrz.nred tn norma i2\u00fcd&amp;7&amp; = 21,318.RUI: ard BHPPBH^TSB\u00b11D1M4 RUUi tMuoe. \u2014ibdb diffwsncec -vse ntataticalY \u25a0s\u00a1ii-ficant.\nInhtaition oeeayo :F g.jre 4J woa pe'fnrned Lcint nwUiy-a-D-niarnapjiw^BitJft D-\u00b1aac-tose and D-Tuzooe cniars for Gon A-EA P>IA-EA ard UEA-FEA. rMoactvBly. - wae oboenad en\necoreeeire dsceaeiti o'tiB AU> valLoa 'or all \u00a1nhblBd erina-AE Hawuver. t\u00edo inhibtiwi of ble PNA-AEwaa relstvflb ower&lt;frnm 27,667 -1.6-8 :\u25a1 15,242 1 2.73BI in HPS ard P\u00eda tie-DLM irrcm 22^301 l_UBtill4 3S3d 1.8811. P\"s:s deceacee in RL>> voIlm ejifaut ttict non-apee-te tirdin\u00ed tez-esr t\u00eda iBctnq-EA ard zel BLrface \u00a3 jcncnrii.iatez payad rwt releva ni role.\nTTe rnlatonohip Detraen RH.J ard tiez jb apea ohowed a linea\" CDmeadon 'or a Inctoa-AE ard trannfo'mod t\u00edDOLce (Figure Bi. TFeee ros Lite \u25a0evB\u00edl thattiB ntanaity af mt zted \u00a1ht e dracty prosart onal :n avalante I\u00edmjb anea m \u00abI atio fr\u00edo en n\u00eda ni nf expoced caniiity-ctctB teodLM.\n\u25a11 s\u00ed uskon\nGlycana na moved in wwk pTroinln\u00ed\u00a1cal ard pathoofu c urdid ora dloI* \u00a34 hoat cazfo\u00ed-sr rr.ernet ore. infla mrration de-Blup-ment and ma 0wmcy [15]. Tbe cancar \u00a1o acoco.atad witb \u00edtrcoaylation aiwationa in iy-cop\u2019otB re ard \u00bfycDipdo&lt;18;. IT-mb chalaco un offset \u00a1Ttersc-Jonc brt-A-oei tL -\u00f1or cell-ou*-ftoce \u00a3I*cane o\u00edd eido^eicue eozina. wiicn ma? detsmine fr\u00eda meuetatic patarttial of tfe (jto- ceil [17]. Ee.eifi commcn stTLCtu-al chan\u00bfM occir \u00a1i :li~izp \u00bfJycan*. indudinfi nceaaso nt?M)levelofmj*icatonardtranch-\u00a1n\u00edofecrLctjree \u00a34-^Bll \u00a34 an kicreaosd sxoree-Bkm of LT.j-sjal terminal oac jonzee [1\u00abJ.\n\u00edtud bo piBwrted evdencBn eu\u00bf\u00bfMt*i\u00bf that tiB \u00bffrrtMiy1a\u00fc<Mi of p\u2019otB no waa nod-fred in botn ==H ard pr3Dtatc earenoma&lt;11-13]. HoYFBh-er, Iheee \"aporta Braloyed 1 Psrsn: aporoachee 'tzt ttiq ^rerk. cecina WBre\n84\nlabeled wth permittees and fr\u00ede atablad \"je-SLee warn orbiuriy cjur.'jfiad by \u00a1Taje analyos.\nThe pwit trtud:- demonsiutedtnutthet's ts-firmed prwtatic tissues presentad ar. sqnt-lim of i C-\u00edlJcaDP.'Tar.iDDP s tnrfcOTt y lower comparad m normal prootctc tMi\u00bbs. Kewvertfc diT\u00edrunce Between m<na* urd ten\u00edan cwiditons was not statist ca ly *\u00bfnifi-can:. These raei\u00edtad suites wth those report ad by :13], 'where t\u00eda? noted an remase of a-C-iilJCDDP. nariiDDB n'arwi cn htvperptor ic tkouM campead to norma and o rost\u00ed ic adenocarcinoma t-noLoe. Clier stud?. also otwnM a h\u00a3h a* \u00f3rese on of flucM^hnun-nose rood see in oroetortic tsaue howawr, it was neo cMaued ciib.ficar.tdirbrencee among tna norma bentn arotu-jc fyperplccic ord prootut c adHioca'cincno ties jbo.\nThe \u25a0ecclntcr of the outteT. of Oa-pil-2)-uoiItec erpmeeian obtained Iff PH4.-AE accord-n;tc this wert showed a deersan ng in these ifrrans w th too \u00eddolo franoto orat on oroeses. The RLU voIlm (Qal-Hi^OMac Mjraasiwi] praoerced the fellow r.i order norma t coue =\u25a0 EH\u00b0 > PCs. \u201cnone raoLlts ora cons etent witn fr\u00edo\u00bb denKnstralBd fry KJ, desoiteche differ-once of msthodolDiiM. l-mer, [11J repo led differed tenoudr. They noted tnut PtIA ores anted a lower ctainirg n normal prostate ard benign prostate bypcpcsic and a ctrosiur sta ninfi in prostate adenocurc norra. It is *ortbrwtii b to a I uttent on to the tact that RU i vallina 'or PNA-AE mgedritna cruneforned tccues :BI-P and \u201cCo are fr\u00eda owMtsufifiwb ini tnut Gul-p(i.-3HtalNac az\u00f3rese on s rtn-rrwtcnily rerfLced indar -j-eaa coeiditons. The t eeue-tact n-A\u00a3 cot\u00ed pm nn tt on ki? is setose wa a so not d: ntanoe I ka for tna ofriar ec-tr>s--E inhfrtian siudes. The ora yah of the tr\u00a3nsforrred prootutc toan with WHE analynb daner. an flrle' ntJdiM.\nWlb resoact fr\u00eda e\u2018preMion of L-Ucoae residues dentified by UEA-I-AE thB worx demon-sfrBtDd fr\u00eda increas ng exprano on in FCs comp aedto norma -jmuo. Howa w, this a* yeco c n decreased n BHPtbat cranerwed a lower RU \u25a0 valuaa tnon PSa and normal \u00eddolo. These remite coto bo rate those \u25a0ecciad n? ;i_L. 12], The nceaoad azareas on of L-hicooa *eciduan in the malignant cond-JDa has abo asen otear,od in :he carbohydrwtDi frarJon of\nnarLri PSA Hom ndir djolo w th pros jatic adenocarcinoma PSQ-\nLectins coq jgatedtc a chromogen c label none bean w doly adopted as h atocnames probes for me]-jiat.on of flycoahenntype from vur-oim humor, normal and malignant tissues [20-24|. The ana yses of these eta nod prapca-tono \u00bfera either permed tf'CJih ght m crime op?- ny an ccserwr or qLC nt-fied try swami morahomafric propoca c. l-ere ctierrilum-reocent pre dm (lactin labeled w th ocridiniLm ectari provided a nimcib. opecic and e'ficent tool in the qLC nt tathe deteminuton of die tissue gfrcoccdn as pwioLdy reporJid by 3, 4] rorhLmun tracot Lseuo. Tfo orocerh.ru etho first re port for proetutic transformed dss J as.\nHere os raporedintfeoa previous \u00abrtstham of oir lab. twasoMarved re adonsh \u25a1 betz-aer. fria \u00a1\u00bfb: amittad ty tna cfemiUrr nascent reacton ifi'Li 'i ard thetiDDLe area. The nature ilinear. Koortiolic and other \u25a1arumatem ofth-s relet onship di-farance ollo-s to study Ute Wnarjcstecween ectins andtooueo.The'efpre fria quanttolhe admntaf\u00bb of die use o' churn -iLm naocanceto ectnbioh the dycophenotype of tMi\u00bb Ta. add otnar oa:s to tbs onutynb DLCb no mazirrirn carootydratspertMuecea erd omoc oton.-dueocict an consccnte.\nIn coficusofi. ncrmal. bon\u00a3n prostate hyoer-ptaoia erd proau'Jc cdarocarcinomc teeue oomolas we hcutcced \u00bftth Ccricancvolin A (Pen A;. Peur.JtaiilLt.nfri iPN^ andiJew eu-o-pools s;i Jtir.n (UEA-I) eednu cori.i\u00bfated to acridiniLm Mtar (uecfin-AEi. Th a dwmilum-rescenca of die 'jssMU-eclin-AE c cm pl ex ezoreooad in rolati,e liiht units fUl showed atstistca ciSnfccntd'TerencBD deoundini on fria lectfri ord tna t ml\u00bb. Tna \u00a1ht am led was dm nh nad kvimhitit nitna imaructon betw aer. tccues and ecJna with their opec fc ca'bohy-rtstM. The ralutonship beewean RLJi andtis-OLe aea snowed a inear conulction Tor al e:-tn-AE and p*04tatic liMUM. \u201cnats reoLlts indcacB that tna used Tslbod c a promb nt tool fo\" upecfic. wna'jie ord qua nt latke analyDaa of proc-tatc ifrtopnancrype\nfc mowlec pern er t\n>03\nIntJDfriEsp Fsdic 2iiL4;7(7i:3ii\u00bb?-\u201c*-<\n5\n\u00edfj. The tecMical bod atanco of Mr. Ota-iuna Timm Cuta \u00a1a olaotnonhed.\nl\u00edis-otor jr? ar ion- ct nrritereot\nNono.\nAdd'eu ronauxyrionM te LuL* Basara ta EiThah\u00fc l\u00fancr, Depanamonb de = oquMta and LfcnrttrtQ de Imunoprrnl\u00fccie Helio Asnm ;UH4j, UriwrjiMv Federal de Fnrrnmhara. Cidado l.ni-jinmtHrn, Ah Fre\u00ed. Vemos Fcrc, s.'n, CCU, Feche Pnrr.imhd\u00fc!,Brar.l.RI:+55iEli2i2ES\u00bf\u00edW: Fai:-t-55\u00a1HlJ212f\u00a1E4B:i F mol:ItqiJtatiim.cci-nJj\nHeTcrcncM\n111\t\u25a1 tazar\u00edan H. Idoni E, \u00ed-apcnhhrrcr F.R. A \u00a3j:\nutialoay mitew: Carta>cr.ircr lertnt. iinrl \u00a1mpfendcris ln ep\u00edfita dic\u00edopejtiY. Mi Hh :ociiom2\u00faii: 113: 2 3 E 247.\n|2] ViH\u00a1n FKA, Vela lunlrr W, VnQJ&amp;FIta JLS, Uns CAE, Tries *J. Aididfto 1 f.:a ccrnpanr fluedoo^prass\u00edoteridun dpprcCaha CnrrB 7 era multares pomrtans de drenaos turnante d: -we. I Era Paral Mnd Let 200* 43: 131 37.\n:<1 CmpnLM, CamburdCL LtawFlha JU Eci Mo E1F. At\u00edldlniam Esic\u00ed ecrlucitcc ce Incl\u00edn en merrlkirlnasrert \u25a0ir.'jchmr.ir. \u25a0narker. 3i--HRer.3DK \u00fc 4834S4\n|41 Bruk*i W. Ota\u00bb! CL MetolJilw W, enrielaMT, Behr.lcEK Con-ritaLE Jr.Oneii tarri n os nent orinal nn a1 sirtati\u00eddr.itns Infla turnarte treast rtsaasts. Afipl Elnctam Be WnJ 2M\u00b1 1E6: 76 fl 275.\n(5J Vela Fet\u00fc MIE, Danilrn \u25a0\u25a0= CmrioMitl O, Coralhn IR P Behrde EJ\u00fc. ImmjiahtTtrxta rrilumres\u00fctrua dmoctlnn A p\u00fci'tti-.erol in ti'rest cononr HFE2 strt\u00b1i ovnlartcn. Din V\u00fcCfs2D12: 34. 373 377.\n|tl Lima LF:. Bcrnna t*=. Arre di SM. Silre LR Bot\u00edn Fl. Cerrfirn LE Ir. Ghupnenriypo EHbLdUnnln Ci.tarooLis-umccs Ltl'ii Lerd's La brice #Mi AcridhLin Esmr. Ha Hachan 2C\u00cd3; 35c 141? 154.\n|T] -iriw l.l. CHriml appltftnris ni memlkirri ItaSCrilM. Anal CtlbTi .\u00a1CtJ 2QD3t 5DQ 275 shb.\n|E1 Jcrrol A, E 'a,- F. Comer W. Ferina 1, tfa d E. Forman \u25a1. 7 chal Canter SWsfleL ranear I cin 2LrU_bl E5M.\n:9] Pal RJ, Mata NL, Mol na K, kvr MA. Di:1n ihg prHi'jrn tercer rt> hetae praaLteetiopsy. LlmlOrK.-:l 2013: n: 14QR 1416.\nI1C-1 A-ml-KdA.^uG.EertM =\u25a0,\u2018^laefTtlra E.Bd\u00edL ana M. Tlsue print al pr\u00f3stata rrinpn&lt;a v--.cl iaol ln t>e dlagptsflQ aracoUra ni a-'-mme comer. Dlap F.fltal 2C1L 6: 34.\n[111 A\u2019artas MI, Romo E, da Gaspar I. de Bcflcr onurt n, E.irr.-nor Ctiopofc M. Fre ln E, Pa\u00f1i a^jo P A lectin htetoctamtetrv conparatta studyln humon nr-mti nr-\u2019-inir-. heripn [rus inri: h\u00f3cenosla, and prest\u00f3te un\u00ed nerta. 511 Lfi\u00fcinJ 1\u00cd.TM: 16.375 3R2.\n1171 Khaboi Wk, McCLro J, Madure 5- Siridon W Ghupnerfltsiu -y nrr r\u00eda: 1 coraromas. Fofa WoiodirmCY^tiol 2013:46:63? 545.\nri31 Lima MR CndQrt CCE, 53*0 MCC. F.llm FMG, CMita LC3E, But\u00fari EE, \u00fcwraa MTS. Hlstanerrlail uj Latine cf hunon preside flasuas ><tfli ErdJIa malte sr\u00bbd Ice\u00edn. J Btond Blrcnohnn mft 2010.16.\n1141 Vfeeta I, Stursnns H, &amp;\u2122n FC. W\u00fcwroad JK. Inmunoauay ulns aorldrliim c-Tiirr Met\u00ed* Erdmol 1-Jfl\u00ed; 133.3\u00e15 3flT\n[lfl LoM-y ffl, Nlr.i L FUtutrrkuli A F.i.ir L Ron dril Fl. Franln moaauramwd >4tti ttc Fr\u00abln nvrd reabre I EU Ct\u00bbm 1!?5L 133: 265 775.\nri\u00a3-l Klm EH, MLt* DF. QMwntarricsBaud IdcrttfcndaT d Caroer Etanahari. Int J Pro raomlnT\u00fcli; 7BLL 1 ID.\n[U] M CA, \u00fcMria H, 2\u00fc-rr. C. Daniel L. AJtnr.i flus in ijicu-ilcckvr os hicrraikars nzr rnr ur deteedor. J Cki Futiol 2D11; 63: 322 3251\n|13\u00a3 HangJahtalW R OcnkEn J, F.ir A roibit^ datacindl'i priTtrirr. in canee' nnd thn-r I pndi er. frcmpcirtic uprrti. l\u00eden Md Med 2DOZEI1E7 132.\n[\u00cdQ] Vflfld A. rumrrints RD. Es-o JD, Frenan -IH. Stanle. P, EerbrriCA, FatGW, FtflnrME.Es s\u00f3ndala o\u00ed Eyoctiuna-. 2nd adflnn. Celd Sprlni Harb:r |NYL Cold 5prirg Hartar Lobo ni ItryFrau. 20C6.AtnlahletTCni: tttpc//f*ww. rubLrtmmpw/lEciaAEK 130B.\n|2\u00fc] Dwtik Mv lankr. A Lur>em AL 4 sen\u00fcflre q \u25a0la? te me:r j n tdn\".:1tfr CycosfoCon derr \u00fciccrutes hereosed lutuayUrUtri ni atatntn iipoctln arricen (TOlfln aoLnntr. >4tdi atatrrtn unurummred^fli benlc x-'-tqiI: F-.ner ^asIn.CErlm mimen Acta 2C1Q 411:15C35 1535.\nf211 Bot\u00edn E1E, Garba VFT. Hc^lredn^lre I, Corita LC. Rlnd r\u00a1 Mriuaflcm ce \u00a1sotarn Cnrt 'illa mrilL lectiri:n Ixmanr nwrmiyflssurs. w Elwhr^ PHmf\u2122i 1358 74.125 134.\n|22] Bot\u00edn EK, VaS\u00fcftH FL, \u00f1MTiJ.CO DG, Flcjeircorj\u00edlw J, 'r.ilr-^a W. Culna LC, Gri\u2019-.'alhn IE t. Parido prnUo tcrln s ttbi dion\u00edsiTY 'vrkrr ta me-nin&amp;cthellai r j-wi.r. ElT JHiitre+cm 2D\u00dc3.47:135142.\n3\u00abD7\nInt J din Eip Faflic- 20L4:7-:7i:3^X>3\"Ok\n86\ne-nfc\u00ediil iiloiri-Kls. I Eras Fatal Mcd Lrfci \u00dcJljjE: 42:455-400.\n[241 IVWd lunlDf MH, Causal C1_B, Puntes FUho N_ GEralhD LEI Jr, BettT\u00e1-:. HCl Lx\u00edn staWnfi. M\u00f1e--ns in tiumcri SErrrrr m\u00fc\u00fcrsje \u00ab\u00bfti iind wjflrout AMprauns tn Hclkxftactnr pytari. Erarl bar\u00ed J Mcrct\u00edrd 200B; 3ft 233240.\n[221 Sctrt\u00ed A-, F:e\u00a3-! MJ, L-.T.nlLiirrtl l\u00ed-.l^\u00fa\u00edI-c LB Jr, aefcrdc- El. Con A ard UEA-I\tris\u00edu\nctiem\u00ed\u00bb o\u00ed pcrmld \u00bfunrl rrijcccnider-\u2019r:4ri cardromas. I Oral Sd 2 DIO; \u00a32:4!> E4_\n3HQH\nInt J C=3n =:\u25a0:\u25a1 Ratfio 2014;7(7i:38CX>3^43e\n87\nCAP\u00cdTULO 2\n88\nArtigo ser\u00e1 submetido a publica\u00e7\u00e3o no peri\u00f3dico Glycobiology.\nFator de Impacto: 3,283\nQualis Capes: A2\nESTROGEN UP-REGULATED ST6GalNAc I EXPRESSION IN PC-3 PROSTATE CANCER CELLS AND MODIFIESTHEIR O-GLYCOSILATION PATTERN AND ENHANCES THEIR MIGRATION CAPACITY\nL\u00facia Patr\u00edcia Bezerra Gomes da Silva , Sinara M\u00f4nica Vitalino de Almeida , ,\nAmanda Pinheiro de Barros Albuquerque1, Igor Teixeira Cavalcanti1, Luiza\nRayanna Amorim de Lima1,Gabriela Ayres Fragoso Nascimento1, Eduardo Isidoro\nCarneiro Beltr\u00e3o , , Luiz Bezerra de Carvalho J\u00fanior ,\n1Laborat\u00f3rio de Imunopatologia Keizo Asami (LIKA), Universidade Federal de\nPernambuco, Cidade Universit\u00e1ria, 50030 Recife, Pernambuco, Brasil.\nDepartamento de Bioqu\u00edmica, Universidade Federal de Pernambuco, Cidade Universit\u00e1ria, 50030 Recife, Pernambuco, Brasil.\n3Faculdade de Ci\u00eancias, Educa\u00e7\u00e3o e Tecnologia de Garanhuns (FACETEG), Universidade de Pernambuco (UPE), Garanhuns 55290-000, PE, Brasil\nCorresponding author. Fone: +55 81 21268484 Fax: +55 81 21268485. Departamento de Bioqu\u00edmica, Universidade Federal de Pernambuco, Cidade Universit\u00e1ria, Recife 50030, Pernambuco, Brasil. E-mail address: lbcj@hotlink.com.br (Luiz B. de Carvalho Junior).\nLitle title: Estrogen up-regulated ST6GalNAc I expression in PC-3 prostate cancer cells\nKeywords\nEstrogen; Prostate cancer; ST6GALNac\n89\nAbstract\nAiming to investigate if estrogen regulates glycosylation we used DU-145 and PC-3 cells both originated from Prostate cancer refractory-androgen. In DU-145 and PC-3 cells treated with estradiol and fulvestrant were observed that estradiol regulates sialyltransferase ST6GalNAc I expression in PC-3 cells and the actin of the antagonist fulvestrant inhibits this regulation. This behavior was not observed in DU -145 cells. The estrogen receptor ERa had decreased expression in PC-3 cells treated with fulvestrant but no detectable differences were seen in estrogen receptor p expression in both cells lines. Through lectin blotting using the VVA (Vicia villosa aglutinin) and SNA (Sambucus nigra aglutinin) lectins were identified sialylation Tn antigen (sTn) in PC-3 cells treated with estradiol as well as the Tn antigen expression in DU-145 under the same conditions of treatment.\nMigration capacity of the PC-3 cells treated with estradiol, fulvestrant and SNA was measured by wound-healing assay (n=2). We observed that estradiol induced cell migration while fulvestrant (ICI) and SNA reduced migration capacity into the wounds. Therefore, we may suggest that estrogen can act up-regulating the expression of sialyltransferase ST6GalNAc and the synthesis of the sTn antigen important for tumor progression.\nKeywords: Estrogen; Prostate cancer; ST6GALNac\n90\n1-\tIntroduction\nProstate cancer (PC) is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the United States (Siegel et al., 2014). Prostate cancer is diseases with heterogenous behavior that can remain indolent for many years or rapidly present a progresson, but, still lacks biomarkers capable of distinguishing between indolent the disease and aggressive disease, the latter with rapidly progression to metastastic disease, which is often lethal (Klotz and Emberton, 2014).\nProstatectomy radical is the treatment strategy to indolent prostate cancer, but is not an interesting option of treatment due some side effects of incontinence and erectile dysfunction. Patients with locally advanced prostate cancer, metastatic prostate cancer, and recurrent disease are treated with androgen-deprivation therapy (ADT) with gonadropin-releasing hormone (GnRH) analogs and anti-androgens (antagonist of androgen receptor local). This therapeutic approach is an effective first-line treatment of prostate cancer, which is often initially effective. However, recurrences of castrationresistant forms of the disease within 2-3 years can subsequently occur, despite continuous hormonal manipulation (Karantanos et al., 2013).\nEstrogens, particularly diethylstilbestrol (DES), have been used to treat prostate cancer. Prostate cancer growth prevention has been achieved by using estrogen thought of the action on hypothalamic release of luteinizing hormone-releasing hormone (LRH) that leads low serum androgen concentrations and castration-like effects. Thus, indirectly estrogens are effective against androgen-dependent prostate cancer (Burns-cox et al., 2002).\n91\nregulated by estrogens (Bosland, 2005; Ho, 2004). Studies have suggested that antiestrogens effectively inhibit the development and progression of experimental and clinical prostate cancer (Steiner and Raghow, 2003; Nakajima et al., 2011; Yuet-Kin et al, 2014).\nIn cells and tissues under hormones tightly regulate these processes and consequently two key enzyme families can play important role: fucosyltransferases and sialyltransferases (Medvedopa et al., 2003). Glycosylation can alter protein function and has a key role in many important biological processes in cancer including cell adhesion, migration, interactions with the cell matrix, immune surveillance, cell signaling and cellular metabolism (Munkley and Elliott, 2016).\nThe prostate produces many glycoproteins highly O-glycosylated called mucins, either secreted or surface-associated. Besides that, study assessing the gene expression of human prostate cancers shown that mucins 1 (MUC1) is upregulated in subgroups with feature clinicopathological aggressive and increased risk of recurrence (Lapointe et al., 2004).\nThe O-glycosylation of protein is an abundant and diverse form of post-translacional modification that is initiated by a family of enzyme called polypeptide N-acetilgalactosaminyltransferase (GalNAc-transferases) that catalyze the transfer of GalNAc from UDP- GalNAc to serine and threonine residues (Clausen and Bennett, 1996).\nThe formation of the sTn antigen can be mediated by expression of the ST6GalNAc1, an enzyme that catalyzes the transfer of a sialic acid molecule in an a-2-6 linkage onto the Tn antigen, resulting in Siaa2-6-GalNAc1-O-serine/threonine, mutations and loss of heterozygosity of the COSMC gene, that codes a COSMC chaperone protein, used for the correct folding and activity da core 1 beta-3-\n92\nThe expression of truncated O-glycans in cancer is perhaps the outcome from several different mechanisms such as glycosyltransferases altered expression, localization or the relocation of o- glycosylation from Golgi apparatus to endoplasmic reticulum stimulatins cell migration and invasiveness (Gill et al., 2013).\nIn prostate cancer, the sTn antigen is detected in high grade prostate carcinomas and the level of sTn-MUC1 have been correlated with worse survival outcomes and higher serum PSA levels in prostate cancer patients (Arai et al., 2005).\nIn this study, we have addressed the effects of estradiol on the expression of the sialyltransferase ST6GalNAc I enzyme (EC 2.4.99.3 - CMP-Neu5Ac:GalNAcalpha2, 6-sialyltransferase:\tCMP-Neu5Ac:\tR-GalNAcalpha1-O-Ser/Thr alpha2, 6-\nsialyltransferase) in the androgen refractory cell line of prostate cancer (DU-145 e PC-\n3).\n2-\tResults\nA - Cell Viability - PC-3 cells\nPC-3 cells treated with E2 at concentrations varying from 10-6 to 10-11M during 24, 48, 72, 96h demonstrated different cell viability when considered the factors: time of the exposition in same concentration and differences between concentrations of the E2 (Figure 01), in which statistical differences significant are described in Table 1.\n93\nFigure 01: Cell viability measured by the MTT assay after 4 days of E2 treatment. PC-3 cells were submitted to treatment with E2 (10-6-10-11) by 24, 48, 72, 96h and was observed different cell viability in relation time and concentration of the E2. Experiment performed in duplicate.\nB - Cell Viability - DU-145cells\nDU-145 cells treated with E2 in concentration range varying (10-6-10-11) for 24, 48, 72 and 96h. Were observed differences dependent-time proliferation, but no change in cell viability when evaluating different concentration of the E2 (Figure 02).\n94\nsignificant statistical differences are described in\nTable II.\nFigure 02: Cell viability though MTT assay. DU-145 prostate cancer cells were submitted to treatment with E2 (10-6-10-11) in time 24, 48, 72, 96h and presented different viability only in relation the factor time. Experiment performed in duplicate.\nC- 17^-estradiol modulates the expression of protein ST6GalNac I and ERa in PC-3 cell line.\nTo analyze the modulation of the ST6GalNac I enzyme by estrogen and estrogen receptor expression in PC-3 cells, were used the western blotting assay. We observed up-expression of the ST6GalNac I enzyme in PC-3 cell when treated with estradiol and down -regulation when treated with estrogen plus antagonist fulvestrant at time 24 and 48 h. Similar behavior was observed in relation to estrogen receptor a, however, there was no change in estrogen receptor P expression (Figure 03 ).\n95\nPC-3\nST6GalNAc/PC-3\tERu'PCS\tER0/PC3\nFigure 03: Analyze of the expression of the ST6GalNac enzyme and estrogen receptor in PC-3 cells treated with estradiol and estradiol plus fulvestrant. In PC-3 cells, increase the expression the ST6GalNacI was significant statistically when treated with E2 and decreased when treated to E2 + fulvestrant at time 24 and 48h. The expression the ER-a was down-regulated when treated with E2 + fulvetsrant at time 24 and 48h while that ERp no significant difference observed in same conditions and time (p<0.05). Experiment performed in duplicate.\nD- Expression of enzyme ST6GalNac I in DU-145 cell line.\nDU-145 cells submitted to hormonal treatment did not demonstrate significant\ndifference in the expression of ST6GalNAc and estrogen receptor p (Figure 04).\n96\n24 h\t48 h\n\t/\t\t/ \u00f3\t\n\t\u2756\t\u2756 \u00d3-\t\u00abS'\t\t\nST\u00f3GALNac I\t\t\tV -\t69KDa\nERP\t\t\t\t\n\t\t\u2014\t\u2022\u2014\u00bb\t\u2014\t*\t49KDa\nB-actin\t\t\t\t43KDa\nFigure 04: Expression of the ST6GalNac I and ER-P in DU-145 cell no demonstrated statistically significant differences (p<0.5) between treatment. Experiment performed in duplicate.\nE- Estradiol induced increased the sialylation of GalNac residues\nGiven the strong induction of ST6GalNAc in response to estrogen exposure in\nPC-3 cells, we evaluated if the STn antigen was being expressed using SNA specific to Sia a2-6Gal/GalNAc. As observed in figure 05A, in 24 and 48 h, estradiol 10-6M induces up-regulation of sTn antigens while that estradiol 10-6M plus antagonist fulvestrant (10x10-6M) inhibits the expression. To confirm that estradiol induced sialylation of GalNAc residues was evaluated using VVA that recognize Tn antigen (GalNAc-O linkage) and observe decreased of expression of the Tn antigen (Figure 05 B). DU-145 cells showed the opposite behavior, a higher number of Tn antigens was\n97\n05 C and D).\nkDa\tCM w\tE2/ICI\tH U\tCM W\tE2/ICI\t-\tkDa\tcm -d\tE2/ICI\tU\tCM td\tE2/ICI\tU\n250-\t\t\t\t\t\t\t250-\t\t\t\t\t\t\n150-\t\t\t\t\t\t\t150-\t\t\t\t\t\t\n100-\t\t\t\t\t\t\t100-\t\t\t\t\t\t\n75 \u2014\t\t\t\t\t\t\t75 \u2014\t\t\ti, \u2022\t\t\t\n50-\t\t\t\t\t\t\t50-\t-\t\t\t\t\t\n37-\t\t\t\t\t\t\t37-\t\t\t\t\t\t\n25-\t\t\t\t\t\t\t25-\t\t\t\t\t\t\n20-\t\t\t\t\t\t\t20-\t\t\t\t\t\t\n10-\t\t\t\t\t\t\t10-\t\t\t\t\t\t\nDU-145 SNA\tDU-145 WA\nFigure 05: Expression profile of the ligands (Tn and sTn antigens) recognize to SNA and VVA in PC-3 and DU-145 cells treated with estradiol 10-6M and estradiol (10-6M) plus antagonist fulvestrant (10x10-6M) during 24 and 48 horas. Experiment performed\nThe migration assay (wound closure) was performed on PC-3 cells treated with estradiol (10-6M), estradiol (10-6M) plus fulvestranto and estradiol (10-6M) plus SNA. Was observed that fulvestrant and SNA reduced the migration capacity into the wounds in PC-3 cell line, 15 and 23%, respectively, whereas PC-3 cell treated whit estradiol were able to fill 47% the wound after 24h (Figure 06).\n99\nhealing assay (n=2). We observed that estradiol induced cell migration while fulvestrant and SNA lectin reduced migration capacity into the wounds. Representative image of the cell cultures with scratches at 24 h are shown. The wound is marked by dotted lines. Percentages of filled wound area are presented.\n3-\tDiscussion\nSimilar expression to another genes, the genes encoding glycosyltransferase is regulated by both transcription factors and epigenetic mechanisms resulting in a specific set of glycosyltransferases, expressed in tissue or cell, that determine specific types of glycans structures on glycoproteins secreted and membrane bound (Vojta et a., 2016). In cancer cells, the expressions of glycosyltransferases are often misregulated resulting in aberrant glycosylation that directly impact cell growth, cell survival, facilitates tumor-induced immunomodulation and eventual metastasis (Stowell et a., 2015).\nThe enzyme ST6GalNAC I catalyzes the synthesis of the cancer-associated sialyl -Tn antigens (sTn) which is up-regulated in same cancer types (gastric, breast and prostate) and directly induces oncogenic features of growth, metastasis and poor prognosis in breast and gastric cancer (Radhakrishnan et al., 2014; Marcos et a., 2014; Sewell R et al, 2006; Julien et a., 2006; Ozaki et al., 2012; Munkley et al., 2015).\nHere, we have investigated the effect of estradiol in regulation of sialyltransferase ST6GalNaC I expression and resultant expression pattern in PC-3 and DU-145 cells. Our results show a decreased ST6GalNAc I enzyme expression in PC-3 cell when treated with E2 plus fulvestrant and opposite behavior when exposed to estradiol agonist only. However, DU-145 cells showed no change in ST6GalNAc I expression when treated under the same conditions.\n100\nThe biological role of estrogen is mediated thought two different genomic signaling pathways, the direct binding of the estrogen receptor-estrogen complex in the promoter region of the target gene or though transcription factors as, SPI, AP1and NFk-P (Bjornstrom &amp; Sjoberg, 2005).\nEstrogen is important for the synthesis of glycoproteins through regulation of the glycosyltransferases including galactosyltransferases (Choi et al., 2012) and sialyltransferases (Peyrat et al., 2000). Here, bioinformatics analyses of the ER binding region in enzyme ST6GALNAC (ID - 55808) were performed based on NCBI database, were found two half estrogen respond element (ERE) and binding site NFk-p.\nThe effect of estradiol on prostate cell lines appears to be dependent on the type expressed estrogen receptors. In prostatic cell the 170- estradiol stimulates proliferation in the presence of ERa, but inhibits proliferation when forms heterodimers with ERP-1, being a regulator of estrogenic signaling (Pravenotti et al., 2005).\nHowever, in prostate tissue there is expression of ERP -2, ERP -4 and ERP -5 isoforms, which form heterodimers with ERa and ERP -1 and may modulate the biological activity of these receptors , interfering in binding affinity to linker, the DNA binding capacity, in the recruitment of transcription coactivators and co-repressors (Fujimura, et al., 2001) .\nPC-3 cell expressed both estrogen receptors ERa and ERP, while DU-145 expressed exclusively ERP. We observed reduced expression of the ERa in PC-3 when treated to ICI-E2 compared to groups controls and estradiol. Thus, we suggest that in PC-3 cell, homodimers to ERa or heterodimers of the ERa with ERP isoforms act as transcriptional factors up- regulating the expression ST6GalNAc enzyme.\n101\nFulvestrant, a pure estrogen receptor antagonist with no kno agonistic action, that acts binds, blocks, and degradation of the ER, resulting in inhibition of estrogen signaling (Curran &amp; Wiseman, 2001). Therefore, down-expression of the ERa in presence of the inhibitor fulvestrant is resultant either of the degradation of receptor or down-regulation of the genic expression.\nIn DU-145 was not observed altered expression of ERP when exposed to fulvestrant. This behavior is justified by the fact that fulvestrant can act activating estrogen receptor P and promoting transcription of gene anti-tumoral, without promoting degradation of the receptor (Yuet-Kin et al., 2014).\nThe increase in sTn antigen corroborate with the increased expression of ST6GalNAc I regulated by estradiol in PC-3 cells, identified by the SNA lectin, that is commonly used to recognize the transfer of sialic acid onto the terminal galactose containing N- glycans substrate (Sia a2-6Gal), but it also recognizes terminal N-acetylgalactosamine residues in O- glycans (Sia a2-6GalNAc) ( Silva etal., 2014) .\nThe migration assay revealed that estradiol up-regulated ST6GalNAc I, resulting in the higher expression of the PC-3 cell migration capability when compared to cells treated with fulvestrant antagonist or SNA lectin. observed that prostate cancer cells expressing ST6GalNAc1 and sTn antigen have decreased expression of the epithelial cell-cell adhesion molecule E-cadherin and increased expression of migration-associated N-cadherin and vimentin proteins (Munkley et al., 2015).\nThus, a larger understanding of how estrogen regulates glycosylation and the role of these glycans in refractory-androgen prostate cancer enable a new approach to this disease using estrogen antagonist or glycans inhibitors.\n102\n4-\tMaterial and Methods\nPC-3 (ERa+/ERp+) cells were a generous gift from Dr. Jo\u00e3o Ernesto de Carvalho (University S\u00e3o Paulo, Campinas, Brazil), whereas DU-145 (ERa-/ERp+) cells were from the Banco de C\u00e9lulas do Rio de Janeiro (Duque de Caxias, Rio de Janeiro, Brazil). Fulvestrant (ICI 182,780) and 17P-estradiol were purchased from Sigma Aldrich (St. Louis, MO).\nRPMI-1640 medium, fetal bovine serum (FBS), charcoal-stripped fetal bovine serum, penicillin/streptomycin and trypsin were purchased from Gibco (Life Technologies, Bethesda, USA). Antibody anti human-ERa, ERP, ST6GALNac and Pactin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); Sambucus Nigra agglutinin (SNA) lectin from Sigma Chemical, Co (ST Louis, USA) and Vicia Villosa agglutinin (VVA) lectin from Vector (CA, USA).\nCell Culture and hormonal treatment condition\nPC-3 and DU-145 cells were routinely maintained in RPMI medium supplemented with 5% and 10% FBS, respectively, and grown at 37\u00b0 C in a humidified atmosphere of 5% CO2.\nFor the hormonal treatment PC3 and DU-145 cells were cultured (T-75 flasks; 37\u00b0C in humidified atmosphere of 5% CO2) in RPMI-1640 (phenol red absent) supplemented, respectively, with 5% and 10% charcoal-stripped FBS, and 1% penicillin/streptomycin. The next day both cells lines were treated with either 10-6 M E2 or 10-6M E2 plus 10x10-6 M ICI, prepared in 0.1% ethanol for 24, 48 h. Stock solutions of 10-3M E2 and 10-3 M ICI were prepared in 100% ethanol. The controls were performed by cultivating PC-3 and DU-145 cells in the absence of E2 and ICI.\nCell Viability Assay - MTT\n103\nPC-3 and DU-145 in RPMI-1640 containing phenol red (100ql containing 0.2 cells) were incubated overnight in wells (96-well plate) and afterwards the media were changed by 100 Lil of the following mixture prepared in RPMI-1640 without phenol red: 5% (PC-3) or 10% (DU-145) charcoal-stripped FBS and E2 at concentrations varying from 10-6 to 10-11M. The controls were carried out by cultivating PC-3 and DU-145 cells in the absence of E2. After 24, 48, 72 and 96 h 10 Lil of MTT (3, [4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, 5 mg/ml; Sigma Aldrich (St. Louis, USA) were added to each well including controls and the plates were incubated for 4 h at 370C. Then 80 Lil of the lysis buffer (20% sodium dodecyl sulfate [SDS] in N, N-dimethylformamide) was added to each well and incubated overnight. Cell viability was evaluated by measuring the mitochondrial-dependent conversion of the yellow tetrazolium salt MTT to purple formazan crystals by metabolic active cells. The optical density (proportional to the number of live cells) was assessed at 590 nm in a microtiter plate reader (Biochrom Anthos MultiRead 400), Isogen Life science (PW De Meern, The Netherlands).\nWestern Blot Analysis\nTotal protein was extracted from the cells treated with 10-6 M E2; 10-6 M E2 plus 10x10-6 M ICI and ethanol (control) using NP40 Cell lysis buffer (Invitrogen, CA, USA) according to the Manufacturer\u2019s instructions and stored at -20\u00b0C until assay. The protein concentrations were determined according the Lowry method. Aliquots (60 qg protein) were separated by 10% SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane using transfer Semidry Bio-Rad (both from Bio-Rad, Hercules, CA, USA). After blocking the membrane with 3% non-fat dry milk for 2 h at 25oC, under gentle agitation, incubation was followed with primary antibodies anti-goat\n104\nagainst estrogen receptor P (ERP 1:250), ST6GALNac (1:250) and anti-mouse estrogen receptor a (ERa 1:250), P-actin (1:1000) at 4\u00b0C overnight. Each membrane was washed three times with TBS-T (50mmol/L Tris-HCL, 150mmol/L NaCl, 0,1%, v/v, Tween-20, pH 7.4). Afterwards, the membrane was incubated with HRP-conjugated secondary antibodies (1:1000 dilution) for 2 h at 25oC. After washing three times with TBST the protein bands were revealed using Western ECL substrate in chemiDoc Imaging System (both from Bio-Rad, Hercules, CA, USA).\nLectin blotting\nThe PVDF membranes containing the transferred proteins were obtained as described in western blotting analysis. After blocking then with 3% BSA (Bovine serum albumin) for 2 h at 25oC, under gentle agitation, they were incubated with biotinylated SNA and VVA lectin solution (20 p.g/mL), under agitation at 4oC overnight. The membranes were washed three times with TBST and glycosylation protein profile were revealed using Western ECL substrate in chemiDoc Imaging System (both from BioRad, Hercules, CA, USA).\nWound closure Assay\nPC-3 cells (1x105) were seeded in 6-well culture plates. After the cells reached 70-80% confluence, a line was scratched in the middle of the well using a pipette tip to create a wound. PC-3 cells were then treated with 10-6M E2 and 10-6M E2 plus 10x10-6M ICI (10uM), prepared in 0.1% ethanol and incubated for 24 h. The images of the denuded area were captures by confocal microscopy as soon as the wound was produced (0 time) and after the hormonal treatments (24 h). For each wound, images were taken in the same field and the distance between the wound edges was analyzed using the ImageJ 1.42 software. The percentage of the wound recovery in respect to the wound area at 0 and 24 h was calculated for each condition (Lau et al., 2010).\n105\nStatistical analysis\nLevene and Kolmogorov-Smirnov tests were firstly applied to test if the distribution of values followed normal curve and presented unequal variance. Afterwards Turkey test was applied.\n5-\tAcknowledgments\nThis work was supported by Funda\u00e7\u00e3o de Amparo \u00e0 Ci\u00eancia e Tecnologia do Estado de Pernambuco - FACEPE (APQ-1399-2.08/12) .\n6-\tAbbreviations\nADT - Androgen Deprivation Therapy\nC1GALT1 - Core 1 beta-3-galactosyltransferase\nE2 - 17P-estradiol\nER - Estrogen receptor\nGnRH - Gonadropin releasing Hormone\nLRH- luteinizing hormone-releasing hormone\nMTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide\nPC - Prostate Cancer\nPVDF - polyvinylidene difluoride\nSNA - Sambucus Nigra Lectin\nVVA - Vicia Villosa Lectin\nFBS - Fetal Bovine Serum\n106\n7-\tReferences\nArai T, Fujita K, Fujime M, Irimura T. 2005. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. International journal of urology: official journal of the Japanese Urological Association. 12:654-661.\nBosland MC. 2005. The Role of Estrogens in Prostate Carcinogenesis: A Rationale for Chemoprevention. Rev. Urol. 7 (suppl. 3), S4-S10.\nCurran M, Wiseman I. 2001. Fulvestrant. Drugs. 61:807-8013.\nBurns-Cox N, Basketter V, Higgins B, Holmes S. 2002. Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. International Journal of Urology. 9: 431-434.\nFerreira JA, Videira PA, Lima L, Pereira S, Silva M, Carrascal M, Severino PF, Fernandes E, Almeida A, Costa C. 2013. Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Mol. Oncol. 7:719-731.\nGill DJ, Tham KM, Chia J, Wang SC, Steentoft C, Clausen H. 2013. Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. Proc Natl Acad Sci U S A. 110:E3152-3161.\nHo SM. 2004. Estrogen and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutics candidates. J. Cell. Biochem. 91: 491-503.\nJu T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE. 2008. Human tumor antigens Tn and sialyl Tn arise from mutations in COSMC. Cancer Res. 68: 1636-1646.\n107\nKarantanos T, Corn PG, Thompson TC. 2013. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate-resistance and therapeutic approaches. Oncogene. 32: 5501-5511.\nKlotz L, Emberton M. 2014. Management of low risk prostate cancer-active surveillance and focal therapy. Nat. Rev. Clin. Oncol. 11, 324-334.\nLapointe J, Li C, Higgins JP, Van RM, Montegomery K, Ferrari M, Eqevad L, Rayford W, Bergerhein U, Ekman P, Delmarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. 2004. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 2004;101:811-816.\nLau KM, Chan QK, Pang JC, Li KK, Yeung WW, Chung NY, Lui PC, Tam YS, Li HM, Zhou L, Wang Y, Mao Y, Nq HK. 2010. Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion. Oncogene 29: 5475-5489.\nMarcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A. 2004. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 64:7050-7057.\nMarcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D. 2011. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front. Biosci. 3:1443-1455.\n108\nMunkley J, Oltean S, Vodak D, Wilson BT, Livermore KE, Zhou Y, Star E, Floros VI, Johannessen B, Knight B. 2015. The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget. 6:34358-34374.\nMyers RB, Meredith RF, Schlom J, LoBuglio AF, Bueschen AJ, Wheeler RH. 1994. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J Urol. 152:243-246.\nOzaki H, Matsuzaki H, Ando H, Kaji H, Nakanishi H, Ikehara Y. 2012. Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin Exp Metastasis. 29:229-238.\nPeyrat J-P, Recchi M-A, Hebbar M, Pawlowski V, Hornez L, Dong-Lebouhris X, Hondermarck H, Harduin-Lepers A, Delannoy P. 2000. Regulation of Sialyltransferase expression by estradiol and 4-OH-Tamoxifen in the human breast cancer cell MCF-7. Mol Cell Biol Research Communication. 3:48-52.\nPinho SS, Reis CA. 2015. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 15:540-555.\nRadhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C. 2014. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci U S A. 111:E4066-4075.\nSean RS, Tongzhong J, Cummings RD. 2015. Protein Glycosylation in cancer. Annu Rev Pathol. 10: 473-510.\n109\nSewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, Noll T. 2006. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem. 281:3586-3594.\nSiegel R, Jiemin MA, Zou Z, Jemal A. 2014. Cancer Statistics. CA Cancer J CLIN. 64:9-29.\nSilva ML, Gutierrez E, Rodriguez J\u00c1, Gomes C, David L. 2014. Biosensors and Bioelectronics. 57:254-261.\nSteiner MS, Raghow S. 2003. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J. Urol. 21, 31-36.\nSingh PB, Matanhelia SS, Martin FL. 2008. A potential paradox in prostate adenocarcinoma progression: Oestrogen as the initiating driver. Eur. J. Cancer. 44: 928-936.\nVojta A, Samarzija L, Bockor L, Zoidos V. 2016. Glyco-genes change expression in c\u00e2ncer through aberrante methylation. Biochim Biophys Acta. 1860: 1766-17865.\n110\n8-\tTable\nPC-3/E2 CELL VIABILITY x T\t\t\t\t(MTT Assay) riME x CONCENTRATION\t\n\tCT\t24h\t48h\t72h\t96h\t\n10-6\t*\t*\tVs. 24h: 0.001\tVs. 24h: 0.001\tVs. 24h: 0.001 Vs. 72h: 0.001\n10-7\t*\t*\tVs. 24h : 0.01\tVs. 24h: 0.001 Vs.48h: 0.001\tVs. 24h: 0.001 Vs. 48h: 0.001 Vs. 72h: 0.01\n10-8\t*\t*\tVs. 24h: 0.01\tVs. 24h: 0.001 Vs. 48h: 0.001\tVs.24h: 0.001 Vs. 72h: 0.001\n10-9\t*\t*\tVs.24h: 0.01\tVs.24h: 0.001 Vs. 48h: 0.001\tVs.24h: 0.001 Vs. 72h: 0.05\n10-10\t*\t*\tVs. 24h: 0.05\tVs. 24h: p 0.01 Vs. 24h: 0.001 Vs.48h: 0.001\tVs. 24h: 0.001 Vs. 48h: 0.001\n10-11\t*\t*\t*\tVs. 48h: p 0.01\t*\n* no significant difference observec\t\t\t\t\t\nTable I: PC-3 cells treated with E2 (10-6-10-11) analyzed though of the MTT assay demonstrated significant statistical differences in relation to E2 time.\nDU-145/E2 CELL VIAB\t\t\t\t(MTT Assay) ILITY x TIME\t\n\tCT\t24h\t48h\t72h\t96h\n10-6\t*\t*\t*\tVs.24h: 0.05 Vs.48h: 0.05\tVs. 24h: 0.01 Vs. 48h: 0.05\n10-7\t*\t*\tVs. 24h: 0.01\tVs. 24h: 0.001 Vs. 48 h: 0.001\tVs. 24h: 0.001 Vs. 48h: 0.001\n10-8\t*\t*\tVs. 24h: 0.01\tVs. 24h: 0.001 Vs.48h: 0.001\tVs. 24h: 0.001 Vs. 48h: 0.001\n10-9\t*\t*\t*\tVs. 24h: 0.001 Vs.48h: 0.001\tVs. 24h: 0.01 Vs 72h: 0.05\n10-10\t*\t*\tVs.24h: 0.05\tVs. 24h: 0.001 Vs. 48h: 0.001\tVs 24h: 0.001 Vs 72h: 0.001\n10-11\t*\t*\t*\t*\t*\n* no significant difference observec\t\t\t\t\t\n8\tPERSPECTIVA\nDiante dos resultados obtidos, alguns estudos complementares s\u00e3o cab\u00edveis para caracterizar melhor o mecanismo de a\u00e7\u00e3o do estradiol proposto no estudo.\nInvestigar a express\u00e3o g\u00eanica da ST6GalNac I bem como de outras sialiltransferases envolvidas no processo na s\u00edntese de ant\u00edgenos glic\u00eddicos envolvidos na progress\u00e3o tumoral. Caracterizar o potencial metast\u00e1tico das linhagens de c\u00e2ncer de pr\u00f3stata DU-145 e PC-3 frente estradiol atrav\u00e9s de ensaio de invas\u00e3o e por fim avaliar se a vitamina D, um secoester\u00f3ide, pode regular a via do estr\u00f3geno em c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio, bem como avaliar sua atividade inibidora de progress\u00e3o de c\u00e2ncer de pr\u00f3stata.\n112\n9\tCONCLUS\u00d5ES\nO desenvolvimento da sonda histoquimiluminescente produzida a partir da conjuga\u00e7\u00e3o das lectinas ao \u00e9ster de acridina possibilitou a investiga\u00e7\u00e3o quantitativa da express\u00e3o de glicanos em hiperplasia prost\u00e1tica benigna (HPB), c\u00e2ncer de pr\u00f3stata (CP) e pr\u00f3stata normal.\nTecidos transformados demonstraram uma menor express\u00e3o de a-D-glucose / manose e Gal-P (1-3) -GalNAc quando comparados \u00e0 tecidos normais. No entanto, uma maior express\u00e3o de a-L-fucose foi observada em CP em rela\u00e7\u00e3o a tecidos normais e a HPB. Esse perfil glic\u00eddico alterado foi analisado em estudos in vitro utilizando linhagens de c\u00e2ncer de pr\u00f3stata andr\u00f3geno refrat\u00e1rio, DU-145 e PC-3 tratadas com estradiol ou estradiol associado \u00e0 fulvestranto.\nObservou-se na linhagem PC-3 aumento de express\u00e3o da enzima ST6GALNac na presen\u00e7a de estradiol e diminui\u00e7\u00e3o quando exposta a fulvestranto. Esse comportamento n\u00e3o foi observado na linhagem DU-145.\nTamb\u00e9m foi observado que ERa apresentou diminui\u00e7\u00e3o de express\u00e3o em c\u00e9lulas PC-3 tratadas com fulvestranto, n\u00e3o sendo observada diferen\u00e7a de express\u00e3o do receptor de estr\u00f3geno P em nenhuma das linhagens.\nUtilizando as lectinas VVA (Vicia villosa aglutinin) e SNA (Sambucus nigra aglutinin) foi poss\u00edvel confirmar a sialila\u00e7\u00e3o do ant\u00edgeno Tn nas c\u00e9lulas PC-3 tratadas com estradiol e sua por fulvestranto. Al\u00e9m disso, foi observado que a express\u00e3o desse ant\u00edgeno pode esta associado a capacidade migrat\u00f3ria das c\u00e9lulas tumorais observado pelo ensaio de migra\u00e7\u00e3o, etapa importante da progress\u00e3o tumoral.\n113\nAssim, podemos concluir que a glicosila\u00e7\u00e3o alterada identificada pela sonda histoquimiluminescente pode ser produto da regula\u00e7\u00e3o de horm\u00f4nios esteroides, em especial, o estradiol e que esse perfil glic\u00eddico pode est\u00e1 associado ao potencial metast\u00e1tico desse tumor.\n114\n10\tProdu\u00e7\u00e3o Cient\u00edfica\nI lmd\u00bbi Pifchdimg Ccrpcrabon Otawe Hartera\nVduiK35 (3SU), line 1, Pign 1-19-151 htlp-j.! drdcLarg.' ID. I I55<'2DI3W 130\nQ>\nHindawi\nResearch Article\nGlycophenotype Evaluation in Cutaneous Tumors Using Lectins Labeled with Acridiniinn Ester\nLuiza Riyuniu Amorim l imn? Mathius Filftieira Bezvrru?\nSinara M\u00f3nita Vltallmi Almeida.1,J Lucia kalrkla lk/ena Gomo Silva?\nLduardn Isidora Carne Iro IJeltrao?3 and Luk Braerra Carvalho Jiijiiorlr3\n1\tiTzbaraJcnodr/juvuvepulci'c^ia Kmr Arnzurj l\u2019LTKj\u00f3J, LVaitrniiiii .''lJl-mL di \u00f1nanihuaj, Cidjidi irir. ersiiff nk JM.-iiRmit PK, !br\u00bfz.:!\n2\tl^iTl ii\u00faiaii! Jc\u00edTrcrariffi, irditrapnce T\u00ab rr jIjj\u00edj di Cjniir'ucL: f\u00bfvAC\u00a3TH71P U\u00f1erado\u00a3\u00a3 ftnwralwT f\u00fcPEl. j\u00dcJLXI Carol ibiiKS, PF, ibrizz!\n' .l\u00cdL,l,virr.ir.'ii;ii: di Srcqamirca. \u00bfjilwiardo^r Padma1 ^rPeimCTibarc. C.'iiiiir LtrirerirJnria. 5\u00dc03\u00da Bmifc. PE. ftnoril\nLiarmpcciikfice iziraldbc uldruml tal\u00f1 li>o\u00bfrra Car\u2122lho]\u00fcrJrc:]hcjipliaLlink.oam.br\nRcmr.-\u00abL 27 March 2013: Revised 13 lune- 20 U: \u00bfacepta! 21 lime 20U\nAcaikfmc JiditarzTiniolby M. Itlack\nCopyright 2013 Lima Rayanna Amarim 1-ima d aL Ihir :s azi open \u25a1cl\u00abj article dismhured cridar the Crerliru liair.n-jcir.-: Artribulim [.\u00a1cense, which permit\u00ed Linre^nctcd uu.dLslribuliixi, uid rcproiLoclim in any moldura, provided the ori-rira] work u properly cited.\n/Liilgniimh Tomar ceUs show al le rali ans in their gtyenryhrian poner tu whan compared la normal cells Lectins can he used, to eval\u00faale diese gzrcc-zc-Je changes. Chemiluminescence soy \u00a1san eflezLi'.'c technique tor q liar. Lia ti ve analysts of proteins, nucleic acids,and-rar hr by'dm les dije to its high sensitivity, spcdliciry, and rapid resting. \u00dcb/ecfnu. To use hi s to chenuJ untie esccnce Eased od lectin caoiugaled Io acridiniuar. ci-ler I AG) for die investigation of g lyccplu: ootype changes ir. oj Linea us tumors. Meikxh. Ccir_car.ivi_ir. A (Coo Al, Penned agglutinin CPNAj. t'lcv mropneiu agg]uLinin-[ iL'LA-lj, and AfoocEm au:nr.aisis agglutinin (hAAAl werecoqugpledtDacridirJujr. ester. IHnpsics of cutaneous lumccs and normal skin were incubated wiLh I he leztira-A, E, and cberr.il urr_ in esconce was quar. tiled and expressed us Relative Light Urdu fRI.L'i. Residir. Actmic kaaloai (A1Q, It er a Iraca echo ma (KA), squamous ceD cardmma (SCC), and brio] cell car cinema IHCCj showed Lokot expression of rr-EL glucoses1 man nose and ii-L.-tucosc residues compared to normal lissue. Cutaneous donors displayed higher erpresiac of GaJ-j5il-3/-Galt4Ac residues Lhuzi normal Lssue. AKandECCcxhiksled higher apres&amp;on of Neu5Ac-rt(23)Gal residues ihannamaJepddenrJs. KA and 1CC showed equivalent RUJ values erm pared to norma] Its sue. Cmnhisrcns. lecLn histochenuJum inescenm allcoved quantiralive assessment ct thecarbobydraLecspnesinn in culanecus Li svjes, contributing tn diznznate the subjectivity nt con vent in nal tn dr \u00f1iques used in the hislopuLhdngpcal diagnusi:.\nI. Introduction\nNearly all types nf malignant edb nd many types of diseased tissue edb demonstrate alteralions Ln. their glycosylation patterns when compared to their normal counterparts ['ll. Alterations in gjycosyltransferascs expression, sugar nucleotide donors, anc disruption of the Golgi cuniribuleto Idle Jjttliipip-.nl of diseases, sucti as hcrcdilaiy disorders, immune delL\u2019ieiKiei, cardieyvascular disease, and cancer 12, 31. In the tumor environment, undcrexprewian, truncation or altered brandling patterns of certain glycans, and/or changes in glycosylation allow neoplasm edb Io usurp many\nof th-.- events that occur in development such as receptor activation, cell adhesion, and cell motility, which permits tumor cells Io invade and spread throughout the organism |1J. lhe investigation oflcctin-carbohydratcs interactions is necessary far the undcnlanding of belli the glycqphcnotype and the behavior of the lumor during its diiferenliaiion and confirms the hypothecs that biochemical changes In the cell are events that may signal the cell differentiation [51.\nLectins hate been used to evaluate the glycophenotype Ln skin tissues |6-9J* Lectin histochemistry based on colorimetric detection has been used as a supporting too] for dilferential diagnosis for skin lesions. but I hi a technic r-e only\n115\nIk. J. AJ\u00fc. Scf. 2M5. J\u00e1, 13013-13042; do\u00ed 103390 inrslSO\u00edl 3023\nTrr-a~i.-n.---i.-l J\u00fcijrZLll of\nMolecular Sciences ISN1422-DM7 izdp :-ee ic rzial |eb\n-dnirifl\nSynthesis, DNA Binding and Antiproliferative Activity uf Navel Aciidiue-Tliioseuiicarbazcne D eitva tires\nSinara l\u00ed\u00f3uca VrUdfaw de Ahneiidal iT, Elizitoedi Almeida Lafayette \\\nLuria Patricia Bezant Goma da Sih a '. C\u00e9sar Angnsto da Cruz Amorim\nTiago Barto de CHrveira &lt;Ana Ln-ria Tasca Gods- RmiJoia Ernesto de L aramlio Ricardo Olimoio de Mourn \\ Ednarda Isidoro C arnsra BdirM '.\nMaria do &lt;jjtdo Alves de t ima J aolLiiz Bezerra d# Can alha J inior 1\n1 Litcimixici de Iimmopaiajogj. Kazo Asami \u00a1LIKA) and.\t*\u00bb it Pingii-n-rn\nL'niverKdadfl Federal de yemambxo (CEPE). Efeafe 50670-901. EE. Brazil\nE-Mails: hxu-pc.\" a J hotmaLjcom (LPB.G.S.); Ap-Ttran^jhnrmail r\u00abn (E.LCB.)-\nlx; \u00a1. hoimk combi \u00a1LB.CJ.)\n3 Faraldade de Cisizins. Edusz\u00e7ao e Tkeoldej de i jorzihmz fF ACE TEG).\nUniversidade de PetejeStxc \u00e7/AE:. Gannijms 55290-000. PE Brazil\nJ D^anamerro de Anribicricos. Lmvenidide Fe\u00f5aral -de Pamurhico iJJFPEj.\nRedse 50670-901. ?E. Brazil. E-Mails: eLzabedtalmeidajfnede^ ^n-1 rrrn rE A T )\u25a0\ncezar amDciiraJ gmaJ.zcm [CACA); oj pb>arjo2M-\u25a1 eet.l com (T.HO.);\nBible-dear e Agri\u00f3las \u00a1DFT CPQBA). Universidade Estadia! de Canpirjis J-WIAM?], t'^rrrim - 130E3-C70. SP. Brazil EAfoils: aajuizg he mail \u00a1soca )A.L T j.Rj; carvalho-I\u00e7pqtn unicmigbriT.E.C.)\n5 Faraldade de Ci\u00eancias Farmac\u00e3iriras. Umrersidade Estadml de Camperas (USIC AMP). \u25a0Ioeeizj 1130B3-859, 5P. Brazil\n*\tO^anamerio de Famsizia. Laboraicrjo de \u2019l\u00edmese e Vennzz.\u00e7-x -de Mol\u00e9culas. Universidade Estadual da Para\u00edba \u00a1UEPE). Campus C-impma Grande 5E419-5D0. PE. Brazil E-Mail: ricnrdo.olm^dodemcun] L zDiail.cocj\n*\tAcriba te Tvtizcc. oxrespcDc.eace shc\u00e3dbe ?z\u00f3e==ec E-Mail: sman. anomcali-EEiaJ cam\nT\u00e9l.: -5S\u00edl-2l2\u00f3-34fi4.Fiv+5Ml-2125-E4S5.\nAcadamr Editor Eno C. Lmz\n116\ninforma\nr-\u00e0i-\u00e0htc-\u2018i-\nCon A conjugated to Europium(lll) cryptate as a new histological tool for prostate cancer investigation using confocal microscopy\nMJBM R\u00eago* 1, LPBG Silva1, JKG Medeiros1, RCBQ Figueiredo2, S Alves-J\u00fanior3, EIC Beltr\u00e3o1-4\nKeizo Asami tmmunopathology Laboratory University Federal of Pernambuco, 2Aggeu Magalh\u00e1es Research Center CPqAMIFIOCRUZ, 3Department of Fundamental Chemistry, University Federal of Pernambuco, and *Department of Biochemistry University Federal of Pernambuco, Brazi\nAccepted September \u00cd6,2tM3\nJiM\u25a0gwzBocjII Be only.\nAbstract\nl ectins are carbohydrate recognition proteins that can be used as probes to reveal the glycosyla-\ntion state of cells. They frequently have been used for diagnostic and prognostic cancer studies.\nFor fluorescence based analysis, lectins commonly are conjugated to fluorescein isothiocyanate (Con A-FITC); however, this molecule loses its fluorescence quickly. We conjugated Europium cryptate to Con A (Con A-cryp-Eu) for use as a histochemical luminescent probe to recognize glucose/mannose residues in benign prostatic hyperplasia and prostatic carcinoma tissues, and used confocal microscopy instead of commercial Con A-FITC. Tissues were treated with Evans blue to suppress intrinsic tissue fluorescence before incubation with Con A-cryp-Eu or Con A-FTTC. Con A-cryp-Eu exhibited hemagglutinating activity. Con A-cryp-Eu showed the same binding pattern as Con A-FITC in prostate stroma and gland cells. Staining was strong in benign prostate hyperplasia and prostate carcinoma tissues. Con A-cryp-Eu probe stained glucose/mannose residues in prostatic carcinoma more intensely than Con A-FITC. Furthermore, staining with Con A-cryp-Eu showed greater fluorescence intensity than Con A-FITC and the emission of Con A-cryp-Eu was more stable than the Con A-FTTC for seven days under the same storage conditions. Maintenance of the luminescent properties and the binding pattern of Con A-cryp-Eu favor its use as an auxiliary histochemistry probe for prostatic tissue studies.\nKey words: confocal microscopy, Con A-Europium, cryptate, histochemistry, lectin\nConfoca I microscop v is a powerful technique ths I is widely used to investigate molecular alterations caused by cancer by providing detailed images of architecture and cellular morphology [Palmieri at al. 2010}. Fluorescein isothiocvanate (FTTCj is the fluorescein derivative of choice for detecting biomolecules using confocal microscopy mainly due to its large quantum yield of fluorescence (Foster at al. 2004, SamueLsson at al. 2009). F1TC has some disadvantages, however, such as pH sensitivity and\nConBspenoancsEaranlc aeltras. LsowaMDo Be Inunopatalaja Ketej Asan, UFPE, Av Plot. Moises R4qt>, 1235. CDU, Redie. Pemantuoo, Brasil E067D-B10. E-mal: Ebeltran trholmall.ccm O2D14 The Bldodcal Stan Cairtsdon amMl HS\u00f1cfleoiBiry 2014, 99(5): 321-336.\nDOI: 10.3109/10520295.2013. B45479\nphoto-bleaching (Waggoner 2006}. New fluorescent molecules that have no light sensitivity have been investigated as alternatives including quantum dots and lanthanide (Santos at al. 2006}.\nLanthanide cryptates have been used for many studies, mainly due to their luminescent properties (Selvin 2003, Hemmila and laitala 200?, Handl and Gillies 2005). Their photophyslcal properties have been known for more than a decade; these cryptates efficiently populate the transmission electron level (HOj) for Europium and for terbium} nf 1he metal ion wilhin it structure and 1hey emit by nonra-diative processes, which provide high amission in aqueous solutions (Galaup at al. 2002, Martins and Isolanl 2005}. These properties have been exploited for spectroscopic studies of biological molecules\n321\nRtBHTBLIIU K<y\n117"}]}}}